LIPÍDEOS CATIÔNICOS IONIZÁVEIS PARA ENTREGA DE RNA

Novel lipids in Formula (I) address the challenges of lipid-based delivery by forming nanoparticles for efficient and targeted nucleic acid delivery, improving therapeutic efficacy and reducing side effects.

BR112025024370A2Pending Publication Date: 2026-11-10ARCTURUS THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025024370
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-10
Filing Date
2024-05-09
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing lipid-based delivery vehicles for nucleic acid therapeutics face challenges such as low biodegradability, in vivo accumulation, adverse immunogenic effects, and low delivery efficiency, necessitating the development of new lipids that can protect and effectively deliver therapeutic agents to target sites.

Method used

Development of novel lipids, including compounds of Formula (I), which self-assemble into nanoparticles for encapsulating nucleic acids, providing protection and targeted delivery while minimizing side effects.

Benefits of technology

The novel lipids enhance the therapeutic efficacy by ensuring effective delivery and release of nucleic acids at target sites, reducing immunogenic effects and improving biodegradability, thus enhancing the overall treatment effectiveness.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure describes compounds of Formula (I) and pharmaceutically acceptable salts thereof:
Need to check novelty before this filing date? Find Prior Art

Description

[001] The modalities herein generally refer to lipids. In particular, the modalities in this document refer to novel lipids and lipid compositions that facilitate the intracellular delivery of biologically active and therapeutic molecules. BACKGROUND

[002] The variety of nucleic acid-based therapeutics for targeted delivery creates a challenge for lipid-based delivery vehicles. For example, nucleic acids are structurally diverse in size and type. Examples include DNA used in gene therapy, plasmids, small interfering nucleic acids (siNA) and microRNA (miRNA) for use in RNA interference (RNAi), antisense molecules, ribozymes, antagomirs, and aptamers.

[003] The design and use of cationic lipids and ionizable cationic lipids for inclusion in such lipid-based delivery vehicles has shown great advantages. However, the use of these lipids can contribute to significant side effects when administered in vivo. One problem that has been observed includes low biodegradability and clearance from target tissues, thus creating an in vivo accumulation of the lipid. Another problem is that large amounts of the lipid can cause adverse immunogenic effects, which can result in discomfort in the subject and a decrease in the therapeutic effect of the active ingredient. A third problem associated with many cationic lipids is a low percentage of effective delivery to the target, thus resulting in a relatively low therapeutic effect or low potency.Finally, it is not only important that the cationic lipid in the delivery vehicle has a specially tuned pKa so that it can be formulated with the nucleic acid-based therapeutic agent and protect it from degradation during administration, but also that... Petition 870250102289, dated 07 / 11 / 2025, page 6 / 408 2 / 379 be able to release the therapeutic agent once the vehicle has reached its target. Thus, there is a need in the art for the development of new lipids that can meet the special requirements of lipid-nucleic acid delivery systems.

[004] Each of the following references is incorporated herein by reference in its entirety: International Application No. PCT / US 2014 / 066242, published as WO2015074085A1, International Application No. PCT / US2015 / 030218, published as WO2016081029A1, US Patent No. US10227302, US Patent No. US10383952, and US Patent No. US10526284, each of which discloses ionizable cationic lipids for RNA delivery; International Application No. PCT / US2016 / 069493, published as WO2017117530A1, which discloses ionizable cationic lipids; International application number PCT / US 2019 / 025246, published as WO2019191780A1, disclosing lipid particles for nucleic acid delivery; and US application number 16 / 823212, published as US2020 / 0297634, disclosing methods for producing lipid-encapsulated RNA nanoparticles. SUMMARY

[005] The present invention relates to lipids of Formula (I), as described herein, useful for delivering lipid-based nucleic acids and other therapeutic agents for the treatment of diseases. These and other uses will be apparent to those skilled in the art. Additional features and advantages of the technology in question will be presented in the description below and, in part, will be apparent from the description or may be learned by practicing the technology in question. The advantages of the technology in question will be perceived and achieved by the structures particularly pointed out in the written description and embodiments.

[006] It should be understood that both the previous general description and the following detailed description are illustrative and explanatory. Petition 870250102289, dated 07 / 11 / 2025, page 7 / 408 3 / 379 and are intended to provide further explanation of the technology in question.

[007] In some embodiments, the present disclosure provides a compound of Formula I or a pharmaceutically acceptable salt thereof: (I) where:

[008] R1 and R2 are each independently H or C1-6 alkyl; or

[009] R1 and R2 are joined to form a saturated heterocyclic ring, where:

[0010] R1 is a linear C1-4 alkylene; and

[0011] R2e-(CH2)m(X)n-, where

[0012] X is O, S or NR9, where R9 is H or C1-6 alkyl;

[0013] m is 1, 2, 3 or 4, and

[0014] n is 0 or 1;

[0015] L1 is a linear C1-6 alkylene optionally substituted with one to three methyl groups;

[0016] Y is selected from the group consisting of: Petition 870250102289, dated 07 / 11 / 2025, p. 8 / 408 4 / 379 I, WW and JVW where:

[0017] each asterisk (*) indicates the atom bonded to L2 and L3; and

[0018] R10 is H or C1-6 alkyl;

[0019] L2 and L3 are each independently a linear C1-8 alkylene;

[0020] L4, L5, L6, L7, L8 and L9 are each independently absent or -CH2-, provided that:

[0021] at least two of L4, L6 and L8 are -CH2-; and

[0022] at least two of L5, L7 and L9 are -CH2-;

[0023] R3e R4são cada um independente, methyl or ethyl; and

[0024] R5, R6, R7 and R8 are each selected independently from the group consisting of:

[0025] C1-20 linear alkyl, wherein each said C1-20 linear alkyl is optionally substituted

[0026] with one or more substituents selected from the group consisting of:

[0027] C6-10 aryl, wherein each C6-10 aryl is a monocyclic or bicyclic aromatic hydrocarbon optionally substituted by one or more C6-10 aryl groups that are optionally substituted by one or more C1-6 alkyl groups;

[0028] 6- to 10-membered heteroaryl, wherein each 6- to 10-membered heteroaryl is a monocyclic or bicyclic aromatic system optionally substituted with one or more C1-6 alkyl groups;

[0029] C6-10 aryl, where each C6-10 aryl is a monocyclic or bicyclic aromatic hydrocarbon optionally substituted by one or more C6-10 aryl groups that are optionally substituted by one or more C1-6 aryl groups. Petition 870250102289, dated 07 / 11 / 2025, p. 9 / 408 5 / 379 alkyl; and

[0030] 6- to 10-membered heteroaryl, wherein each 6- to 10-membered heteroaryl is a monocyclic or bicyclic aromatic system optionally substituted with one or more C1-6 alkyl groups.

[0031] In some embodiments, the present disclosure provides a lipid nanoparticle comprising a plurality of ligands, wherein each ligand is independently a compound described herein, wherein the plurality of ligands self-assembles to form the lipid nanoparticle comprising an interior and an exterior.

[0032] In some embodiments, the present disclosure provides a pharmaceutical composition comprising the compound described herein or the lipid nanoparticle described herein and a pharmaceutically acceptable excipient.

[0033] In some embodiments, the present disclosure provides a method of treating a disease in a subject in need thereof, comprising administering a therapeutically effective amount to the subject of the compound described herein, the lipid nanoparticle described herein, or the pharmaceutical composition described herein.

[0034] In some embodiments, the present disclosure provides a method of delivering a nucleic acid to a subject in need thereof, comprising encapsulating a therapeutically effective amount of the nucleic acid in the lipid nanoparticle described herein and administering the lipid nanoparticle to the subject. DETAILED DESCRIPTION GENERAL

[0035] It is understood that various configurations of the technology in question will become readily apparent to those skilled in the art from the disclosure, in which various configurations of the technology in question are shown and described by way of illustration. How will it be Petition 870250102289, dated 07 / 11 / 2025, page 10 / 408 6 / 379 perceived, the technology in question is capable of other and different configurations and its various details are capable of modification in several other aspects, all without departing from the scope of the technology in question. Thus, the summarized and detailed description should be considered illustrative and not restrictive.

[0036] The detailed description presented below is intended to be a description of various configurations of the technology in question and is not intended to represent the only configurations in which the technology in question may be practiced. The detailed description includes specific details for the purpose of providing a complete understanding of the technology in question. However, it will be evident to those skilled in the art that the technology in question may be practiced without these specific details. DEFINITIONS

[0037] In several places in this descriptive report, the substituents of the compounds in this disclosure are disclosed in groups or ranges. It is specifically intended that this disclosure include any and all individual subcombinations of the members of such groups and ranges. For example, the term “C1-6 alkyl” is specifically intended to individually disclose methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl.

[0038] The term “approximately” or “about”, as applied to one or more values ​​of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term approximately or about refers to a range of values ​​that are within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less in any direction (greater or less than) the stated reference value, unless otherwise indicated or evident from the context (except when that number exceeds 100% of a possible value). Petition 870250102289, dated 07 / 11 / 2025, p. 11 / 408 7 / 379

[0039] In claims, articles such as “a,” “an,” and “the” may mean one or more of one, unless indicated otherwise or otherwise evident from the context. Claims or descriptions that include “or” among one or more members of a group are considered satisfied if one, more than one, or all members of the group are present, employed, or otherwise relevant to a particular product or process, unless indicated otherwise or otherwise evident from the context. Disclosure includes embodiments in which exactly one member of the group is present, employed, or otherwise relevant to a particular product or process. Disclosure includes embodiments in which more than one or all members of the group are present, employed, or otherwise relevant to a particular product or process.

[0040] The term alkoxy, as used herein, alone or in combination, refers to an alkyl ether radical, wherein the term alkyl is as defined below. Alkoxy groups may have the general formula: alkyl-O-. As for the alkyl group, alkoxy groups may have any suitable number of carbon atoms, such as C1-6. Alkoxy groups include, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, 2-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy, hexoxy and the like. Alkoxy groups may be further optionally substituted as defined herein.

[0041] As used herein, “alkyl” refers to a linear or branched hydrocarbon chain that is fully saturated (i.e., contains no double or triple bonds). The alkyl group may have from 1 to 20 carbon atoms (wherever it appears herein, a numerical range such as “1 to 20” refers to each whole number in the given range; for example, “1 to 20 carbon atoms” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, Petition 870250102289, dated 07 / 11 / 2025, p. 12 / 408 8 / 379 carbon atoms, etc., up to and including 20 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated). The alkyl group may have 1 carbon, 2 carbons, 3 carbons, 4 carbons, 5 carbons, 6 carbons, 7 carbons, 8 carbons, 9 carbons, 10 carbons, 11 carbons, 12 carbons, 13 carbons, 14 carbons, 15 carbons, 16 carbons, 17 carbons, 18 carbons, 19 carbons, or 20 carbons. The alkyl group may be linear or branched. Alkyl groups can include any number of carbons, such as C1-2, C1-3, C1-4, C1-5, C1-6, C1-7, C1-8, C1-9, C1-10, C2-3, C2-4, C2-5, C2-6, C3-4, C3-5, C3-6, C4-5, C4-6, and C5-6. The alkyl group can also be a medium-sized alkyl with 1 to 9 carbon atoms. The alkyl group can also be a lower-sized alkyl with 1 to 6 carbon atoms. The alkyl group may be designated as "C1-4 alkyl" or similar designations.By way of example only, “C1-4 alkyl” indicates that there are one to four carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and t-butyl. Typical alkyl groups include, but are by no means limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, and the like.

[0042] Alkylene refers to a saturated aliphatic radical, linear or branched, having the indicated number of carbon atoms and connecting at least two other groups, i.e., a divalent hydrocarbon radical. The two moieties attached to the alkylene may be attached to the same atom or to different atoms of the alkylene group. For example, a linear chain alkylene may be the divalent radical de-(CH2)n where “n” is 1, 2, 3, 4, 5, or 6. Representative alkylene groups include, but are not limited to, methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec-butylene, pentylene, and hexylene. Alkylene groups may be substituted or unsubstituted. Petition 870250102289, dated 07 / 11 / 2025, p. 13 / 408 9 / 379

[0043] The term “lower alkyl” means a group with one to six carbons in the chain which may be linear or branched. Non-limiting examples of suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl and hexyl.

[0044] The term amino, as used herein, represents N(RN1)2, wherein each RN1 is independently H, OH, NO2, N(RN2)2, SO2ORN2, SO2RN2, SORN2, an N protecting group, alkyl, alkenyl, alkynyl, alkoxy, aryl, alkaryl, cycloalkyl, alkylcycloalkyl, carboxyalkyl (for example, optionally substituted with an O protecting group, such as optionally substituted arylalkoxycarbonyl groups or any other described herein), sulfoalkyl, acyl (for example, acetyl, trifluoroacetyl or others described herein), alkoxycarbonylalkyl (for example, optionally substituted with an O protecting group, such as optionally substituted arylalkoxycarbonyl groups or any other described herein), heterocyclyl (for example, heteroaryl) or alkyl-heterocyclyl (for example, alkyl-heteroaryl), in that each of these recited RN1 groups may be optionally substituted, as defined in this document for each group;or two RN1s combine to form a heterocycline or an N protecting group, wherein each RN2 is independently H, alkyl, or aryl. The amino groups of the disclosure may be an unsubstituted amino (i.e., -NH2) or a substituted amino (i.e., -N(R')2). In a preferred embodiment, amino is -NH2 or NHRN1, wherein RN1 is independently OH, NO2, NH2, N(RN2)2, SO2ORN2, SO2RN2, SORN2, alkyl, carboxyalkyl, sulfoalkyl, acyl (e.g., acetyl, trifluoroacetyl, or others described herein), alkoxycarbonylalkyl (e.g., t-butoxycarbonylalkyl), or aryl, and each RN2 may be H, C1-20 alkyl (e.g., C1-6 alkyl), or C1-10 aryl.

[0045] The term “anionic lipid” means a lipid that is negatively charged at physiological pH. These lipids include, but are not limited to, phosphatidylglycerols, cardiolipins, diacylphosphatidylserines, Petition 870250102289, dated 07 / 11 / 2025, p. 14 / 408 10 / 379 diacylphosphatidic acids, N-dodecanoyl phosphatidylethanolamines, N-succinyl phosphatidylethanolamines, N-glutaryl phosphatidylethanolamines, lysylphosphatidylglycerol, palmitoylleyolphosphatidylglycerol (POPG) and other anionic modifiers. groups attached to neutral lipids.

[0046] The term aryl, as used herein, alone or in combination, means an aromatic carbocyclic system containing one, two, or three rings in which such rings may be linked together in a pendant manner or may be fused. The term aryl encompasses aromatic radicals such as benzyl, phenyl, naphthyl, anthracenyl, phenantryl, indanyl, indenyl, anulenyl, azulenyl, tetrahydronaphthyl, and biphenyl. A C10 aryl of the present disclosure includes a C10 aryl, a C7 aryl, a C5 aryl, a C9 aryl, or a C10 aryl. In embodiments, the C10 aryl is monocyclic, as is a phenyl group. In embodiments, the C10 aryl is bicyclic, such as a biphenyl, a naphthyl group, or an indanyl group. The substituents for the aryl ring systems mentioned above are selected from the group of acceptable substituents described below. An arylene, alone or as part of another substituent, means a divalent radical derived from an aryl group.

[0047] The phrase “at least one of” preceding a series of items, with the term “and” or “or” to separate any of the items, modifies the list as a whole, rather than each member of the list (i.e., each item). The phrase “at least one of” does not require the selection of at least one of each item listed; instead, the phrase allows for a meaning that includes at least one of any of the items, and / or at least one of any combination of the items, and / or at least one of each of the items. As an example, the phrases “at least one of A, B, and C” or “at least one of A, B, or C” each refer to only A, only B, or only C; any combination of A, B, and C; and / or at least one of each of A, B, and C.

[0048] Terms include, have or similar are used in Petition 870250102289, dated 07 / 11 / 2025, p. 15 / 408 11 / 379 description or in the claims, such term is intended to be inclusive in a manner similar to the term includes, since includes is interpreted when used as a transitive word in a claim.

[0049] The term “cationic lipid” means amphiphilic lipids and their salts having a positively charged hydrophilic head group; one, two, three, or more hydrophobic fatty acid or alkyl fatty acid chains; and a connector between these two domains. An ionizable or protonable cationic lipid is typically protonated (i.e., positively charged) at a pH below its pKa and is substantially neutral at a pH above the pKa. Preferred ionizable cationic lipids are those having a pKa lower than physiological pH, which is typically around 7.4. Disclosure cationic lipids may also be termed titratable cationic lipids. Cationic lipids may be an “aminolipid” having a protonable (i.e., pH-titratable) tertiary amine head group. Some exemplary amino acids may include C18 alkyl chains; and ether, ester, or ketal linkages between the head group and the alkyl chains.Such cationic lipids include, but are not limited to, DSDMA, DODMA, DLinDMA, DLenDMA, γ-DLenDMA, DLin-K-DMA, DLin-K-C2-DMA (also known as DLinC2K-DMA, XTC2 and C2K), DLin-K-C3-DMA, DLin-K-C4-DMA, DLenC2K-DMA, γ-DLen-C2K-DMA, DLin-M-C2-DMA (also known as MC2), DLin-M-C3-DMA (also known as MC3) and DLinMP-DMA (also known as 1-Bl 1).

[0050] The term “comprising” is intended to be open-ended and allows, but does not require, the inclusion of additional elements or steps. When the term “comprising” is used in this document, the terms “consisting of” and “consisting essentially of” are therefore also encompassed and disclosed.

[0051] The term commercially available chemicals and Petition 870250102289, dated 07 / 11 / 2025, page 16 / 408 12 / 379 The chemicals used in the Examples set forth herein may be obtained from standard commercial sources, where such sources include, for example, Acros Organics (Pittsburgh, Pennsylvania), Sigma-Adrich Chemical (Milwaukee, Wisconsin), Avocado Research (Lancashire, United Kingdom), Bionet (Cornwall, United Kingdom), Boron Molecular (Research Triangle Park, NC), Combi-Blocks (San Diego, California), Eastman Organic Chemicals, Eastman Kodak Company (Rochester, NY), Fisher Scientific Co. (Pittsburgh, Pennsylvania), Frontier Scientific (Logan, Utah), ICN Biomedicals, Inc. (Costa Mesa, California), Lancaster Synthesis (Windham, NH), Maybridge Chemical Co. (Rockford, Illinois), Riedel de Haen (Hannover, Germany), Spectrum Quality Product, Inc. (New Brunswick, NJ), TCI America (Portland, OR), and Wako Chemicals USA, Inc. (Richmond, Virginia).

[0052] The phrase “compounds described in the chemical literature” can be identified through reference books and databases focused on chemical compounds and chemical reactions, as is known to someone versed in the art. Suitable reference books and treatises detailing the synthesis of reagents useful in the preparation of compounds disclosed herein, or providing references to articles describing the preparation of compounds disclosed herein, include, for example, “Synthetic Organic Chemistry”, John Wiley and Sons, Inc. New York; SR Sandler et al, “Organic Functional Group Preparations”, 2nd Ed., Academic Press, New York, 1983; HO House, “Modern Synthetic Reactions”, 2nd Ed., WA Benjamin, Inc. Menlo Park, California, 1972; TL Glichrist, “Heterocyclic Chemistry”, 2nd Ed. John Wiley and Sons, New York, 1992; J. March, “Advanced Organic Chemistry: Reactions, Mechanisms and Structure,” 5th Ed., Wiley Interscience, New York, 2001; Specific reagents and analogues can also be identified through indices of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society, which are available at. Petition 870250102289, dated 07 / 11 / 2025, page 17 / 408 13 / 379 most public and university libraries, as well as through online databases (American Chemical Society, Washington, DC can be contacted for more details). Known chemicals, but not commercially available in catalogs, can be prepared by custom chemical synthesis companies, where many of the standard chemical supply companies (such as those listed above) provide custom synthesis services.

[0053] The term “effective amount” of an agent, as used herein, is that amount sufficient to effect beneficial or desired results, for example, clinical results, and as such, an “effective amount” depends on the context in which it is being applied. For example, in the context of administering an agent that treats cancer, an effective amount of an agent is, for example, an amount sufficient to achieve treatment, as defined herein, of the cancer, compared to the response obtained without administering the agent.

[0054] The term fully encapsulated means that the nucleic acid (e.g., mRNA) in the nucleic acid lipid particle is not significantly degraded upon exposure to serum or a nuclease assay that would significantly degrade free RNA. When fully encapsulated, preferably less than 25% of the nucleic acid in the particle is degraded in a treatment that would normally degrade 100% of the free nucleic acid, more preferably less than 10%, and most preferably less than 5% of the nucleic acid in the particle is degraded. “Fully encapsulated” also means that the nucleic acid lipid particles do not rapidly decompose into their component parts after in vivo administration.

[0055] The term compound is intended to include all stereoisomers, geometric isomers, tautomers and isotopes of the structures represented. Petition 870250102289, dated 07 / 11 / 2025, page 18 / 408 14 / 379

[0056] The term cycloalkyl, or alternatively carbocyclo, as used herein, alone or in combination, refers to a saturated or partially saturated monocyclic or bicyclic alkyl radical, wherein each cyclic moiety contains from 3 to 12 carbon atom ring members and which may optionally be a fused ring system with benzo that is optionally substituted as defined in this document. In some embodiments, a cycloalkyl may comprise from 3 to 8 carbon atoms or from 7 to 12 carbon atoms. Examples of such cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, octahydronaphthyl, 2,3-dihydro-1-hindenyl, adamantyl and the like. Bicyclic and tricyclic, as used herein, are intended to include both fused ring systems, such as decahydronaphthalene, octahydronaphthalene, as well as the saturated or partially unsaturated multicyclic (multicentric) type.The last type of isomer is generally exemplified by bicyclo[1.1.1]pentane, camphor, adamantane, and bicyclo[3.2.1]octane. In embodiments, the cycloalkyl ring is a monocyclic ring of 3 to 8 carbons. In embodiments, the monocyclic ring has 3 carbons, 4 carbons, 5 carbons, 6 carbons, 7 carbons, or 8 carbons. In embodiments, the cycloalkyl ring is a bicyclic ring of 7 to 12 carbons. In embodiments, the bicyclic ring has 7 carbons, 8 carbons, 9 carbons, 10 carbons, 11 carbons, or 12 carbons.

[0057] The term “delivery” refers to the act or manner of delivering a compound, substance, entity, portion, cargo or payload.

[0058] The term fragment, as used herein, refers to a portion. For example, protein fragments may comprise polypeptides obtained by digestion of whole proteins isolated from cultured cells.

[0059] The terms “heteroatom” or “ring heteroatom”, as used herein, should include oxygen (O), nitrogen (N), sulfur Petition 870250102289, dated 07 / 11 / 2025, page 19 / 408 15 / 379 (S), phosphorus (P), selenium (Se), and silicon (Si). In some embodiments, the terms “heteroatom” or “ring heteroatom” should include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).

[0060] The term “heteroaryl”, “heteroaromatic ring” or “heteroaromatic group” refers to an aromatic group containing at least one heteroatom, such as N, O or S, in which the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. Thus, the term “heteroaryl” includes fused ring heteroaryl groups (i.e., multiple fused rings in which at least one of the fused rings is a heteroaromatic ring and in which the multiple rings are linked to the original molecular portion through any atom contained within a heteroaromatic ring of the multiple rings). A 5,6 fused ring heteroarylene refers to two fused rings, where one ring has 5 members and the other ring has 6 members, and where at least one ring is a heteroaryl ring.Similarly, a 6,6-ring fused heteroarylene refers to two fused rings, where one ring has 6 members and the other ring has 6 members, and where at least one ring is a heteroaryl ring. And a 6,5-ring fused heteroarylene refers to two fused rings, where one ring has 6 members and the other ring has 5 members, and where at least one ring is a heteroaryl ring. A heteroaryl group can be attached to the rest of the molecule via a carbon or heteroatom.Non-limiting examples of heteroaryl groups include pyrrolyl, pyrazolyl, pyridazinyl, triazinyl, pyrimidinyl, imidazolyl, pyrazinyl, purinyl, oxazolyl, isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzofuran, isobenzofuranyl, indolyl, isoindolyl, benzothiophenyl, isoquinolyl, quinoxalinyl, quinolyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4. Petition 870250102289, dated 07 / 11 / 2025, page 20 / 408 16 / 379 isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl and 6-quinolyl. The substituents for each of the heteroaryl ring systems mentioned above are selected from the group of acceptable substituents described below. A “heteroarylene”, alone or as part of another substituent, means a divalent radical derived from a heteroaryl. A heteroaryl group substituent can be attached -O- to a nitrogen heteroatom of the ring.

[0061] The term hydrophobic lipids means compounds with nonpolar groups which include, but are not limited to, long-chain saturated and unsaturated aliphatic hydrocarbon groups and such groups optionally substituted by one or more aromatic, cycloaliphatic or heterocyclic groups. Suitable examples include, but are not limited to, diacylglycerol, dialkylglycerol, NN-dialkylamino, l,2-diacyloxy-3-aminopropane l,2-dialkyl-3-aminopropane.

[0062] The term “lipid” means an organic compound comprising a fatty acid ester and characterized by being insoluble in water but soluble in many organic solvents. Lipids are generally divided into at least three classes: (1) “simple lipids,” which include fats and oils, as well as waxes; (2) “compound lipids,” which include phospholipids and glycolipids; and (3) “derived lipids,” such as steroids.

[0063] The term “lipid delivery vehicle” means a lipid formulation that can be used to deliver a therapeutic nucleic acid (e.g., mRNA) to a target site of interest (e.g., cell, tissue, organ, and the like). The lipid delivery vehicle can be a nucleic acid lipid particle, which can be formed from a cationic lipid, a non-cationic lipid (e.g., a Petition 870250102289, dated 07 / 11 / 2025, page 21 / 408 17 / 379 phospholipid), a conjugated lipid that prevents particle aggregation (e.g., a PEG lipid), and optionally, cholesterol. Typically, the therapeutic nucleic acid (e.g., mRNA) can be encapsulated in the lipid portion of the particle, thus protecting it from enzymatic degradation.

[0064] The term encapsulated lipid means a lipid particle that provides a therapeutic nucleic acid, such as mRNA, with complete encapsulation, partial encapsulation, or both. In a preferred embodiment, the nucleic acid (e.g., mRNA) is fully encapsulated within the lipid particle.

[0065] The term “amphipathic lipid” or “amphiphilic lipid” refers to material in which the hydrophobic portion of the lipid material is oriented toward a hydrophobic phase, while the hydrophilic portion is oriented toward the aqueous phase. Hydrophilic characteristics derive from the presence of polar or charged groups, such as carbohydrates, phosphate, carboxylic, sulfate, amino, sulfhydryl, nitro, hydroxyl, and other similar groups. Hydrophobicity can be conferred by the inclusion of nonpolar groups, which include, but are not limited to, long-chain saturated and unsaturated aliphatic hydrocarbon groups, and such groups substituted by one or more aromatic, cycloaliphatic, or heterocyclic groups. Examples of amphipathic compounds include, but are not limited to, phospholipids, aminolipids, and sphingolipids.

[0066] The term heteroalkyl, as used herein, alone or in combination, refers to a stable straight-chain or branched-chain radical, or cyclic hydrocarbon, or combinations thereof, fully saturated or containing from 1 to 3 degrees of unsaturation, consisting of the indicated number of carbon atoms and one to three heteroatoms selected from the group consisting of O, N and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized (i.e., bonded). Petition 870250102289, dated 07 / 11 / 2025, p. 22 / 408 18 / 379 to 4 groups). The heteroatom(s) O, N, and S can be placed in any interior position of the heteroalkyl group. Up to two heteroatoms can be consecutive, such as, for example, -CH2NHOCH3.

[0067] The term linker or linking moiety refers to a group of atoms, for example, 10-100 atoms, and may include atoms or groups such as, but not limited to, carbon, amino, alkylamino, oxygen, sulfur, sulfoxide, sulfonyl, carbonyl, and imine. The linker may be of sufficient length so as not to interfere with incorporation into an amino acid sequence. Examples of chemical groups that may be incorporated into the linker include, but are not limited to, alkyl, alkenyl, alkynyl, amido, amino, ether, thioether, ester, alkyl, heteroalkyl, aryl, or heterocyclyl, each of which may be optionally substituted as described in this document. Examples of ligands include, but are not limited to, unsaturated alkanes, polyethylene glycols (e.g., monomeric units of ethylene or propylene glycol, e.g., diethylene glycol, dipropylene glycol, triethylene glycol, tripropylene glycol, tetraethylene glycol, or tetraethylene glycol) and dextran polymers.Other examples include, but are not limited to, cleavable portions within the linker, such as, for example, a disulfide bond (—S—S—) or an azo bond (—N=N—), which can be cleaved using a reducing agent or photolysis. Non-limiting examples of a selectively cleavable bond include an amide bond, which can be cleaved, for example, by the use of tris(2-carboxyethyl)phosphine (TCEP) or other reducing agents and / or photolysis, as well as an ester bond, which can be cleaved, for example, by acid or base hydrolysis.

[0068] The term mammal means a human or another mammal or means a human being.

[0069] The term “messenger RNA” (mRNA) refers to any polynucleotide that codes for a protein or polypeptide of interest and Petition 870250102289, dated 07 / 11 / 2025, p. 23 / 408 19 / 379 that is capable of being translated to produce the encoded protein or polypeptide of interest in vitro, in vivo, in situ, or ex vivo.

[0070] The term modified refers to an altered state or structure of a disclosure molecule. Molecules can be modified in various ways, including chemically, structurally, and functionally. In one embodiment, the active ingredients of nucleic acids are modified by the introduction of non-natural nucleosides and / or nucleotides, for example, with regard to the natural ribonucleotides A, U, G, and C. Non-canonical nucleotides, such as cap structures, are not considered “modified,” although they may differ from the chemical structure of ribonucleotides A, C, G, U.

[0071] The term “natural occurrence” means existing in nature without artificial help.

[0072] The term “patient” refers to a subject who may seek or require treatment, requires treatment, is receiving treatment, will receive treatment, or a subject who is under the care of a trained professional for a specific disease or condition.

[0073] The phrase “X optionally substituted” (e.g., optionally substituted alkyl) is intended to be equivalent to “X, wherein X is optionally substituted” (e.g., “alkyl, wherein said alkyl is optionally substituted”). that the feature “X” (e.g., alkyl) itself is optional.

[0074] The phrase “pharmaceutically acceptable” is used here to refer to compounds, materials, compositions and / or pharmaceutical forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response or other problem or complication, proportionate to a reasonable benefit / risk ratio.

[0075] The phrase pharmaceutically acceptable excipient, such as Petition 870250102289, dated 07 / 11 / 2025, p. 24 / 408 20 / 379 used herein refers to any ingredient other than the compounds described herein (for example, a vehicle capable of suspending or dissolving the active compound) and having the properties of being substantially non-toxic and non-inflammatory in a patient. Excipients may include, for example: anti-adherents, antioxidants, binders, coatings, compression aids, disintegrants, colorants, emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspending or dispersing agents, sweeteners, and hydration waters.Examples of excipients include, but are not limited to: butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, cross-linked polyvinylpyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methylparaben, microcrystalline cellulose, polyethylene glycol, polyvinylpyrrolidone, povidone, pregelatinized starch, propylparaben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethylcellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.

[0076] The phrase “pharmaceutically acceptable salts” refers to derivatives of the disclosed compounds in which the original compound is modified by converting an existing acid or base moiety into its salt form (e.g., by reacting the free base group with a suitable organic acid). Examples of pharmaceutically acceptable salts include, but are not limited to, salts of mineral or organic acids from basic residues such as amines; alkaline or organic salts from acidic residues such as carboxylic acids; and the like. Representative acid addition salts include acetate, adipate, alginate, Petition 870250102289, dated 07 / 11 / 2025, page 25 / 408 21 / 379 ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, iodide, 2-hydroxyethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate salts and similar substances.Representative salts of alkali or alkaline earth metals include sodium, lithium, potassium, calcium, magnesium and the like, as well as non-toxic ammonium, quaternary ammonium and amine cations, including but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine and the like. Pharmaceutically acceptable salts of this disclosure include conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. Pharmaceutically acceptable salts of this disclosure may be synthesized from the parent compound containing a basic or acidic moiety by conventional chemical methods.Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate acid or base in water or an organic solvent, or a mixture of the two; generally, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418, Pharmaceutical Salts: Properties, Selection and Use, PH Stahl and CG Wermuth (eds.), WileyVCH, 2008, and Berge et al., Journal of Pharmaceutical Science, 66, 1-19. Petition 870250102289, dated 07 / 11 / 2025, p. 26 / 408 22 / 379 (1977), each of which is incorporated herein by reference in full.

[0077] The term “pharmacokinetics” refers to any one or more properties of a molecule or compound as it relates to determining the fate of substances administered to a living organism. Pharmacokinetics is divided into several areas, including extent and rate of absorption, distribution, metabolism, and excretion. This is commonly referred to as ADME where: (A) Absorption is the process of a substance entering the bloodstream; (D) Distribution is the dispersion or dissemination of substances throughout the body fluids and tissues; (M) Metabolism (or Biotransformation) is the irreversible transformation of parent compounds into daughter metabolites; and (E) Excretion (or Elimination) refers to the removal of substances from the body. In rare cases, some drugs accumulate irreversibly in body tissues.

[0078] The term “pharmaceutically acceptable solvate”, as used herein, means a compound of disclosure in which molecules of a suitable solvent are incorporated into the crystal lattice. A suitable solvent is physiologically tolerable at the administered dosage. For example, solvates can be prepared by crystallization, recrystallization or precipitation from a solution that includes organic solvents, water or a mixture thereof. Examples of suitable solvents are ethanol, water (e.g., mono-, di-, and tri-hydrates), N-methylpyrrolidinone (NMP), dimethyl sulfoxide (DMSO), N,N'-dimethylformamide (DMF), N,N-dimethylacetamide (DMAC), 1,3-dimethyl-2-imidazolidinone (DMEU), 1,3-dimethyl-3,4,5,6-tetrahydro-2-(1H)-pyrimidinone (DMPU), acetonitrile (ACN), propylene glycol, ethyl acetate, benzyl alcohol, 2-pyrrolidone, benzyl benzoate, and the like. When water is the solvent, the solvate is referred to as a "hydrate".

[0079] The term “phosphate” is used in its common sense as understood by those skilled in the art and includes its protonated forms, Petition 870250102289, dated 07 / 11 / 2025, page 27 / 408 23 / 379 for example and

[0080] As used herein, the terms monophosphate, diphosphate and triphosphate are used in their common sense as understood by those skilled in the art, and include protonated forms.

[0081] The term “prevent” refers to partially or completely delaying the onset of an infection, disease, disorder and / or condition; partially or completely delaying the onset of one or more symptoms, features or clinical manifestations of a specific infection, disease, disorder and / or condition; partially or completely delaying the onset of one or more symptoms, features or manifestations of a specific infection, disease, disorder and / or condition; partially or completely delaying the progression of a particular infection, disease, disorder and / or condition; and / or reducing the risk of developing pathology associated with the infection, disease, disorder and / or condition.

[0082] The term “RNA” refers to ribonucleic acid and means a molecule comprising at least one ribonucleotide residue. By “ribonucleotide” is meant a nucleotide having a hydroxyl group at the 2' position of a β-D-ribofuranose moiety. The term includes double-stranded RNA, single-stranded RNA, isolated RNA, such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinant RNA, as well as altered RNA that differs from naturally occurring RNA by the addition, deletion, substitution, and / or alteration of one or more nucleotides. Such alterations may include the addition of non-nucleotide material, such as at the end(s) of an interfering RNA or internally, for example, within one or more nucleotides of the RNA. The nucleotides in the RNA molecules of this disclosure may also comprise non-standard nucleotides, such as Petition 870250102289, dated 07 / 11 / 2025, page 28 / 408 24 / 379 as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These altered RNAs may be called analogs or analogues of naturally occurring RNA. As used herein, the terms ribonucleic acid and RNA refer to a molecule containing at least one ribonucleotide residue, including siRNA, antisense RNA, single-stranded RNA, microRNA, mRNA, non-coding RNA, and multivalent RNA.

[0083] The term “sample” or “biological sample” refers to a subset of its tissues, cells, or component parts (e.g., body fluids, including, but not limited to, blood, mucus, lymphatic fluid, synovial fluid, cerebrospinal fluid, saliva, amniotic fluid, amniotic cord blood, urine, vaginal fluid, and semen). A sample may also include a homogenate, lysate, or extract prepared from a whole organism or a subset of its tissues, cells, or component parts, or a fraction or portion thereof, including, but not limited to, for example, plasma, serum, spinal fluid, lymphatic fluid, outer sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, blood cells, tumors, organs. A sample also refers to a medium, such as a nutrient broth or gel, which may contain cellular components, such as proteins or nucleic acid molecules.

[0084] The terms “significant” or “significantly” are used as synonyms for the term “substantially”.

[0085] The phrase “single unit dose” refers to a dose of any therapeutic agent administered in one dose / all at once / single route / single point of contact, i.e., a single administration event.

[0086] The term “siRNA” or small interfering RNA, sometimes known as short interfering RNA or silencing RNA, refers to a class of non-coding double-stranded RNA molecules, typically 18-27 base pairs in length, similar Petition 870250102289, dated 07 / 11 / 2025, page 29 / 408 25 / 379 to miRNA, and operating within the RNA interference (RNAi) pathway. It interferes with the expression of specific genes with complementary nucleotide sequences, degrading mRNA after transcription, thus preventing translation.

[0087] The term “solvate” means a physical association of a compound of this disclosure with one or more solvent molecules. This physical association involves various degrees of ionic bonding, including hydrogen bonds. In certain cases, the solvate will be able to be isolated, for example, when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid. “Solvate” encompasses solution-phase and isolable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like.

[0088] The term “stable” refers to a compound that is robust enough to survive isolation to a useful degree of purity from a reaction mixture and, preferably, capable of being formulated into an effective therapeutic agent.

[0089] The terms “stabilize”, “stabilized”, “stabilized region” mean to make or become stable.

[0090] The term replaced means replacement by specific groups other than hydrogen, or by one or more groups, moieties or radicals that may be the same or different, each one being selected independently, for example.

[0091] The term “substantially” refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. Someone versed in biological techniques will understand that biological and chemical phenomena rarely, if ever, reach a conclusion and / or proceed to a conclusion or achieve or avoid an absolute result. The term “substantially” is therefore used here to capture the potential lack of completeness inherent in many biological and chemical phenomena. Petition 870250102289, dated 07 / 11 / 2025, page 30 / 408 26 / 379

[0092] The phrase “substantially equal” refers to time differences between doses, the term means plus / minus 2%.

[0093] The phrase “substantially simultaneously” refers to the plurality of doses, the term means within 2 seconds.

[0094] The phrase “suffering from” refers to an individual who is “suffering from” a disease, disorder and / or condition that has been diagnosed or exhibits one or more symptoms of a disease, disorder and / or condition.

[0095] The phrase “susceptible to” refers to an individual who is “susceptible to” a disease, disorder and / or condition, has not been diagnosed and / or may not exhibit symptoms of the disease, disorder and / or condition, but harbors a predisposition to developing a disease or its symptoms.In some modalities, an individual who is susceptible to a disease, disorder, and / or condition (e.g., cancer) may be characterized by one or more of the following: (1) a genetic mutation associated with the development of the disease, disorder, and / or condition; (2) a genetic polymorphism associated with the development of the disease, disorder, and / or condition; (3) increased and / or decreased expression and / or activity of a protein and / or nucleic acid associated with the disease, disorder, and / or condition; (4) habits and / or lifestyles associated with the development of the disease, disorder, and / or condition; (5) a family history of the disease, disorder, and / or condition; and (6) exposure to and / or infection by a microbe associated with the development of the disease, disorder, and / or condition. In some modalities, an individual who is susceptible to a disease, disorder, and / or condition will develop the disease, disorder, and / or condition.In some modalities, an individual who is susceptible to a disease, disorder, and / or condition will not develop the disease, disorder, and / or condition.

[0096] The term “synthetic” means produced, prepared and / or manufactured Petition 870250102289, dated 07 / 11 / 2025, p. 31 / 408 27 / 379 made by the hand of man. The synthesis of polynucleotides or polypeptides or other molecules of the present disclosure may be chemical or enzymatic.

[0097] The term therapeutic agent refers to any agent that, when administered to a subject, has a therapeutic, diagnostic and / or prophylactic effect and / or causes a desired biological and / or pharmacological effect.

[0098] The term therapeutically effective amount means an amount of an agent to be administered (e.g., nucleic acid, drug, therapeutic agent, diagnostic agent, prophylactic agent, etc.) that is sufficient, when administered to a subject suffering from or susceptible to an infection, disease, disorder and / or condition, to treat, improve symptoms, diagnose, prevent and / or delay the onset of the infection, disease, disorder and / or condition.

[0099] The term therapeutically effective outcome means an outcome that is sufficient in a subject suffering from or susceptible to an infection, disease, disorder and / or condition, to treat, improve symptoms, diagnose, prevent and / or delay the onset of the infection, disease, disorder and / or condition.

[00100] The term “total daily dose” is an amount given or prescribed over a 24-hour period. It may be administered as a single dose.

[00101] The term treat refers to alleviating, improving, enhancing, relieving, delaying the onset, inhibiting the progression, reducing the severity and / or reducing the incidence of one or more symptoms or particular characteristics of a given infection, disease, disorder, and / or condition, partially or completely. For example, “treating” cancer may refer to inhibiting the survival, growth and / or spread of a tumor. Treatment may be administered to a subject who does not show signs of a disease, disorder and / or condition and / or to a subject Petition 870250102289, dated 07 / 11 / 2025, p. 32 / 408 28 / 379 which presents only early signs of a disease, disorder and / or condition in order to reduce the risk of developing pathology associated with the disease, disorder and / or condition.

[00102] The term “unmodified” refers to any substance, compound, or molecule before it has been altered in any way. Unmodified may, but does not always, refer to the wild type or native form of a biomolecule. Molecules can undergo a series of modifications in which each modified molecule can serve as the initial “unmodified” molecule for a subsequent modification.

[00103] The compounds described herein may be asymmetric (e.g., having one or more stereocenters). All stereoisomers, as well as enantiomers and diastereomers, are intended unless otherwise indicated. The compounds of this disclosure containing asymmetrically substituted carbon atoms may be isolated in optically active or racemic forms. Methods for preparing optically active forms from optically active starting materials are known in the art, such as by resolution of racemic mixtures or by enantioselective and / or stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds and the like may also be present in the compounds described herein, and all such stable isomers are contemplated in this disclosure. c / se trans geometric isomers of the compounds of this disclosure are described and may be isolated as a mixture of isomers or as separate isomeric forms.

[00104] The compounds in this disclosure also include tautomeric forms. Tautomeric forms result from the exchange of a single bond for an adjacent double bond and the concomitant migration of a proton. Tautomeric forms include prototropic tautomers that are isomeric protonation states with the same form. Petition 870250102289, dated 07 / 11 / 2025, p. 33 / 408 29 / 379 empirical mule and total charge. Examples of prototropic tautomers include ketone-enol pairs, amide-imidic acid pairs, lactam-lactim pairs, enamine-imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, such as 1H- and 3H-imidazole, 1H-, 2H- and 4H-1,2,4-triazole, 1H- and 2H-isoindole, and 1H- and 2H-pyrazole. Tautomeric forms may be in equilibrium or sterically blocked in a form by appropriate substitution.

[00105] The compounds in this disclosure also include all isotopes of the atoms that occur in the intermediate or final compounds. “Isotopes” refers to atoms with the same atomic number but different mass numbers, resulting from a different number of neutrons in the nuclei. For example, isotopes of hydrogen include tritium and deuterium.

[00106] The compounds and salts of this disclosure can be prepared in combination with solvent or water molecules to form solvates and hydrates by routine methods.

[00107] The term “half-life” is the time required for a quantity, such as the concentration or activity of a nucleic acid or protein, to fall to half of its value measured at the beginning of a period of time.

[00108] The term “in vitro” refers to events that occur in an artificial environment, for example, in a test tube or reaction vessel, in a cell culture, in a Petri dish, etc., and not within an organism (e.g., animal, plant, or microbe).

[00109] The term “in vivo” refers to events that occur within an organism (e.g., animal, plant, or microbe, or a cell or tissue thereof).

[00110] The term monomer refers to a single unit, for example, a single nucleic acid, that can be joined to another molecule. Petition 870250102289, dated 07 / 11 / 2025, page 34 / 408 30 / 379 of the same type or of a different type to form an oligomer. In some embodiments, a monomer may be an unblocked nucleic acid, that is, a UNA monomer.

[00111] The term neutral lipid means a lipid species that exists in a neutral or uncharged zwitterionic form at a selected pH. At physiological pH, such lipids include, for example, diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, cephalin, cholesterol, cerebrosides, and diacylglycerols.

[00112] The term non-cationic lipid means an amphipathic lipid or a neutral lipid or an anionic lipid and is described herein.

[00113] The terms “subject” or “patient” refer to any organism to which a composition in accordance with the disclosure may be administered, for example, for experimental, diagnostic, prophylactic and / or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates and humans) and / or plants.

[00114] The term “translatable” can be used interchangeably with the term “expressable” and refers to the ability of a polynucleotide, or a portion thereof, to be converted into a polypeptide by a host cell. As understood in the art, translation is the process by which ribosomes in the cytoplasm of a cell create polypeptides. In translation, messenger RNA (mRNA) is decoded by tRNAs in a ribosome complex to produce a specific chain of amino acids, or polypeptide. Furthermore, the term “translatable,” when used in this descriptive report in reference to an oligomer, means that at least a portion of the oligomer, for example, the coding region of an oligomeric sequence (also known as the coding sequence or CDS), is capable of being converted into a protein or a fragment thereof.

[00115] The abbreviations used here are defined as follows Petition 870250102289, dated 07 / 11 / 2025, page 35 / 408 31 / 379 format: “1x” for once, “2x” for twice, “3x” for three times, “°C” for degrees Celsius, “eq” for equivalent or equivalents, “g” for gram or grams, “mg” for milligram or milligrams, “L” for liter or liters, “mL” for milliliter or milliliters, “μL” for microliter or microliters, “N” for normal, “M” for molar, “mmol” for millimole or millimoles, “min” for minute or minutes, “h” for hour or hours, “rt” for room temperature, “RT” for retention time, “RBF” for round-bottom flask, “atm” for atmosphere, “psi” for pounds per square inch, “conc.” for concentrate, “RCM” for ring-closure metathesis, “sat” or “sat'd” for saturated, “SFC” for supercritical fluid chromatography, “MW” for molecular weight, “mp” for melting point, “ee” for enantiomeric excess, “MS” or “Mass Spec” for mass spectrometry, “ESI” for electrospray ionization mass spectrometry, “HR” for high resolution,“HRMS” stands for high-resolution mass spectrometry, “LCMS” for liquid chromatography mass spectrometry, “HPLC” for high-performance liquid chromatography, “RP HPLC” for reversed-phase HPLC, “TLC” or “tlc” for thin-layer chromatography, “NMR” for nuclear magnetic resonance spectroscopy, “nOe” for nuclear Overhauser effect spectroscopy, “1KH” for proton, “δ” for delta, “s” for singlet, “d” for doublet, “t” for triplet, “q” for quartet, “m” for multiplet, “br” for wide, “Hz” for hertz, and “α”, “β”, “R”, “S”, “E”, and “Z” are stereochemical designations familiar to one skilled in the art. Me methyl Ethyl Pr propyl i- Pr isopropyl Bu butyl i- Bu isobutyl t- Bu tert -butyl Ph phenyl Petition 870250102289, dated 07 / 11 / 2025, page 36 / 408 32 / 379 Bn benzyl iodine Boc or BOC tert-butyloxycarbonyl BOC2O di-tert-butyl dicarbonate AcOH or HOAc acetic acid AlCl3 aluminum chloride AIBN aqueous azobisisobutyronitrile BBr3 boron tribromide BCl3 boron trichloride BEMP 2-tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine BOC tert-butyloxycarbonyl reagent BOP benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate Burgess reagent 1-methoxy-N-triethylammoniosulfonyl-methanimidate Cbz carbobenzyloxy DCM or CH2CI2 dichloromethane CH3CN or ACN acetonitrile CDCl3 deuterochloroform CHCI3 chloroform mCPBA or m-CPBA meta-chloroperbenzoic acid CRISPR Clustered regularly spaced short palindromic repeats Cs2CO3 cesium carbonate Cu(OAc)2 copper(II) acetate CuI copper(I) iodide CuSO4 copper(II) sulfate Cy2NMe N-cyclohexyl-N-methylcyclohexanamine DBU 1,8-diazabicyclo[5.4.0]undec-7-ene DCE 1,2-dichloroethane DEA diethylamine Dess-Martin 1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziziodoxol-3-(1H)-one. Petition 870250102289, dated 07 / 11 / 2025, page 37 / 408 33 / 379 DIC or DIPCDI diisopropylcarbodiimide DIEA, DIPEA or Hunig's base DMAP diisopropylethylamine 4-dimethylaminopyridine DME 1,2-dimethoxyethane DMF dimethyl formamide DMSO dimethylsulfoxide cDNA Complementary DNA Dppp (R )-(+)-1,2-bis(diphenylphosphine)propane DuPhos (+)-1,2-bis((2S,5S)-2,5-diethylphospholane)benzene EDC N-(3-dimethylaminopropyl)-N '-ethylcarbodiimide EDCI N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride EDTA ethylenediaminetetraacetic acid (S,S )-EtDuPhosRh(I) (+)-1,2-bis((2S,5S)-2,5-diethylphospholane)benzene (1,5-cyclooctadiene)rhodium(I) trifluoromethanesulfonate Et3N or TEA triethylamine EtOAc ethyl acetate Et2O diethyl ether EtOH ethanol GMF glass microfiber filter Grubbs II (1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(phenylmethylene)(tricyclohexylphosphine)ruthenium HCl hydrochloric acid HATU O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate HEPES 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid Hex hexane HOBT or HOBT 1-hydroxybenzotriazole H2O2 hydrogen peroxide H2SO4 sulfuric acid Petition 870250102289, dated 07 / 11 / 2025, page 38 / 408 34 / 379 IBX 2-Iodoxybenzoic acid InCl3 Indium(III) chloride Jones reagent CrO3 in aqueous H2SO4, 2 M K2CO3 potassium carbonate K2HPO4 dibasic potassium phosphate K3PO4 tribasic potassium phosphate KOAc potassium acetate K3PO4 potassium phosphate LAH lithium aluminum hydride LG leaving group LiOH lithium hydroxide MeOH methanol MgSO4 magnesium sulfate MsOH or MSA methylsulfonic acid NaCl sodium chloride NaH sodium hydride NaHCO3 sodium bicarbonate Na2CO3 sodium carbonate NaOH sodium hydroxide Na2SO3 sodium sulfite Na2SO4 sodium sulfate NBS N-bromosuccinimide NCS N-chlorosuccinimide NH3 ammonia NH4Cl ammonium chloride NH4OH ammonium hydroxide NH4COOH ammonium formate NMM N-methylmorpholine OTf triflate or trifluoromethanesulfonate PEG polyethylene glycol Pd2(dba)3 tris(dibenzylideneacetone)dipalladium(O) Pd(OAc)2 palladium(II) acetate Pd / C palladium on carbon Petition 870250102289, dated 07 / 11 / 2025, page 39 / 408 35 / 379 Pd(dppf)Cl2 [1,1'-bis(diphenylphosphine)-ferrocene]dichloropalladium(II) Ph3PCl2 triphenylphosphine dichloride PG protecting group POCl3 phosphorus oxychloride i-PrOH or IPA isopropanol PS Polystyrene room temperature SEM-Cl 2-(trimethylsilyl)ethoxymethyl chloride SiO2 silica oxide SnCl2 tin(II) chloride TALEN Effector nucleases similar to transcription activators TBAI tetra-n-butylammonium iodide TBN t-butyl nitrite TFA trifluoroacetic acid THF tetrahydrofuran TMSCHN2 trimethylsilyldiazomethane T3P® phosphonic acid anhydride propane TRIS aminomethane tris(hydroxymethyl) pTsOH p-toluenesulfonic acid

[00116]

[0001] Although this disclosure has been described in relation to certain embodiments, and many details have been presented for illustrative purposes, it will be evident to those skilled in the art that this disclosure includes additional embodiments, and that some of the details described herein can be varied considerably without departing from this disclosure. This disclosure includes such additional embodiments, modifications and equivalents. In particular, this disclosure includes any combination of the features, terms or elements of the various components and illustrative examples. I. COMPOUNDS

[00117] In some embodiments, the present disclosure provides a compound of Formula I or a pharmaceutically acceptable salt of Petition 870250102289, dated 07 / 11 / 2025, pp. 40 / 408 36 / 379 same: (I) where:

[00118] R1 and R2 are each independently H or C1-6 alkyl; or

[00119] R1 and R2 are joined to form a saturated heterocyclic ring, where:

[00120] R1 is a linear C1-4 alkylene; and

[00121] R2é-(CH2)m(X)n-, where

[00122] X is O, S or NR9, where R9 is H or C1-6 alkyl;

[00123] m is 1, 2, 3 or 4, and

[00124] n is 0 or 1;

[00125] L1 is a linear C1-6 alkylene optionally substituted with one to three methyl groups;

[00126] Y is selected from the group consisting of: O0 0O O o I, TVW and UWV where:

[00127] each asterisk (*) indicates the atom bonded to L2 and L3; and Petition 870250102289, dated 07 / 11 / 2025, p. 41 / 408 37 / 379

[00128] R10 is H or C1-6 alkyl;

[00129] L2 and L3 are each independently a linear C1-8 alkylene;

[00130] L4, L5, L6, L7, L8 and L9 are each independently absent or -CH2-, provided that:

[00131] at least two of L4, L6 and L8 are-CH2-; and

[00132] at least two of L5, L7 and L9 are-CH2-;

[00133] R3e R4são cada um independente, methyl or ethyl; and

[00134] R5, R6, R7 and R8 are selected independently of the group consisting of:

[00135] C1-20 linear alkyl, wherein each said C1-20 linear alkyl is optionally substituted

[00136] with one or more substituents selected from the group consisting of:

[00137] C6-10 aryl, where each C6-10 aryl is a monocyclic or bicyclic aromatic hydrocarbon optionally substituted by one or more C6-10 aryl groups that are optionally substituted by one or more C1-6 alkyl groups;

[00138] 6- to 10-membered heteroaryl, wherein each 6- to 10-membered heteroaryl is a monocyclic or bicyclic aromatic system optionally substituted with one or more C1-6 alkyl groups;

[00139] C6-10 aryl, where each C6-10 aryl is a monocyclic or bicyclic aromatic hydrocarbon optionally substituted with one or more C6-10 aryl groups that are optionally substituted with one or more C1-6 alkyl groups; and

[00140] 6- to 10-membered heteroaryl, wherein each 6- to 10-membered heteroaryl is a monocyclic or bicyclic aromatic system optionally substituted with one or more C1-6 alkyl groups.

[00141] In some embodiments, R1 is H or C1-6 alkyl and R2 is C1-6 Petition 870250102289, dated 07 / 11 / 2025, p. 42 / 408 38 / 379 alkyl; or R1 and R2 are joined to form said saturated heterocyclic ring. In some embodiments, R1 is H or C1-6 alkyl and R2 is C1-6 alkyl. In some embodiments, R1 and R2 are joined to form said saturated heterocyclic ring.

[00142] In some modalities, Y is selected from the group consisting of: ΛNΝΑδΛ and 4. _SA, 1'1 1 λλ / 1'W' 'W' .

[00143] In some modalities, Y is: the

[00144] In some modalities, Y is: the

[00145] In some modalities, Y is:

[00146] In some modes, at least one of R1 and R2 is H; L1 is -CH2- or -CH2CH2-.

[00147] In some embodiments, R1 and R2 are each independently C1-6 alkyl.

[00148] In some embodiments, R1 and R2 are each independently C1-3 alkyl.

[00149] In some forms, R1 and R2 are each methyl.

[00150] In some modes, R1 and R2 are joined to form the Petition 870250102289, dated 07 / 11 / 2025, p. 43 / 408 39 / 379 referred to as the heterocyclic ring. In some embodiments, the heterocyclic ring is selected from the group consisting of: and where each asterisk (*) indicates the atom bonded to L1.

[00151] In some embodiments, the heterocyclic ring is selected from the group consisting of: and

[00152] In some embodiments, the heterocyclic ring is selected from the group consisting of:

[00153] In some embodiments, the heterocyclic ring is:

[00154] In some embodiments, the heterocyclic ring is:

[00155] In some embodiments, the heterocyclic ring is: Petition 870250102289, dated 07 / 11 / 2025, page 44 / 408 40 / 379 * / \ — NO

[00156] In some embodiments, the heterocyclic ring is: s * fN S

[00157] In some embodiments, the heterocyclic ring is:

[00158] In some embodiments, the heterocyclic ring is: s * / 1 ? NJ

[00159] In some embodiments, the heterocyclic ring is: ς * / ***** θ S Μ I

[00160] In some embodiments, the heterocyclic ring is: c * S

[00161] In some embodiments, the heterocyclic ring is: s / 'NR9

[00162] In some embodiments, the heterocyclic ring is:

[00163] In some embodiments, the heterocyclic ring is: * / \ — NO Petition 870250102289, dated 07 / 11 / 2025, page 45 / 408 41 / 379

[00164] In some embodiments, the heterocyclic ring is:

[00165] In some embodiments, the heterocyclic ring is:

[00166] In some embodiments, R5, R6, R7 and R8 are each independently linear C1-8 alkyl groups, wherein each of said linear C1-8 alkyl groups is optionally substituted by one or more substituents selected from:

[00167] Ce-10 aryl, wherein each Ce-10 aryl is a monocyclic or bicyclic aromatic hydrocarbon optionally substituted with one or more C6-10 aryl groups that is optionally substituted with one or more C1-6 alkyl groups; and

[00168] 6- to 10-membered heteroaryl, wherein each 6- to 10-membered heteroaryl is a monocyclic or bicyclic aromatic system optionally substituted with one or more C1-6 alkyl groups. In some embodiments, R5, R6, R7, and R8 are each independently linear C1-8 alkyl groups. In some embodiments, each linear C1-8 alkyl group is substituted with one or more substituents selected from: C6-10 aryl groups, wherein each C6-10 aryl group is a monocyclic or bicyclic aromatic hydrocarbon optionally substituted with one or more C6-10 aryl groups that is optionally substituted with one or more C1-6 alkyl groups; and 6- to 10-membered heteroaryl groups, wherein each 6- to 10-membered heteroaryl group is a monocyclic or bicyclic aromatic system optionally substituted with one or more C1-6 alkyl groups.

[00169] In some embodiments, R5, R6, R7 and R8 are each independently Ce-10 arils, where each of said Ce-10 arils is a Petition 870250102289, dated 07 / 11 / 2025, p. 46 / 408 42 / 379 monocyclic or bicyclic aromatic hydrocarbon. In some embodiments, each referred C6-10 aryl is a monocyclic or bicyclic aromatic hydrocarbon optionally substituted by one or more C6-10 aryl groups that are optionally substituted by one or more C1-6 alkyl groups. In some embodiments, each referred C6-10 aryl is a monocyclic aromatic hydrocarbon optionally substituted by one or more C6-10 aryl groups that are optionally substituted by one or more C1-6 alkyl groups. In some embodiments, each referred C6-10 aryl is a bicyclic aromatic hydrocarbon optionally substituted by one or more C6-10 aryl groups that are optionally substituted by one or more C1-6 alkyl groups.

[00170] In some embodiments, R5, R6, R7 and R8 are each independently a 6- to 10-membered heteroaryl, wherein each of the 6- to 10-membered heteroaryls is a monocyclic or bicyclic aromatic system optionally substituted with one or more C1-6 alkyl groups.

[00171] In some modes, R5 and R6 are the same.

[00172] In some modes, R7 and R8 are the same.

[00173] In some embodiments, L1 is unsubstituted linear alkylene.

[00174] In some embodiments, L1 is propylene.

[00175] In some embodiments, L2 and L3 are each independently linear C1-5 alkylenes.

[00176] In some modes, L2 and L3 are the same.

[00177] In some modes, L4 and L5 are the same.

[00178] In some modes, L6 and L7 are the same.

[00179] In some modes, L8 and L9 are the same.

[00180] In some modes, L4, L5, L6, L7, L8 and L9 are each -CH2-.

[00181] In some embodiments, L6, L7, L8 and L9 are each CH2-; and L4 and L5 are absent.

[00182] In some modalities, L4, L5, L8 and L9 are each Petition 870250102289, dated 07 / 11 / 2025, p. 47 / 408 43 / 379 CH2-; and L6 and L7 are absent.

[00183] In some embodiments, L4, L5, L6 and L7 are each CH2-; and L8 and L9 are absent.

[00184] In some embodiments, R3 and R4 are each independently H or methyl. In some embodiments, R3 and R4 are each H. In some embodiments, R3 and R4 are each methyl.

[00185] In some embodiments, the compound is selected from the group consisting of: Lipid 42 Lipid 43, and Lipid 45; or pharmaceutically acceptable salts thereof. In some embodiments, the compound is Lipid 42 or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Lipid 44 or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Lipid 45 or a pharmaceutically acceptable salt thereof.

[00186] In some embodiments, the present disclosure provides a compound selected from the group consisting of: Petition 870250102289, dated 07 / 11 / 2025, pages 48 / 408 44 / 379 Lipid 44 Lipid 47 Lipid 46 Lipid 49 Lipid 48 Lipid 51 Lipid 50 Petition 870250102289, dated 07 / 11 / 2025, pp. 49 / 408 45 / 379 Lipid 54 o Lipid 57 Lipid 56 Petition 870250102289, dated 07 / 11 / 2025, page 50 / 408 46 / 379 , Lipid 59 Lipid 60 Lipid 61 Lipid 63; or pharmaceutically acceptable salts thereof. In some embodiments, the compound is Lipid 44 or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Lipid 46 or a salt thereof. Petition 870250102289, dated 07 / 11 / 2025, p. 51 / 408 47 / 379 pharmaceutically acceptable thereof. In some embodiments, the compound is Lipid 47 or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Lipid 48 or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Lipid 49 or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Lipid 50 or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Lipid 51 or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Lipid 52 or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Lipid 53 or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Lipid 54 or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Lipid 55 or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Lipid 56 or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is Lipid 57 or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Lipid 58 or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Lipid 59 or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Lipid 60 or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Lipid 61 or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Lipid 62 or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is Lipid 63 or a pharmaceutically acceptable salt thereof.

[00187] In some embodiments, the present disclosure provides a lipid composition comprising a nucleic acid and a compound of the present disclosure. In some embodiments, the nucleic acid is selected from an siRNA, an mRNA, a self-replicating RNA, a DNA plasmid, and an antisense oligonucleotide. In Petition 870250102289, dated 07 / 11 / 2025, p. 52 / 408 48 / 379 In some embodiments, the nucleic acid is an siRNA. In some embodiments, the nucleic acid is an mRNA. In some embodiments, the nucleic acid is a self-replicating RNA. In some embodiments, the nucleic acid is a DNA plasmid. In some embodiments, the nucleic acid is an antisense oligonucleotide.

[00188] In some embodiments, the nucleic acid is a self-replicating mRNA or RNA comprising a coding region that encodes a therapeutic protein of interest. In some embodiments, the nucleic acid is an mRNA comprising a coding region that encodes a therapeutic protein of interest. In some embodiments, the nucleic acid is a self-replicating RNA comprising a coding region that encodes a therapeutic protein of interest. In some embodiments, the therapeutic protein of interest is an enzyme, an antibody, an antigen, a receptor, or a transporter. In some embodiments, the therapeutic protein of interest is an enzyme. In some embodiments, the therapeutic protein of interest is an antibody. In some embodiments, the therapeutic protein of interest is an antigen. In some embodiments, the therapeutic protein of interest is a receptor. In some embodiments, the therapeutic protein of interest is a transporter.In some embodiments, the therapeutic protein of interest is a gene-editing enzyme. In some embodiments, the gene-editing enzyme is selected from a TALEN, a CRISPR, a meganuclease, or a zinc finger nuclease. In some embodiments, the gene-editing enzyme is a TALEN. In some embodiments, the gene-editing enzyme is a CRISPR. In some embodiments, the gene-editing enzyme is a meganuclease. In some embodiments, the gene-editing enzyme is a zinc finger nuclease.

[00189] In some embodiments, the lipid composition comprises liposomes, lipoplexes, or lipid nanoparticles. In some Petition 870250102289, dated 07 / 11 / 2025, page 53 / 408 In 49 / 379 embodiments, the lipid composition comprises liposomes. In some embodiments, the lipid composition comprises lipoplexes. In some embodiments, the lipid composition comprises lipid nanoparticles.

[00190] In some embodiments, the present disclosure provides a lipid nanoparticle comprising a plurality of ligands, wherein each ligand is independently a compound of the present disclosure. In some embodiments, the plurality of ligands self-organizes to form the lipid nanoparticle comprising an interior and an exterior.

[00191] In some embodiments, the average particle size of the lipid nanoparticle is less than about 100 nm. In some embodiments, the average particle size of the lipid nanoparticle is from about 55 nm to about 85 nm.

[00192] In some embodiments, the lipid nanoparticle further comprises an encapsulated nucleic acid. In some embodiments, the nucleic acid is selected from an siRNA, an mRNA, a self-replicating RNA, a DNA plasmid, and an antisense oligonucleotide. In some embodiments, the nucleic acid is an mRNA or a self-replicating RNA comprising a coding region that encodes a therapeutic protein of interest. In some embodiments, the nucleic acid is an siRNA. In some embodiments, the nucleic acid is an mRNA. In some embodiments, the nucleic acid is a self-replicating RNA. In some embodiments, the nucleic acid is a DNA plasmid. In some embodiments, the nucleic acid is an antisense oligonucleotide. In some embodiments, the nucleic acid is an mRNA comprising a coding region that encodes a therapeutic protein of interest. In some embodiments, the nucleic acid is a self-replicating RNA comprising a region Petition 870250102289, dated 07 / 11 / 2025, p. 54 / 408 50 / 379 encoding a therapeutic protein of interest. In some embodiments, the therapeutic protein of interest is an enzyme, an antibody, an antigen, a receptor, or a transporter. In some embodiments, the therapeutic protein of interest is an enzyme. In some embodiments, the therapeutic protein of interest is an antibody. In some embodiments, the therapeutic protein of interest is an antigen. In some embodiments, the therapeutic protein of interest is a receptor. In some embodiments, the therapeutic protein of interest is a transporter. In some embodiments, the therapeutic protein of interest is a gene-editing enzyme. In some embodiments, the gene-editing enzyme is selected from a TALEN, a CRISPR, a meganuclease, or a zinc finger nuclease. In some embodiments, the gene-editing enzyme is a TALEN. In some embodiments, the gene-editing enzyme is a CRISPR.In some embodiments, the gene-editing enzyme is a meganuclease. In some embodiments, the gene-editing enzyme is a zinc finger nuclease.

[00193] In some embodiments, the lipid nanoparticle further comprises an auxiliary lipid selected from: dileoylphosphatidyl ethanolamine (DOPE), dimyristoylphosphatidylcholine (DMPC), distearolylphosphatidylcholine (DSPC), dimyristoylphosphatidyl glycerol (DMPG), dipalmitoyl phosphatidylcholine (DPPC), and phosphatidylcholine (PC). In some embodiments, the auxiliary lipid is DOPE. In some embodiments, the auxiliary lipid is DMPC. In some embodiments, the auxiliary lipid is DSPC. In some embodiments, the auxiliary lipid is DMPG. In some embodiments, the auxiliary lipid is DPPC. In some embodiments, the auxiliary lipid is PC.

[00194] In some embodiments, the lipid nanoparticle also includes cholesterol.

[00195] In some embodiments, the lipid nanoparticle further comprises a polyethylene glycol (PEG)-lipid conjugate. In some Petition 870250102289, dated 07 / 11 / 2025, p. 55 / 408 In 51 / 379 modalities, the PEG-lipid conjugate is PEG-DMG. In some modalities, PEG-DMG is PEG2000-DMG.

[00196] In some embodiments, the lipid nanoparticle comprises about 45 molar percent to 65 molar percent of a compound of the present disclosure, about 2 molar percent to about 15 molar percent of an auxiliary lipid, about 20 molar percent to about 42 molar percent of cholesterol, and about 0.5 molar percent to about 3 molar percent of a PEG-lipid conjugate.

[00197] In some embodiments, the lipid nanoparticle comprises about 50 molar percent to about 61 molar percent of a compound of the present disclosure, about 5 molar percent to about 9 molar percent of the auxiliary lipid, about 29 molar percent to about 38 molar percent of cholesterol and about 1 molar percent to about 2 molar percent of the PEG-lipid conjugate.

[00198] In some embodiments, the lipid nanoparticle comprises about 56 molar percent to about 58 molar percent of a compound of the present disclosure, about 6 molar percent to about 8 molar percent of DSPC, about 31 molar percent to about 34 molar percent of cholesterol, and about 1.25 molar percent to about 1.75 molar percent of the PEG-lipid conjugate.

[00199] In some embodiments, the lipid nanoparticle has a total lipid:nucleic acid weight ratio of about 50:1 to about 10:1. In some embodiments, the lipid nanoparticle has a total lipid:nucleic acid ratio of about 40:1 to about 20:1. In some embodiments, the lipid nanoparticle has a total lipid:nucleic acid ratio of about 35:1 to about 25:1. In some embodiments, the lipid nanoparticle has a total lipid:nucleic acid ratio of about 32:1 to about 28:1. In some embodiments, the lipid nanoparticle has a total lipid:nucleic acid weight ratio of about 31:1 to about 29:1.

[00200] In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound of the present disclosure or a lipid nanoparticle of the present disclosure, Petition 870250102289, dated 07 / 11 / 2025, p. 56 / 408 52 / 379 and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition is a lyophilized composition. In some embodiments, the pharmaceutical composition comprises a HEPES buffer at a pH of about 7.4. In some embodiments, the HEPES buffer is at a concentration of about 7 mg / mL to about 15 mg / mL. In some embodiments, the pharmaceutical composition further comprises about 2.0 mg / mL to about 4.0 mg / mL of NaCl. In some embodiments, the pharmaceutical composition further comprises one or more cryoprotectants. In some embodiments, one or more cryoprotectants are selected from sucrose, glycerol, or a combination of sucrose and glycerol. In some embodiments, one or more cryoprotectants is sucrose. In some embodiments, one or more cryoprotectants is glycerol. In some embodiments, one or more cryoprotectants are a combination of sucrose and glycerol.In some embodiments, the pharmaceutical composition comprises a combination of sucrose at a concentration of about 70 mg / mL to about 110 mg / mL and glycerol at a concentration of about 50 mg / mL to about 70 mg / mL. II. Lipid Formulations and Nanoparticles Lipid-Based Formulations

[00201] Therapies based on the intracellular delivery of nucleic acids to target cells face extracellular and intracellular barriers. In fact, nucleic acid materials cannot be easily administered systemically due to their toxicity, low serum stability, rapid renal clearance, reduced uptake by target cells, phagocyte uptake, and their ability to activate the immune response—all characteristics that hinder their clinical development. When exogenous nucleic acid material (e.g., mRNA) enters the human biological system, it is recognized by the reticuloendothelial system (RES) as a foreign pathogen and eliminated from the bloodstream before it has a chance to encounter target cells. Petition 870250102289, dated 07 / 11 / 2025, page 57 / 408 53 / 379 inside or outside the vascular system. The half-life of naked nucleic acid in the bloodstream has been reported to be several minutes (Kawabata K, Takakura Y, Hashida M Pharm Res. 1995 Jun; 12(6):82530). Chemical modification and a suitable delivery method can reduce uptake by the RES and protect nucleic acids from degradation by ubiquitous nucleases, increasing the stability and efficacy of nucleic acid-based therapies. Furthermore, RNAs or DNAs are anionic hydrophilic polymers that are not favorable for uptake by cells, which are also anionic on their surface. The success of nucleic acid-based therapies therefore largely depends on the development of vehicles or vectors that can efficiently and effectively deliver genetic material to target cells and achieve sufficient levels of expression in vivo with minimal toxicity.

[00202] Furthermore, after internalization into a target cell, nucleic acid delivery vectors are challenged by intracellular barriers, including endosome trapping, lysosomal degradation, nucleic acid decoupling from vectors, translocation across the nuclear membrane (for DNA), and release into the cytoplasm (for RNA). Successful nucleic acid-based therapy thus depends on the vector's ability to deliver nucleic acids to target sites within cells in order to achieve sufficient levels of a desired activity, such as gene expression.

[00203] While several gene therapies have been able to successfully utilize a viral delivery vector (e.g., AAV), lipid-based formulations have been increasingly recognized as one of the most promising delivery systems for RNA and other nucleic acid compounds due to their biocompatibility and ease of large-scale production.One of the most significant advances in lipid-based nucleic acid therapies occurred in... Petition 870250102289, dated 07 / 11 / 2025, p. 58 / 408 54 / 379 August 2018, when Patisiran (ALN-TTR02) was the first therapeutic siRNA approved by the Food and Drug Administration (FDA) and the European Commission (EC). ALN-TTR02 is an siRNA formulation based on the so-called stable nucleic acid lipid particle transfection (SNALP) technology. Despite the success of Patisiran, the delivery of nucleic acid therapeutics, including mRNA, through lipid formulations is still under development. The use of mRNA in lipid delivery vehicles rapidly gained prominence as a result of the COVID-19 pandemic, with several vaccines delivering mRNA encoding the COVID-19 spike protein showing strong protective capabilities. These lipid-based mRNA vaccines include Pfizer and BioNTech's BNT162b2 and Moderna's mRNA-1273, which received emergency use authorization worldwide.

[00204] Some lipid-based delivery vehicles recognized in the art for nucleic acid therapeutics include, according to various embodiments, polymer-based carriers such as polyethyleneimine (PEI), lipid nanoparticles and liposomes, nanoliposomes, ceramide-containing nanoliposomes, multivesicular liposomes, proteoliposomes, both natural and synthetically derived exosomes, natural, synthetic and semi-synthetic lamellar bodies, nanoparticles, micelles and emulsions. These lipid formulations may vary in their structure and composition and, as may be expected in a rapidly evolving field, several different terms have been used in the art to describe a single type of delivery vehicle.At the same time, the terms for lipid formulations have varied in their intended meaning throughout the scientific literature, and this inconsistent usage has caused confusion as to the exact meaning of various terms for lipid formulations. Among the various potential lipid formulations, liposomes, cationic liposomes, and lipid nanoparticles are specifically described in detail. Petition 870250102289, dated 07 / 11 / 2025, page 59 / 408 55 / 379 defined in this document for the purposes of this disclosure. Liposomes

[00205] Conventional liposomes are vesicles consisting of at least one bilayer and an internal aqueous compartment. Liposome bilayer membranes are typically formed from amphiphilic molecules, such as lipids of synthetic or natural origin comprising spatially separated hydrophilic and hydrophobic domains (Lasic, Trends Biotechnol., 16: 307-321, 1998). Liposome bilayer membranes can also be formed from amphiphilic polymers and surfactants (e.g., polymerosomes, niosomes, etc.). They generally present as spherical vesicles and can vary in size from 20 nm to a few microns. Liposomal formulations can be prepared as a colloidal dispersion or can be lyophilized to reduce stability risks and improve the shelf life of liposome-based drugs. The methods for preparing liposomal compositions are known in the art and are within the skill of one skilled in the art.

[00206] Liposomes that have only one bilayer are called unilamellar, and those that have more than one bilayer are called multilamellar. The most common types of liposomes are small unilamellar vesicles (SUV), large unilamellar vesicles (LUV), and multilamellar vesicles (MLV). In contrast to liposomes, lysosomes, micelles, and inverted micelles are composed of lipid monolayers. Generally, a liposome is considered to have a single interior compartment; however, some formulations may be multivesicular liposomes (MVL), which consist of numerous discontinuous internal aqueous compartments separated by several non-concentric lipid bilayers.

[00207] Liposomes have long been recognized as drug delivery vehicles due to their biocompatibility. Petition 870250102289, dated 07 / 11 / 2025, page 60 / 408 56 / 379 superior, given that liposomes are basically analogs of biological membranes and can be prepared from natural and synthetic phospholipids (Int. J. Nanomedicine. 2014; 9:1833-1843). In their use as drug delivery vehicles, because a liposome has an aqueous solution core surrounded by a hydrophobic membrane, hydrophilic solutes dissolved in the core cannot easily pass through the bilayer, and hydrophobic compounds will associate with the bilayer. Thus, a liposome can be loaded with hydrophobic and / or hydrophilic molecules. When a liposome is used to transport a nucleic acid such as RNA, the nucleic acid is contained within the liposomal compartment in an aqueous phase. Cationic Liposomes

[00208] Liposomes can be composed of cationic, anionic, and / or neutral lipids. As an important subclass of liposomes, cationic liposomes are liposomes that are made wholly or partly of positively charged lipids, or more specifically of a lipid comprising both a cationic group and a lipophilic moiety. In addition to the general characteristics described above for liposomes, the positively charged moieties of cationic lipids used in cationic liposomes provide several advantages and some unique structural features. For example, the lipophilic moiety of the cationic lipid is hydrophobic and therefore will move away from the aqueous interior of the liposome and associate with other non-polar and hydrophobic species. Conversely, the cationic moiety will associate with aqueous media and, more importantly, with polar molecules and species with which it can complex within the aqueous environment of the cationic liposome.For these reasons, cationic liposomes are being increasingly researched for use in gene therapy due to their preference for negatively charged nucleic acids through electrostatic interactions. Petition 870250102289, dated 07 / 11 / 2025, page 61 / 408 57 / 379 resulting in complexes that offer biocompatibility, low toxicity, and the possibility of large-scale production necessary for vivo clinical applications. Suitable cationic lipids for use in cationic liposomes are listed below. Lipid nanoparticles

[00209] In contrast to liposomes and cationic liposomes, lipid nanoparticles (LNPs) have a structure that includes a single monolayer or bilayer of lipids encapsulating a compound in a solid phase. Thus, unlike liposomes, lipid nanoparticles do not have an aqueous or other liquid phase inside, but rather the lipids of the bilayer or monolayer shell are directly complexed to the internal compound, thus encapsulating it in a solid core. Lipid nanoparticles are typically spherical vesicles with a relatively uniform dispersion of shape and size. Although sources vary as to the size that qualifies a lipid particle as a nanoparticle, there is some overlap in agreement that a lipid nanoparticle can have a diameter in the range of 10 nm to 1000 nm. However, they are more commonly considered to be smaller than 120 nm or even 100 nm.

[00210] For lipid nanoparticle nucleic acid delivery systems, the lipid shell can be formulated to include an ionizable cationic lipid that can complex and associate with the negatively charged backbone of the nucleic acid core. Ionizable cationic lipids with apparent pKa values ​​below about 7 have the benefit of providing a cationic lipid to complex with the negatively charged backbone of the nucleic acid and charge onto the lipid nanoparticle at pH values ​​below the pKa of the ionizable lipid where it is positively charged. Then, at physiological pH values, the lipid nanoparticle can adopt a relatively neutral exterior, allowing Petition 870250102289, dated 07 / 11 / 2025, page 62 / 408 58 / 379 showing a significant increase in the circulating half-lives of particles after IV administration. In the context of nucleic acid delivery, lipid nanoparticles offer many advantages over other lipid-based nucleic acid delivery systems, including high nucleic acid encapsulation efficiency, potent transfection, better tissue penetration for therapeutic product delivery, and low levels of cytotoxicity and immunogenicity.

[00211] Prior to the development of lipid nanoparticle delivery systems for nucleic acids, cationic lipids were extensively studied as synthetic materials for nucleic acid drug delivery. In these early efforts, after mixing at physiological pH, nucleic acids were condensed by cationic lipids to form lipid-nucleic acid complexes known as lipoplexes. However, lipoplexes proved unstable and characterized by wide size distributions, ranging from the submicrometer scale to a few microns. Lipoplexes, such as the LIPOFECTAMINE® reagent, found considerable utility for in vitro transfection. However, these first-generation lipoplexes did not prove useful in vivo. The large particle size and positive charge (transmitted by the cationic lipid) result in rapid plasma clearance, hemolytic toxicity, and other adverse effects, as well as activation of the immune system.

[00212] In some embodiments, the lipid nanoparticle comprises a lipid of Formula I: (I) where: Petition 870250102289, dated 07 / 11 / 2025, p. 63 / 408 59 / 379

[00213] R1 and R2 are each independently H or C1-6 alkyl; or

[00214] R1 and R2 are joined to form a saturated heterocyclic ring, where:

[00215] R1 is a linear C1-4 alkylene; and

[00216] R2é-(CH2)m(X)n-, where

[00217] X is O, S or NR9, where R9 is H or C1-6 alkyl;

[00218] m is 1, 2, 3 or 4, and

[00219] n is 0 or 1;

[00220] L1 is a linear C1-6 alkylene optionally substituted with one to three methyl groups;

[00221] Y is selected from the group consisting of: uv\ , ΛΛΛ and ww where:

[00222] each asterisk (*) indicates the atom bonded to L2 and L3; and

[00223] R10 is H or C1-6 alkyl;

[00224] L2 and L3 are each independently a linear C1-8 alkylene;

[00225] L4, L5, L6, L7, L8 and L9 are each independently absent or -CH2-, provided that:

[00226] at least two of L4, L6 and L8 are-CH2-; and

[00227] at least two of L5, L7 and L9 are-CH2-;

[00228] R3e R4são cada um independente, methyl or ethyl; Petition 870250102289, dated 07 / 11 / 2025, p. 64 / 408 60 / 379

[00229] R5, R6, R7 and R8 are selected independently of the group consisting of:

[00230] C1-20 linear alkyl, wherein each said C1-20 linear alkyl is optionally substituted

[00231] with one or more substituents selected from the group consisting of:

[00232] C6-10 aryl, where each C6-10 aryl is a monocyclic or bicyclic aromatic hydrocarbon optionally substituted by one or more C6-10 aryl groups that are optionally substituted by one or more C1-6 alkyl groups;

[00233] 6- to 10-membered heteroaryl, wherein each 6- to 10-membered heteroaryl is a monocyclic or bicyclic aromatic system optionally substituted with one or more C1-6 alkyl groups;

[00234] C6-10 aryl, where each C6-10 aryl is a monocyclic or bicyclic aromatic hydrocarbon optionally substituted by one or more C6-10 aryl groups that are optionally substituted by one or more C1-6 alkyl groups; and

[00235] 6- to 10-membered heteroaryl, wherein each 6- to 10-membered heteroaryl is a monocyclic or bicyclic aromatic system optionally substituted with one or more C1-6 alkyl groups.

[00236] In some embodiments, any one or more of the lipids mentioned here may be expressly excluded.

[00237] In some embodiments, the present disclosure provides a lipid nanoparticle comprising a plurality of ligands, wherein each ligand is independently a compound described herein, wherein the plurality of ligands self-assembles to form the lipid nanoparticle comprising an interior and an exterior.

[00238] In some embodiments, the average size of the lipid nanoparticle is about 100 nm. In some embodiments, the average size of the lipid nanoparticle is less than about 100 nm. In Petition 870250102289, dated 07 / 11 / 2025, p. 65 / 408 61 / 379 In some embodiments, the average particle size of the lipid nanoparticle is from about 40 nm to about 100 nm. In some embodiments, the average particle size of the lipid nanoparticle is from about 50 nm to about 90 nm. In some embodiments, the average particle size of the lipid nanoparticle is from about 55 nm to about 85 nm.

[00239] In some embodiments, the lipid nanoparticle further comprises nucleic acids within. In some embodiments, the nucleic acid is selected from an siRNA, an mRNA, a self-replicating RNA, a DNA plasmid, and an antisense oligonucleotide. In some embodiments, the nucleic acid is an mRNA or a self-replicating RNA comprising a coding region that encodes a therapeutic protein of interest. In some embodiments, the therapeutic protein of interest is an enzyme and an antibody, an antigen, a receptor, or a transporter. In some embodiments, the therapeutic protein of interest is a gene-editing enzyme. In some embodiments, the gene-editing enzyme is selected from a TALEN, a CRISPR, a meganuclease, or a zinc finger nuclease.

[00240] In some embodiments, the lipid nanoparticle also comprises siRNA or mRNA inside. In some embodiments, the lipid nanoparticle also comprises mRNA inside.

[00241] In some embodiments, the lipid nanoparticle further comprises an auxiliary lipid as described below. In some embodiments, the lipid nanoparticle further comprises PEG-lipid conjugates as described in this document.

[00242] In some embodiments, the lipid nanoparticle comprises about 45 mol% to 65 mol% of the compound of the present disclosure, about 2 mol% to about 15 mol% of an auxiliary lipid, about 20 mol% to about 42 mol% of cholesterol, and Petition 870250102289, dated 07 / 11 / 2025, page 66 / 408 62 / 379 approximately 0.5 mol% to approximately 3 mol% of a PEG-lipid conjugate. In some embodiments, the lipid nanoparticle comprises approximately 50 mol% to approximately 61 mol% of the compound of the present disclosure, approximately 5 mol% to approximately 9 mol% of the auxiliary lipid, approximately 29 mol% to approximately 38 mol% of cholesterol, and approximately 1 mol% to approximately 2 mol% of the PEG-lipid conjugate. In some embodiments, the lipid nanoparticle comprises about 56 mol% to about 58 mol% of the compound of the present disclosure, about 6 mol% to about 8 mol% of DSPC, about 31 mol% to about 34 mol% of cholesterol, and about 1.25 mol% to about 1.75 mol% of the PEG-lipid conjugate.

[00243] In some embodiments, the lipid nanoparticle comprises about 50 mol% to 61 mol% of the compound of the present disclosure, about 2 mol% to about 12 mol% of DSPC, about 25 mol% to about 42 mol% of cholesterol, and about 0.5 mol% to about 3 mol% of PEG2000-DMG. In some embodiments, the lipid nanoparticle comprises about 50 mol% to about 61 mol% of the compound of the present disclosure, about 5 mol% to about 9 mol% of DSPC, about 29 mol% to about 38 mol% of cholesterol, and about 1 mol% to about 2 mol% of PEG2000-DMG. In some embodiments, the lipid nanoparticle comprises about 56 mol% to about 58 mol% of the compound of the present disclosure, about 6 mol% to about 8 mol% of DSPC, about 31 mol% to about 34 mol% of cholesterol, and about 1.25 mol% to about 1.75 mol% of PEG2000-DMG.

[00244] In some embodiments, the lipid nanoparticle has a total weight ratio of lipid to nucleic acid of about 50:1 to about 10:1. In some embodiments, the lipid nanoparticle has a total weight ratio of lipid to nucleic acid of about 40:1 to about Petition 870250102289, dated 07 / 11 / 2025, p. 67 / 408 63 / 379 of 20:1. In some embodiments, the lipid nanoparticle has a total weight ratio of lipid to nucleic acid of about 35:1 to about 25:1. In some embodiments, the lipid nanoparticle has a total weight ratio of lipids to nucleic acid of about 32:1 to about 28:1. In some embodiments, the lipid nanoparticle has a total weight ratio of lipid to nucleic acid of about 31:1 to about 29:1.

[00245] In some embodiments, the lipid nanoparticle has a total weight ratio of lipid:mRNA of about 50:1 to about 10:1. In some embodiments, the lipid nanoparticle has a total weight ratio of lipid:mRNA of about 40:1 to about 20:1. In some embodiments, the lipid nanoparticle has a total weight ratio of lipid:mRNA of about 35:1 to about 25:1. In some embodiments, the lipid nanoparticle has a total weight ratio of lipid:mRNA of about 32:1 to about 28:1. In some embodiments, the lipid nanoparticle has a total weight ratio of lipid:mRNA of about 31:1 to about 29:1.

[00246] In some embodiments, the lipid nanoparticle comprises a HEPES buffer at a pH of about 7.4. In some embodiments, the HEPES buffer is at a concentration of about 7 mg / mL to about 15 mg / mL. In some embodiments, the lipid nanoparticle further comprises about 2.0 mg / mL to about 4.0 mg / mL of NaCl.

[00247] In some embodiments, the lipid nanoparticle further comprises one or more cryoprotectants. In some embodiments, one or more cryoprotectants are selected from sucrose, glycerol, or a combination of sucrose and glycerol. In some embodiments, the lipid nanoparticle comprises a combination of sucrose at a concentration of about 70 mg / mL to about 110 mg / mL and glycerol at a concentration of about 50 mg / mL to about 70 mg / mL. Petition 870250102289, dated 07 / 11 / 2025, page 68 / 408 64 / 379 Lipid-nucleic acid formulations

[00248] A nucleic acid or a pharmaceutically acceptable salt thereof may be incorporated into a lipid formulation (i.e., a lipid-based delivery vehicle).

[00249] In the context of this disclosure, a lipid-based delivery vehicle typically serves to transport a desired nucleic acid (siRNA, plasmid DNA, mRNA, self-replicating RNA, etc.) to a target cell or tissue. The lipid-based delivery vehicle can be any suitable lipid-based delivery vehicle known in the art. In some embodiments, the lipid-based delivery vehicle is a liposome, a cationic liposome, or a lipid nanoparticle containing a nucleic acid. In some embodiments, the lipid-based delivery vehicle comprises a nanoparticle or a bilayer of lipid molecules and a nucleic acid. In some embodiments, the lipid bilayer preferably further comprises a neutral lipid or a polymer. In some embodiments, the lipid formulation preferably comprises a liquid medium. In some embodiments, the formulation preferably further encapsulates a nucleic acid.In some embodiments, the lipid formulation preferably comprises a nucleic acid and a neutral lipid or a polymer. In some embodiments, the lipid formulation preferably encapsulates the nucleic acid.

[00250] The description provides lipid formulations comprising one or more therapeutic nucleic acid molecules encapsulated in the lipid formulation. In some embodiments, the lipid formulation comprises liposomes. In some embodiments, the lipid formulation comprises cationic liposomes. In some embodiments, the lipid formulation comprises lipid nanoparticles.

[00251] In some embodiments, the nucleic acid is fully encapsulated within the lipid portion of the lipid formulation so that Petition 870250102289, dated 07 / 11 / 2025, page 69 / 408 65 / 379 the nucleic acid in the lipid formulation is resistant in aqueous solution to nuclease degradation. In other embodiments, the lipid formulations described herein are substantially non-toxic to mammals, such as humans.

[00252] The lipid formulations of the disclosure also typically have a total lipid:nucleic acid ratio (mass / mass ratio) of about 1:1 to about 100:1, about 1:1 to about 50:1, about 2:1 to about 45:1, about 3:1 to about 40:1, about 5:1 to about 38:1, or about 6:1 to about 40:1, or about 7:1 to about 35:1, or about 8:1 to about 30:1; or about 10:1 to about 25:1; or about 8:1 to about 12:1; or about 13:1 to about 17:1; or about 18:1 to about 24:1; or from about 20:1 to about 30:1. In some preferred embodiments, the total lipid:nucleic acid ratio (mass / mass ratio) is from about 10:1 to about 25:1. The ratio may be any value or subvalue within the indicated ranges, including endpoints.

[00253] The lipid formulations of the present disclosure typically have an average diameter of about 30 nm to about 150 nm, about 40 nm to about 150 nm, about 50 nm to about 150 nm, about 60 nm to about 130 nm, about 70 nm to about 110 nm, about 70 nm to about 100 nm, about 80 nm to about 100 nm, about 90 nm to about 100 nm, about 70 nm to about 90 nm, about 80 nm to about 90 nm, or about 30 nm, about 35 nm, about 40 nm, about 45 nm, about 50 nm, about 55 nm, about 60 nm, about 65 nm, about 70 nm, about 75 nm, about 80 nm, about 85 nm, about 90 nm, about 95 nm, about 100 nm, about 105 nm, about 110 nm, about 115 nm, about 120 nm, about 125 nm, about 130 nm, about 135 nm, about 140 nm, about 145 nm or about 150 nm and are substantially non Petition 870250102289, dated 07 / 11 / 2025, p. 70 / 408 66 / 379 toxic. The diameter can be any value or subvalue within the indicated ranges, including endpoints. Furthermore, nucleic acids, when present in the lipid nanoparticles of this disclosure, are resistant in aqueous solution to degradation with a nuclease.

[00254] In preferred embodiments, the lipid formulations comprise a nucleic acid, a cationic lipid (e.g., one or more cationic lipids or their salts described herein), a phospholipid, and a conjugated lipid that inhibits particle aggregation (e.g., one or more PEG-lipid conjugates and / or other lipid disclosure conjugates). The lipid formulations may also include cholesterol.

[00255] In some embodiments, the lipid nanoparticle further comprises a PEG-lipid conjugate. In some embodiments, the PEG-lipid conjugate is PEG-DMG. In some embodiments, the PEG-DMG is PEG2000-DMG. In some embodiments, PEG2000-DMG is the addition of polyethylene glycol to myristoyl diglyceride.

[00256] In nucleic acid-lipid formulations, the nucleic acid can be fully encapsulated within the lipid portion of the formulation, thus protecting the nucleic acid from nuclease degradation. In preferred embodiments, a lipid formulation comprising a nucleic acid is fully encapsulated within the lipid portion of the lipid formulation, thus protecting the nucleic acid from nuclease degradation. In certain cases, the nucleic acid in the lipid formulation is not substantially degraded after exposure of the particle to a nuclease at 37°C for at least 20, 30, 45, or 60 minutes. In some other cases, the nucleic acid in the lipid formulation is not substantially degraded after incubation of the formulation in serum at 37°C for at least 30, 45, or 60 minutes, or for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, or 36 hours. Petition 870250102289, dated 07 / 11 / 2025, page 71 / 408 67 / 379 other modalities, the nucleic acid is complexed with the lipid portion of the formulation.

[00257] In the context of nucleic acids, complete encapsulation can be determined by performing a membrane-impermeable fluorescent dye exclusion assay, which uses a dye that exhibits increased fluorescence when associated with the nucleic acid. Encapsulation is determined by adding the dye to a lipid formulation, measuring the resulting fluorescence, and comparing it to the fluorescence observed after the addition of a small amount of non-ionic detergent. Detergent-mediated disruption of the lipid layer releases the encapsulated nucleic acid, allowing it to interact with the membrane-impermeable dye. Nucleic acid encapsulation can be calculated as E = (I0-I) / I0, where I and I0 refer to the fluorescence intensities before and after the addition of detergent.

[00258] In other embodiments, the present disclosure provides a nucleic acid lipid composition comprising a plurality of nucleic acid liposomes, cationic nucleic acid liposomes, or nucleic acid lipid nanoparticles. In some embodiments, the nucleic acid lipid composition comprises a plurality of nucleic acid liposomes. In some embodiments, the nucleic acid lipid composition comprises a plurality of cationic nucleic acid liposomes. In some embodiments, the nucleic acid lipid composition comprises a plurality of nucleic acid lipid nanoparticles.

[00259] In some embodiments, the lipid formulations comprise a nucleic acid that is fully encapsulated within the lipid portion of the formulation, such that from about 30% to about 100%, from about 40% to about 100%, from about 50% to about 100%, from about 60% to about 100%, from about 70% to about Petition 870250102289, dated 07 / 11 / 2025, page 72 / 408 68 / 379 from 100%, from about 80% to about 100%, from about 90% to about 100%, from about 30% to about 95%, from about 40% to about 95%, from about 50% to about 95%, from about 60% to about 95%, from about 70% to about 95%, from about 80% to about 95%, from about 85% to about 95%, from about 90% to about 95%, from about 30% to about 90%, from about 40% to about 90%, from about 50% to about 90%, from about 60% to about 90%, from about 70% to about 90%, from about 80% to about 90%, or at least about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% (or any fraction thereof or range contained therein) of the particles have nucleic acid encapsulated in them. The value may be any value or subvalue within the indicated ranges, including endpoints.

[00260] In some modalities, the polydispersity index (PDI) varies from 0.010 to 1.10. In some modalities, the PDI varies from 0.010 to 1.05, from 0.010 to 1.00, from 0.010 to 0.95, from 0.010 to 0.90, from 0.010 to 0.85, from 0.010 to 0.80, from 0.010 to 0.75, from 0.010 to 0.70, from 0.010 to 0.65, from 0.010 to 0.60, from 0.010 to 0.55, from 0.010 to 0.50, from 0.010 to 0.45, from R$ 0.010 to R$ 0.40, from R$ 0.010 to R$ 0.35, from R$ 0.010 to R$ 0.30, from R$ 0.010 to R$ 0.25, from R$ 0.010 to R$ 0.20, from 0.010 to 0.07, from 0.010 to 0.06, 0.010 to 0.05, 0.010 to 0.04, 0.010 to 0.03, 0.010 to 0.02, 0.010 to 0.019, 0.010 to 0.018, 0.010 to 0.017, 0.010 to 0.016, 0.010 to 0.015, 0.010 to 0.014, 0.010 to 0.013, 0.010 to 0.012, 0.010 to 0.011 (or any interval between them). The value can be any value or subvalue within the indicated intervals, including endpoints.

[00261] Depending on the intended use of the lipid formulation, Petition 870250102289, dated 07 / 11 / 2025, p. 73 / 408 69 / 379 the proportions of the components can be varied and the delivery efficiency of a specific formulation can be measured using tests known in the art.

[00262] According to some embodiments, expressible polynucleotides, nucleic acid active agents, and mRNA constructs can be lipid-formulated. The lipid formulation is preferably selected from, but not limited to, liposomes, cationic liposomes, and lipid nanoparticles. In a preferred embodiment, a lipid formulation is a cationic liposome or a lipid nanoparticle (LNP) comprising: i. a nucleic acid (mRNA, siRNA, etc.), ii. a lipid of the present disclosure, which may be cationic, iii. optionally a non-cationic lipid (such as a neutral lipid), and iv. optionally, a sterol. Cationic Lipids

[00263] The lipid formulation preferably includes a cationic lipid suitable for forming a cationic liposome or lipid nanoparticle. Cationic lipids are widely studied for nucleic acid delivery because they can bind to negatively charged membranes and induce uptake. Generally, cationic lipids are amphiphilic, containing a positively charged hydrophilic head group, two (or more) lipophilic tails or a steroid moiety, and a connector between these two domains. Preferably, the cationic lipid carries a net positive charge near physiological pH. Cationic liposomes have traditionally been the most commonly used non-viral delivery systems for oligonucleotides, including plasmid DNA, antisense oligos, and siRNA / shRNA-RNA loops. Petition 870250102289, dated 07 / 11 / 2025, page 74 / 408 70 / 379 small hair. Cationic lipids, such as DOTAP (1,2-dioleoyl-3-trimethylammonium-propane) and DOTMA (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate), can form complexes or lipoplexes with negatively charged nucleic acids through electrostatic interaction, providing high transfection efficiency in vitro.

[00264] In the presently disclosed lipid formulations, the cationic lipid may include, for example, N,N-dimethyl-N,N-di-9cis-octadecynilammonium chloride (DODAC), N,N-lame bromide,disteniodimethium-AB 1,2-dioleoyltrimethylammoniopropane (DOTAP) (also known as N-(2,3-dioleoyloxy)propyl chloride)-N,N,N-trimethylammonium and chloride salt of l,2-dioleyloxy-3-trimethylaminopropane), N-(l-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium (DOTMA), N,Ndymethyl-2,3-dioleyloxy)propylamine (DODMA), l,2-DiLinoleyloxy-N,N-dimethylaminopropane (DLinDMA,l-propalene,l-loxyne-Dithylalyl (DLenDMA), l,2-di-y-linoleniloxy-N,N-dimethylaminopropane (γ-DLenDMA), 1,2-Dilinoleylcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), l,2-Dilinoleioxy-3-(dimethylamine) l,2-Dilinoleoxy-3-morpholinopropane (DLin-MA), l,2-Dilinoleoyl-3-dimethylaminopropane (DLinDAP), l,2-Dilinoleylthio-3-dimethylaminopropane (DLin-SDMA),l-Linoleoyl-2-linoleyloxy-3-dimethylaminopropane (DLin-2-DMAP), l,2-Dilinoleyoxy chloride salt of-3-trimethylaminopropane (DLin-TMA.Cl), chloride salt of l,2-dilinoleoyl-3-trimethylaminopropane (DLin-TAP.Cl), l,2-dilinoleyloxy-3-(N-methylpiperazino)propane (DLin-MPZ), or 3-(N,N-Dilinoleylamino)-l,2-propanediol (DLinAP), 3-(N,N-Dioleylamino)-1,2-propanediol (DOAP), l,2-Dilinoleyloxo-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA), 2,2-Dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA) or analogues thereof, (3aR,5s,6aS)-N,N-dimethyl-2,2di((9Z,12Z)-octadeca-9,12-dienyl)tetra-hidro-3aH-ciclopenta[d][1,3]dioxol-5-amina, (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl-4Petição 870250102289, de 07 / 11 / 2025, pág. 75 / 408, 71 / 379 (dimethylamino)butanoate (MC3), l,l'-(2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethylazanediyl)didodecan-2-ol (C12-200), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolano (DLin-K-C2-DMA), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolano (DLin-K-DMA), 3-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,3 l-tetraen-19ylóxi)-N,N-dimethylpropan-l-amina (Eter MC3), 4-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yloxy)-N,N-dimethylbutan-l-amine (Ether MC4) or any combination thereof. Other cationic lipids include, but are not limited to, N,N-distearyl-N,N-dimethylammonium bromide (DDAB), 3P-(N-(N',N'-dimethylaminoethane)-carbamoyl)cholesterol (DC-Chol), N-(1-(2,3-dioleyloxy)propyl)-N-2-(sperminecarboxamido)ethyl)N,N-dimethylammonium trifluoroacetate (DOSPA), dioctadecylamidoglycyl carboxespermine (DOGS), 1,2-dioleoyl-sn-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-3-dimethylammonium propane (DODAP), N-(1,2-dimyristyloxypropyl-3-yl)-N,N-dimethyl-N-hydroxyethyl ammonium bromide (DMRIE), and 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (XTC). Additionally, commercial cationic lipid preparations may be used, such as, for example, LIPOFECTIN (including DOTMA and DOPE, available from GIBCO / BRL) and Lipofectamine (comprising DOSPA and DOPE, available from GIBCO / BRL).

[00265] Other suitable cationic lipids are disclosed in International Publications Nos. WO 09 / 086558, WO 09 / 127060, WO 10 / 048536, WO 10 / 054406, WO 10 / 088537, WO 10 / 129709 and WO 2011 / 153493; U.S. Patent Publications Nos. 2011 / 0256175, 2012 / 0128760 and 2012 / 0027803; U.S. Patent No. 8,158,601; and Love et al., PNAS, 107(5), 1864-69, 2010, the contents of which are incorporated herein by reference.

[00266] Other suitable cationic lipids include those having alternative fatty acid groups and other dialkylamino groups, including those in which the alkyl substituents are different. Petition 870250102289, dated 07 / 11 / 2025, page 76 / 408 72 / 379 (e.g., N-ethyl-N-methylamino- and N-propyl-N-ethylamino-). These lipids are part of a subcategory of cationic lipids called aminolipids. In some embodiments of the lipid formulations described herein, the cationic lipid is an aminolipid. In general, amino acids having less saturated alkyl chains are more easily sized, particularly when complexes must be sized below about 0.3 microns for filter sterilization purposes. Aminolipids containing unsaturated fatty acids with carbon chain lengths in the range of C14 to C22 can be used. Other structures can also be used to separate the amino group and the fatty acid or alkyl fatty acid portion of the aminolipid.

[00267] In some embodiments, the cationic lipids of the present disclosure are ionizable and have at least one protonable or deprotonable group, such that the lipid is positively charged at a pH equal to or less than physiological pH (e.g., pH 7.4) and neutral at a second pH, preferably at or above physiological pH. Naturally, it will be understood that the addition or removal of protons as a function of pH is an equilibrium process, and that reference to a charged or neutral lipid refers to the nature of the predominant species and does not require that all of the lipid be present in the charged or neutral form. Lipids possessing more than one protonable or deprotonable group, or that are zwitterionic, are not excluded from use in the disclosure. In certain embodiments, protonable lipids have a protonable group pKa in the range of about 4 to about 11. In some embodiments, the ionizable cationic lipid has a pKa of about 5 to about 7.In some embodiments, the pKa of an ionizable cationic lipid is around 6 to around 7.

[00268] In some embodiments, the lipid formulation comprises a lipid of Formula I: Petition 870250102289, dated 07 / 11 / 2025, p. 77 / 408 73 / 379 (I) where:

[00269] R1 and R2 are each independently H or C1-6 alkyl; or

[00270] R1 and R2 are joined to form a saturated heterocyclic ring, where:

[00271] R1 is a linear C1-4 alkylene; and

[00272] R2é-(CH2)m(X)n-, where

[00273] X is O, S or NR9, where R9 is H or C1-6 alkyl;

[00274] m is 1, 2, 3 or 4, and

[00275] n is 0 or 1;

[00276] L1 is a linear C1-6 alkylene optionally substituted with one to three methyl groups;

[00277] Y is selected from the group consisting of: άλ , tvw e uwv Petition 870250102289, dated 07 / 11 / 2025, p. 78 / 408 74 / 379 where:

[00278] each asterisk (*) indicates the atom bonded to L2 and L3; and

[00279] R10 is H or C1-6 alkyl;

[00280] L2 and L3 are each independently a linear C1-8 alkylene;

[00281] L4, L5, L6, L7, L8 and L9 are each independently absent or -CH2-, provided that:

[00282] at least two of L4, L6 and L8 are-CH2-; and

[00283] at least two of L5, L7 and L9 are-CH2-;

[00284] R3e R4são cada um independente, methyl or ethyl; and

[00285] R5, R6, R7 and R8 are selected independently of the group consisting of:

[00286] C1-20 linear alkyl, wherein each said C1-20 linear alkyl is optionally substituted

[00287] with one or more substituents selected from the group consisting of:

[00288] C6-10 aryl, wherein each C6-10 aryl is a monocyclic or bicyclic aromatic hydrocarbon optionally substituted by one or more C6-10 aryl groups that are optionally substituted by one or more C1-6 alkyl groups;

[00289] 6- to 10-membered heteroaryl, wherein each 6- to 10-membered heteroaryl is a monocyclic or bicyclic aromatic system optionally substituted with one or more C1-6 alkyl groups;

[00290] C6-10 aryl, wherein each C6-10 aryl is a monocyclic or bicyclic aromatic hydrocarbon optionally substituted by one or more C6-10 aryl groups that are optionally substituted by one or more C1-6 alkyl groups; and

[00291] Heteroarila of 6 to 10 members, in which each heteroarila of Petition 870250102289, dated 07 / 11 / 2025, page 79 / 408 75 / 379 a 10 members is a monocyclic or bicyclic aromatic system optionally substituted by one or more C1-6 alkyl groups.

[00292] In some embodiments, any one or more of the lipids mentioned here may be expressly excluded. Lipids and Auxiliary Sterols

[00293] The mRNA lipid formulations of the present disclosure may comprise an auxiliary lipid, which may be referred to as a neutral lipid, a neutral auxiliary lipid, a non-cationic lipid, a non-cationic auxiliary lipid, an anionic lipid, an anionic auxiliary lipid, or a non-cationic auxiliary lipid. zwitterionic lipid. Lipid formulations, particularly cationic liposomes and lipid nanoparticles, have been found to enhance cellular uptake if auxiliary lipids are present in the formulation. (Curr. Drug Metab. 2014; 15(9):882-92).For example, some studies have indicated that neutral and zwitterionic lipids, such as 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), Di-Oleoyl-Phosphatidyl-Ethanoalamine (DOPE), and 1,2-Distearoyl-sn-α-glycero-3-phosphocholine (DSPC), being more fusogenic (i.e., facilitating fusion) than cationic lipids, can affect the polymorphic characteristics of lipid-nucleic acid complexes, promoting the transition from a lamellar phase to a hexagonal phase and thus inducing fusion and rupture of the cell membrane. (Nanomedicine (Lond). 2014 Jan; 9(1):105-20). Furthermore, the use of auxiliary lipids can help reduce any potential detrimental effects of using many prevalent cationic lipids, such as toxicity and immunogenicity.

[00294] Non-limiting examples of non-cationic lipids suitable for lipid formulations of the present disclosure include phospholipids such as lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, sphingo Petition 870250102289, dated 07 / 11 / 2025, page 80 / 408 76 / 379 egg myelin (ESM), cephalin, cardiolipin, phosphatidic acid, cerebrosides, dicetyl phosphate, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoylleoyl-phosphatidylcholine (POPC), palmitoylleoyl-phosphatidylethanolamine (POPE), palmitoylleoyl-phosphatidylglycerol (POPG), dioleoylphosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoylphosphatidylethanolamine (DMPE), distearoylphosphatidylethanolamine (DSPE), monomethylphosphatidylethanolamine, dimethylphosphatidylethanolamine, dielaidoylphosphatidylethanolamine (DEPE), stearoylleoylphosphatidylethanolamine (SOPE), lysophosphatidylcholine, dilinoleoylphosphatidylcholine and mixtures thereof. Other phospholipids such as diacylphosphatidylcholine and diacylphosphatidylethanolamine may also be used.The acyl groups in these lipids are preferentially acyl groups derived from fatty acids with carbon chains C10-C24, for example, lauroyl, myristoyl, palmitoyl, stearoyl or oleoyl.

[00295] In some embodiments, the auxiliary lipid is selected from among: dileoylphosphatidyl ethanolamine (DOPE), dimyristoylphosphatidylcholine (DMPC), distearolylphosphatidylcholine (DSPC), dimyristoylphosphatidyl glycerol (DMPG), dipalmitoyl phosphatidylcholine (DPPC), and phosphatidylcholine (PC). In some embodiments, the auxiliary lipid is distearolylphosphatidylcholine (DSPC).

[00296] Additional examples of non-cationic lipids include sterols such as cholesterol and its derivatives. One study concluded that, as an auxiliary lipid, cholesterol increases the charge spacing of the lipid layer that interfaces with nucleic acid, causing the charge distribution to more closely match that of the nucleic acid. (JR Soc. Interface. 2012 Mar 7; 9(68): 548-561). Non-limiting examples of cholesterol derivatives include polar analogs such as 5α-cholestanol, 5α-coprostanol, cholesteryl-(2'-hydroxy)-ethyl ether, Petition 870250102289, dated 07 / 11 / 2025, page 81 / 408 77 / 379 cholestyrel-(4'-hydroxy)-butyl ether and 6-ketocholestanol; nonpolar analogues such as 5α-cholestan, cholestenone, 5α-cholestanone, 5α-cholestanone and cholestyrel decanoate; and mixtures thereof. In preferred embodiments, the cholesterol derivative is a polar analogue such as cholestyrel-(4'-hydroxy)-butyl ether.

[00297] In some embodiments, the auxiliary lipid present in the lipid formulation comprises or consists of a mixture of one or more phospholipids and cholesterol or a derivative thereof. In other embodiments, the auxiliary lipid present in the lipid formulation comprises or consists of one or more phospholipids, for example, a cholesterol-free lipid formulation. In still other embodiments, the auxiliary lipid present in the lipid formulation comprises or consists of cholesterol or a derivative thereof, for example, a phospholipid-free lipid formulation. In some embodiments, the lipid nanoparticle also comprises cholesterol.

[00298] Other examples of auxiliary lipids include non-phosphorus-containing lipids, such as, for example, stearylamine, dodecylamine, hexadecylamine, acetyl palmitate, glyceryl ricinoleate, hexadecyl stearate, isopropyl myristate, amphoteric acrylic polymers, triethanolamine-lauryl sulfate, alkyl-aryl sulfate polyethyloxylated fatty acid amides, dioctadecyldimethyl ammonium bromide, ceramide, and sphingomyelin.

[00299] In some embodiments, the auxiliary lipid comprises from about 1 mol% to about 50 mol%, from about 5 mol% to about 48 mol%, from about 5 mol% to about 46 mol%, from about 25 mol% to about 44 mol%, from about 26 mol% to about 42 mol%, from about 27 mol% to about 41 mol%, from about 28 mol% to about 40 mol%, or about 29 mol%, about 30 mol%, about 31 mol%, about 32 mol%, about 33 mol%, about 34 mol%, about Petition 870250102289, dated 07 / 11 / 2025, p. 82 / 408 78 / 379 35 mol%, about 36 mol%, about 37 mol%, about 38 mol%, or about 39 mol% (or any fraction thereof or its range) of the total lipid present in the lipid formulation. In some embodiments, the auxiliary lipid comprises from about 1 mol% to about 20 mol%, about 2 mol% to about 12 mol%, about 5 mol% to about 9 mol%, or about 6 mol% to about 8 mol%.

[00300] In some embodiments, the total amount of auxiliary lipids in the formulation comprises two or more auxiliary lipids and the total amount of auxiliary lipids comprises from about 20 mol% to about 50 mol%, from about 22 mol% to about 48 mol%, from about 24 mol% to about 46 mol%, from about 25 mol% to about 44 mol%, from about 26 mol% to about 42 mol%, from about 27 mol% to about 41 mol%, from about 28 mol% to about 40 mol%, or about 29 mol%, about 30 mol%, about 31 mol%, about 32 mol%, about 33 mol%, about 34% in mol, approximately 35% by mol, approximately 36% by mol, approximately 37% by mol, approximately 38% by mol, or approximately 39% by mol (or any portion thereof or its range) of the total lipid present in the lipid formulation. In some embodiments, the auxiliary lipids are a combination of DSPC and DOTAP. In some embodiments, the auxiliary lipids are a combination of DSPC and DOTMA.

[00301] The cholesterol or cholesterol derivative in the lipid formulation may comprise up to about 40 mol%, about 45 mol%, about 50 mol%, about 55 mol%, or about 60 mol% of the total lipid present in the lipid formulation. In some embodiments, the cholesterol or cholesterol derivative comprises about 15 mol% to about 45 mol%, about 20 mol% to about 40 mol%, about 30 mol% to about 40 mol%, or about 35 mol%, about 36 mol%, about 37 mol%, about 38 mol% Petition 870250102289, dated 07 / 11 / 2025, page 83 / 408 79 / 379 mol, approximately 39% by mol or approximately 40% by mol of the total lipid present in the lipid formulation.

[00302] The percentage of auxiliary lipid present in the lipid formulation is a target amount and the actual amount of auxiliary lipid present in the formulation may vary, for example, by ± 5% molar. Mechanism of action for cellular uptake of lipid formulations

[00303] Lipid formulations for the intracellular delivery of nucleic acids, particularly liposomes, cationic liposomes, and lipid nanoparticles, are designed for cellular uptake by penetrating target cells through exploitation of the target cell's endocytic mechanisms, where the contents of the lipid delivery vehicle are delivered to the target cell's cytosol. (Nucleic Acid Therapeutics, 28(3):146-157, 2018). Specifically, in the case of nucleic acid lipid formulations described herein, the lipid formulation enters cells via receptor-mediated endocytosis. Prior to endocytosis, functionalized ligands, such as the lipid conjugate released on the surface of the lipid delivery vehicle, can be shed from the surface, triggering internalization into the target cell.During endocytosis, some part of the cell's plasma membrane envelops the vector and wraps it in a vesicle that then separates from the cell membrane, enters the cytosol, and eventually passes through the endolysosomal pathway. For delivery vehicles containing ionizable cationic lipids, the increased acidity as the endosome ages results in a vehicle with a strong positive charge on its surface. Interactions between the delivery vehicle and the endosomal membrane then result in a membrane fusion event that leads to cytosolic delivery of the payload. For self-replicating mRNA or RNA payloads, the cell's own internal translation processes will then translate the RNA into the encoded protein. The encoded protein may further undergo post-translational processing, including transport to a target organelle or location within the cell. Petition 870250102289, dated 07 / 11 / 2025, page 84 / 408 80 / 379 cell.

[00304] By controlling the composition and concentration of the lipid conjugate, one can control the rate at which the lipid conjugate leaves the lipid formulation and, in turn, the rate at which the lipid formulation becomes fusogenic. Furthermore, other variables, including, for example, pH, temperature, or ionic strength, can be used to vary and / or control the rate at which the lipid formulation becomes fusogenic. Other methods that can be used to control the rate at which the lipid formulation becomes fusogenic will become apparent to those skilled in the art after reading this disclosure. Additionally, by controlling the composition and concentration of the lipid conjugate, one can control the size of the liposomal or lipid particles. Manufacture of lipid formulations

[00305] There are many different methods for the preparation of lipid formulations comprising a nucleic acid. (Curr. Drug Metabol. 2014, 15, 882-892; Chem. Phys. Lipids 2014, 177, 8-18; Int. J. Pharm. Stud. Res. 2012, 3, 14-20). Thin-film hydration, double emulsion, reverse-phase evaporation, microfluidic preparation, double asymmetric centrifugation, ethanol injection, detergent dialysis, spontaneous vesicle formation by ethanol dilution, and encapsulation in pre-formed liposomes are briefly described here. Thin Film Hydration

[00306] In Thin Film Hydration (TFH) or the Bangham method, lipids are dissolved in an organic solvent and then evaporated using a rotary evaporator, leading to the formation of a thin lipid layer. After hydration of the layer by an aqueous buffer solution containing the compound to be loaded, Multilamellar Vesicles (MLVs) are formed, which can be reduced in size to produce Small or Large Unilamellar Vesicles (LUVs). Petition 870250102289, dated 07 / 11 / 2025, page 85 / 408 81 / 379 and SUV) by extrusion through membranes or by sonication of the initial MLV. Double Emulsion

[00307] Lipid formulations can also be prepared using the Double Emulsion technique, which involves dissolving lipids in a water / organic solvent mixture. The organic solution, containing water droplets, is mixed with an excess of aqueous medium, leading to the formation of a water-in-oil-in-water (W / O / W) double emulsion. After vigorous mechanical agitation, some of the water droplets collapse, forming Large Unilamellar Vesicles (LUVs). Reverse-phase evaporation

[00308] The Reverse Phase Evaporation (REV) method also allows obtaining nucleic acid-loaded LUVs. In this technique, a biphasic system is formed by dissolving phospholipids in organic solvents and aqueous buffer. The resulting suspension is then briefly sonicated until the mixture becomes a clear monophasic dispersion. The lipid formulation is obtained after evaporation of the organic solvent under reduced pressure. This technique has been used to encapsulate different large and small hydrophilic molecules, including nucleic acids. Microfluidic Preparation

[00309] The microfluidic method, unlike other bulk techniques, offers the possibility of controlling the lipid hydration process. The method can be classified into continuous-flow microfluidic and droplet-based microfluidic, according to how the flow is manipulated. In the microfluidic hydrodynamic focusing (MHF) method, which operates in continuous-flow mode, lipids are dissolved in isopropyl alcohol that is hydrodynamically focused at a cross-junction of microchannels between two aqueous buffer streams. The size of the vesicles can be controlled by modulating the flow rates, thus controlling the dilution process of the lipid / buffer solution. The Petition 870250102289, dated 07 / 11 / 2025, page 86 / 408 The 82 / 379 method can be used to produce lipid oligonucleotide (ON) formulations using a microfluidic device consisting of three inlet ports and one outlet. Double Asymmetric Centrifugation

[00310] Double asymmetric centrifugation (DAC) differs from more common centrifugation because it utilizes an additional rotation around its own vertical axis. Efficient homogenization is achieved due to the two overlapping movements generated: the sample is pushed outwards, as in a normal centrifuge, and then pushed towards the center of the flask due to the additional rotation. By mixing lipids and a NaCl solution, a viscous vesicular phospholipid gel (VPC) is obtained, which is then diluted to obtain a lipid formulation dispersion. The size of the lipid formulation can be regulated by optimizing the DAC speed, the lipid concentration, and the homogenization time. Ethanol Injection

[00311] The ethanol injection (EI) method can be used for nucleic acid encapsulation. This method provides for the rapid injection of an ethanolic solution, in which the lipids are dissolved, into an aqueous medium containing nucleic acids to be encapsulated, through the use of a needle. Vesicles are formed spontaneously when the phospholipids are dispersed in the medium. Dialysis Detergent

[00312] The detergent dialysis method can be used to encapsulate nucleic acids. Briefly, the lipid and plasmid are solubilized in a detergent solution of appropriate ionic strength; after removal of the detergent by dialysis, a stabilized lipid formulation is formed. The unencapsulated nucleic acid is then removed by ion-exchange chromatography, and the empty vesicles by centrifugation in a sucrose density gradient. The technique is highly Petition 870250102289, dated 07 / 11 / 2025, page 87 / 408 83 / 379 is sensitive to the cationic lipid content and salt concentration of the dialysis buffer, and the method is also difficult to scale. Spontaneous Vesicle Formation by Dilution in Ethanol

[00313] Stable lipid formulations can also be produced by the Spontaneous Vesicle Formation by Ethanol Dilution method, in which a gradual or dropwise dilution in ethanol provides the instantaneous formation of nucleic acid-laden vesicles by the controlled addition of lipid dissolved in ethanol to a fast-mixing aqueous buffer containing the nucleic acid. III. PHARMACEUTICAL COMPOSITIONS AND DELIVERY METHODS

[00314] To facilitate nucleic acid activity (e.g., mRNA expression or knockdown by an ASO or siRNA) in vivo, the lipid formulation delivery vehicles described herein may be combined with one or more additional nucleic acids, carriers, targeting ligands or stabilizing reagents, or in pharmaceutical compositions where it is mixed with suitable excipients. Techniques for formulating and administering drugs can be found in “Remington's Pharmaceutical Sciences”, Mack Publishing Co., Easton, Pa., latest edition.

[00315] The lipid formulations and pharmaceutical compositions of this disclosure may be administered and dosed according to current medical practice, taking into account the subject's clinical condition, the site and method of administration, the administration schedule, the subject's age, sex, body weight, and other factors relevant to physicians with average knowledge of the art. The "effective amount" for the purposes of this document may be determined by relevant considerations known to those skilled in experimental clinical research, pharmacological, clinical, and medical arts. In some embodiments, the amount administered is effective in achieving at least some stabilization, improvement, or elimination of symptoms and Petition 870250102289, dated 07 / 11 / 2025, page 88 / 408 84 / 379 other indicators selected as appropriate measures of disease progress, regression, or improvement by those skilled in the art. For example, an adequate amount and dosage regimen are those that elicit at least transient protein production (e.g., enzymes).

[00316] The pharmaceutical compositions disclosed herein may be formulated using one or more excipients to: (1) increase stability; (2) increase cell transfection; (3) allow sustained or delayed release (e.g., from a nucleic acid depot formulation); (4) alter biodistribution (e.g., targeting nucleic acid to specific tissues or cell types); (5) increase the activity of the nucleic acid or a protein expressed from it in vivo; and / or (6) alter the release profile of the nucleic acid or an encoded protein in vivo.

[00317] Lipid formulations may preferably be administered locally rather than systemically. Local distribution may be affected in several ways depending on the tissue to be targeted. For example, aerosols containing compositions of the present disclosure may be inhaled (for nasal, tracheal or bronchial distribution).

[00318] Pharmaceutical compositions can be administered to any desired tissue. In some embodiments, the nucleic acid distributed by a formulation or lipid composition of this disclosure is active in the tissue to which the formulation and / or lipid composition was administered. In some embodiments, the nucleic acid is active in a tissue different from the tissue to which the formulation and / or lipid composition was administered. Examples of tissues to which the nucleic acid can be administered include, but are not limited to, lung, trachea and / or nasal passages, muscle, liver, eye, or central nervous system.

[00319] The pharmaceutical compositions described herein may be Petition 870250102289, dated 07 / 11 / 2025, p. 89 / 408 85 / 379 prepared by any method known or subsequently developed in the art of pharmacology. In general, such preparatory methods include the step of combining the active ingredient (i.e., nucleic acid) with an excipient and / or one or more other accessory ingredients. A pharmaceutical composition according to this disclosure may be prepared, packaged and / or sold in bulk, as a single unit dose and / or as a plurality of single unit doses.

[00320] Pharmaceutical compositions may additionally comprise a pharmaceutically acceptable excipient, which, as used herein, includes, but is not limited to, any and all solvents, dispersing media, diluents or other liquid vehicles, dispersing or suspending aids, surfactants, isotonic agents, thickening or emulsifying agents, preservatives and the like, as appropriate to the specific dosage form desired.

[00321] In addition to traditional excipients, such as any and all solvents, dispersing media, diluents or other liquid vehicles, dispersing or suspending aids, surfactants, isotonic agents, thickening or emulsifying agents, preservatives, excipients in this disclosure may include, without limitation, liposomes, lipid nanoparticles, polymers, lipoplexes, core-shell nanoparticles, peptides, proteins, cells transfected with a primary DNA or mRNA construct (e.g., for transplantation into a subject), hyaluronidase, nanoparticle mimics, and combinations thereof.

[00322] Consequently, the formulations described herein may include one or more excipients, each in an amount that together increases the stability of the nucleic acid in the lipid formulation, increases cellular transfection by the nucleic acid (e.g., mRNA or siRNA), increases the expression of an encoded protein and / or alters the release profile of the encoded protein or increases the Petition 870250102289, dated 07 / 11 / 2025, page 90 / 408 86 / 379 knockdown of a target native nucleic acid. Furthermore, a nucleic acid can be formulated using self-assembled nucleic acid nanoparticles.

[00323] Various excipients for formulating pharmaceutical compositions and techniques for preparing the composition are known in the art (see Remington: The Science and Practice of Pharmacy, 21st Edition, AR Gennaro, Lippincott, Williams & Wilkins, Baltimore, Maryland, 2006; incorporated herein by reference in its entirety). The use of a conventional excipient medium may be contemplated within the scope of the embodiments of this disclosure, except to the extent that any conventional excipient medium may be incompatible with a substance or its derivatives, such as by producing any undesirable biological effect or otherwise interacting in a detrimental manner with any other component(s) of the pharmaceutical composition.

[00324] One dosage form of the composition of this disclosure may be a solid, which may be reconstituted into a liquid prior to administration. The solid may be administered as a powder. In some embodiments, the pharmaceutical composition comprises a lyophilized nucleic acid lipid formulation.

[00325] In a preferred embodiment, the pharmaceutical form of the pharmaceutical compositions described herein may be a liquid suspension of the nucleic acid lipid nanoparticles described herein. In some embodiments, the liquid suspension is in a buffered solution. In some embodiments, the buffered solution comprises a buffer selected from the group consisting of HEPES, MOPS, TES, and TRIS. In some embodiments, the buffer has a pH of about 7.4. In some preferred embodiments, the buffer is HEPES. In some other embodiments, the buffered solution further comprises a cryoprotectant. In some embodiments, the cryoprotectant is selected from a sugar and glycerol or a combination of sugar and glycerol. Petition 870250102289, dated 07 / 11 / 2025, page 91 / 408 87 / 379 In some embodiments, the sugar is a dimeric sugar. In some embodiments, the sugar is sucrose. In some preferred embodiments, the buffer comprises HEPES, sucrose, and glycerol at a pH of 7.4. In some embodiments, the suspension is frozen during storage and thawed before administration. In some embodiments, the suspension is frozen at a temperature below about -70°C. In some embodiments, the suspension is diluted with sterile water before inhalation administration. In some embodiments, inhalation administration comprises diluting the suspension with about 1 volume to about 4 volumes of sterile water. In some embodiments, a lyophilized nucleic acid lipid nanoparticle formulation may be resuspended in a buffer as described herein.

[00326] One dosage form of the composition in this disclosure may be solid, which can be reconstituted into a liquid before administration. The solid may be administered as a powder. The solid may be in capsule, tablet, or gel form.

[00327] To formulate compositions for pulmonary distribution within the scope of this disclosure, the nucleic acid-lipid formulation may be combined with various pharmaceutically acceptable additives, as well as a base or vehicle for dispersion of the nucleic acid-lipid formulation(s). Examples of additives include pH control agents such as arginine, sodium hydroxide, glycine, hydrochloric acid, citric acid, and mixtures thereof. Other additives include local anesthetics (e.g., benzyl alcohol), isotonic agents (e.g., sodium chloride, mannitol, sorbitol), adsorption inhibitors (e.g., Tween 80), solubility enhancers (e.g., cyclodextrins and their derivatives), stabilizers (e.g., serum albumin), and reducing agents (e.g., glutathione). When the composition for mucosal delivery is a liquid, the tonicity of Petition 870250102289, dated 07 / 11 / 2025, page 92 / 408 88 / 379 formulation, measured with reference to the tonicity of 0.9% (w / v) physiological saline solution taken as a unit, is typically adjusted to a value at which no substantial and irreversible tissue damage will be induced in the mucosa at the site of administration. Generally, the tonicity of the solution is adjusted to a value of 1 / 3 to 3, more typically 1 / 2 to 2, and most frequently 3 / 4 to 1.7.

[00328] The nucleic acid lipid formulation may be dispersed in a base or carrier, which may comprise a hydrophilic compound capable of dispersing the nucleic acid lipid formulation and any desired additives. The base may be selected from a wide range of suitable carriers, including, but not limited to, copolymers of polycarboxylic acids or salts thereof, carboxylic anhydrides (e.g., maleic anhydride) with other monomers (e.g., methyl (meth)acrylate, acrylic acid, etc.), hydrophilic vinyl polymers such as polyvinyl acetate, polyvinyl alcohol, polyvinylpyrrolidone, cellulose derivatives such as hydroxymethylcellulose, hydroxypropylcellulose, etc., and natural polymers such as chitosan, collagen, sodium alginate, gelatin, hyaluronic acid and its non-toxic metallic salts.Often, a biodegradable polymer is selected as a base or carrier, for example, polylactic acid, poly(lactic acid-glycolic acid) copolymer, polyhydroxybutyric acid, poly(hydroxybutyric acid-glycolic acid) copolymer, and mixtures thereof. Alternatively or additionally, synthetic fatty acid esters, such as polyglycerol fatty acid esters, sucrose fatty acid esters, etc., may be employed as carriers. Hydrophilic polymers and other carriers may be used alone or in combination, and improved structural integrity may be imparted to the carrier by partial crystallization, ionic bonding, crosslinking, and the like. The carrier may be rendered in a variety of forms, including... Petition 870250102289, dated 07 / 11 / 2025, page 93 / 408 89 / 379 including fluid or viscous solutions, gels, pastes, powders, microspheres and films for direct application to the nasal mucosa. The use of a vehicle selected in this context may result in the promotion of absorption of the nucleic acid lipid formulation.

[00329] The compositions in this disclosure may alternatively contain pharmaceutically acceptable carrier substances as necessary to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents and humectants, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate and mixtures thereof. For solid compositions, conventional pharmaceutically acceptable non-toxic carriers may be used, including, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate and the like.

[00330] According to the present disclosure, a therapeutically effective dose of the provided composition, when administered regularly, results in an increase in the level of nucleic acid activity in a subject compared to a baseline activity level before treatment. Typically, the activity level is measured in a biological sample obtained from the subject, such as blood, plasma or serum, urine, or solid tissue extracts. The baseline level can be measured immediately before treatment. In some embodiments, administration of a pharmaceutical composition described herein results in an increased level of nucleic acid activity in a biological sample (e.g., plasma / serum or lung epithelial smear) by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% compared to a baseline level before treatment. In some embodiments, administration of the provided composition results Petition 870250102289, dated 07 / 11 / 2025, p. 94 / 408 90 / 379 in an increased level of nucleic acid activity in a biological sample (e.g., plasma / serum or lung epithelial smear) by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% compared to a baseline level before treatment for at least about 24 hours, at least about 48 hours, at least about 72 hours, at least about 4 days, at least about 5 days, at least about 6 days, at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, or at least about 15 days.

[00331] In some embodiments, the present disclosure provides a pharmaceutical composition comprising the compounds described herein, or the lipid nanoparticle described herein, and a pharmaceutically acceptable excipient.

[00332] In some embodiments, the present disclosure provides a method of delivering a nucleic acid to a subject in need thereof, comprising encapsulating a therapeutically effective amount of the nucleic acid in the lipid nanoparticle described herein and administering the lipid nanoparticle to the subject.

[00333] In some embodiments, the present disclosure provides a method of delivering mRNA to a subject in need thereof, comprising encapsulating a therapeutically effective amount of mRNA in the lipid nanoparticle described herein and administering the lipid nanoparticle to the subject. IV. TREATMENT METHOD

[00334] In some embodiments, the present disclosure provides a method of treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound described herein, the lipid nanoparticle. Petition 870250102289, dated 07 / 11 / 2025, page 95 / 408 91 / 379 described herein or the pharmaceutical composition described herein. In some embodiments, the lipid compound, composition, or nanoparticle is administered intravenously or intramuscularly. In some embodiments, the lipid compound, composition, or nanoparticle is administered intravenously. In some embodiments, the lipid compound, composition, or nanoparticle is administered intramuscularly.

[00335] In some embodiments, it is a method of treating a disease in a subject in need thereof, comprising administering to the subject a lipid composition described herein. In some embodiments, the lipid composition is administered intravenously or intramuscularly. In some embodiments, the lipid composition is administered intravenously. In some embodiments, the lipid composition is administered intramuscularly.

[00336] In some embodiments, methods are provided for treating a disease or disorder in a mammal. A therapeutically effective amount of a composition comprising a lipid, as disclosed herein, specifically a cationic lipid, a nucleic acid, an amphiphilic lipid, a phospholipid, cholesterol, and a PEG-linked cholesterol, may be administered to a subject with a disease or disorder associated with the expression or overexpression of a gene that may be reduced, decreased, downregulated, or silenced by the composition. The compositions described herein may be used in methods for treating cancer or inflammatory disease. The disease may be selected from the group consisting of central nervous system disorders, peripheral nervous system disorders, muscular atrophies, muscular dystrophies, immunological disorders, cancer, renal disease, fibrotic disease, genetic abnormality, inflammation, and cardiovascular disorder.

[00337] In some embodiments, the present disclosure provides a method of administering a nucleic acid to a subject who needs it. Petition 870250102289, dated 07 / 11 / 2025, page 96 / 408 92 / 379 site, comprising encapsulating a therapeutically effective amount of a nucleic acid in a lipid nanoparticle, as described herein, and administering the lipid nanoparticle to the subject. V. EXAMPLES Example.1 Synthesis of LIPID 1: ((4,4'-((((3-(Dimethylamino)propyl)thio)carbonyl) azanediyl)bis(butanoyl))bis(oxy))bis(propane-2,1,3-triyl) tetranonanoate General Outline: Petition 870250102289, dated 07 / 11 / 2025, page 97 / 408 93 / 379 HCl in EtOAc EtOAc Synthesis of 1-1: 2-oxopropane-1,3-diyl dinonanoate the

[00338] In a 500 mL round-bottom flask reactor with 3 necks under a N2 atmosphere, a solution of 1,3-dihydroxyacetone (6.8 g, 1 eq) in CH2Cl2 was added. Stirring was started and the Petition 870250102289, dated 07 / 11 / 2025, page 98 / 408 94 / 379 temperature to room temperature. Pyridine (17.9 g, 3 eq) was loaded into the reactor while maintaining the temperature at 25 ± 5°C. 4-Dimethylaminopyridine (DMAP) (0.276 g, 0.03 eq) was loaded into the reactor while maintaining the temperature at 25 ± 5°C. Nonanoyl chloride (20 g, 1.5 eq) was loaded dropwise into the reactor at 0-5°C. After loading, the temperature was maintained at room temperature and stirred for 6 hours. Another 6.66 g of nonanoyl chloride (0.5 eq) was loaded into the reactor dropwise at 0-5°C. The reaction temperature was raised to room temperature and stirred under nitrogen overnight. The pyridine hydrochloride formed was removed by filtration and washed with CH2Q2. The combined filtrate and washes were then washed with 200 mL each of 5% aqueous solution of NaHCO3, 0.1N HCl, and brine. The solution was then dried over Na2SO4 and concentrated under vacuum. The residue was then crystallized in methanol (50 mL) to yield a white solid.This resulted in 16 g (59.7%) of white product. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., hold 0.7 min): RT 2.26 min, m / z (Calc.) 370.27, (obtained) 371.00 (M+H+). Synthesis of 1-2: 2-Hydroxypropane-1,3-diyl dinonanoate

[00339] In a 250 mL three-necked round-bottom flask, a solution of Lipid-1-1 (9.6 g, 1.0 eq) was placed in 100 mL of THF. AcOH (2.02 g, 1.3 eq) was added to the solution at 0 °C. Then NaBHaCN (1.96 g, 1.2 eq) was added to the mixture at 0 °C. The mixture was stirred for 16 hours at room temperature under a nitrogen atmosphere. The reaction mixture was quenched with 100 mL of water. A Petition 870250102289, dated 07 / 11 / 2025, p. 99 / 408 The 95 / 379 mixture was extracted with 100 mL of EtOAc three times. The organic layers were combined, washed with brine (300 mL), and concentrated under vacuum. This resulted in 9.5 g (crude) of 1-2, which is used in the next step without purification. Synthesis of 1-3: Dimethyl 4,4'-(benzylazanediyl)dibutyrate

[00340] In a 1 L three-necked round-bottom flask, purged and maintained with an inert nitrogen atmosphere, acetonitrile (208 mL), K2CO3 (31 g, 2.3 eq), benzylamine (10.3 g, 1.0 eq), and methyl 4-bromobutyrate (40 g, 2.3 eq) were charged at 25°C. The mixture was heated to 80°C and stirred for 15 h. The reaction was cooled to 25°C. Water (200 mL, 20 V) was charged into the flask and extracted with EtOAc (2 x 200 mL). The organic phase was dried (Na2SO4) and concentrated at 35°C under reduced pressure. This resulted in 1-3 (23 g, crude) as a crude product which was transported without further purification. ELSD A: water / 0.05% TFA: B: CHaCN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., wait 0.7 min): RT 2.26 min, m / z (Calc.) 370.27, (obtained) 371.00 (M+H). Synthesis of 1-4: Dimethyl 4,4'-((tert-butoxycarbonyl)azanediyl)dibutyrate

[00341] Charged EtOH (230 mL, 10 V), 1-3 (23.0 g, 1.0 eq), (Boc)2O (18.0 g, 1.1 eq) and Pd / C (2.3 g, 10% w / w) in a 1 L hydrogenation autoclave at room temperature. Stirred for 16 hours at room temperature under a hydrogen atmosphere at 5 atm. TLC observation indicated that 1-3 was completely consumed. The reaction mixture was filtered and concentrated under vacuum at 40°C to obtain 22 g of Petition 870250102289, dated 07 / 11 / 2025, page 100 / 408 96 / 379 gross product 1-4. Synthesis of 1-5:4,4'-((tert-butoxycarbonyl)azanediyl)dibutyric acid H3CO2C—\ HO2C—\ '—\ 6N aq. NaOH'—\ N-Boc ---------►N-Boc ,— / EtOH.— / H3CO2C^HOoC^ 1-421-5

[00342] In a 500 mL round-bottom flask with three necks, purged and maintained with an inert nitrogen atmosphere, a solution of 1-4 (22 g, 1.0 eq) in ethanol (110 mL) was charged. An aqueous solution of NaOH (6M, 110 mL, 5 V) was added at room temperature. The reaction mixture was stirred at 60°C for 2 hours. The reaction was then diluted with brine (220 mL, 10 V) and extracted with t-BuOH / n-heptane (2:1, 220 mL, 2x) to remove organic impurities. The aqueous phase was acidified by the addition of 3M aqueous HCl solution to approximately pH=3 and then extracted with t-BuOH:n-heptane (2:1) (220 mL). The organic layers were concentrated under reduced pressure. The residue was suspended with diethyl ether (44 mL, 2 V) and filtered. The filter cake was collected to yield 1-5 (14 g, 43% yield in three steps) as a white solid. Synthesis of 1-6: ((4,4'-(( tert- Butoxycarbonyl)azanodiyl)bis(butanoyl)) bis(oxy))bis (propane-2,1,3-triyl) tetranonanoate Petition 870250102289, dated 07 / 11 / 2025, page 101 / 408 97 / 379

[00343] In a 250 mL round-bottom, three-necked flask, purged and maintained with an inert nitrogen atmosphere, a solution of 1-5 (3.7 g, 1.00 equiv) in 100 mL of CH2Cl2 was placed. To the solution was added 1-2 (9.5 g, 2.00 equiv), DMAP (4.69 g, 3 equiv) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) (7.35 g, 3 equiv) at 0 °C. The reaction mixture was stirred overnight at 25 °C. The reaction was then quenched with 200 mL of 10% aqueous citric acid solution. The organic layer was washed with 200 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 12 g of 1-6 and was used in the next step without further purification. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., hold 0.7 min): RT 2.46 min, m / z (Calc.) 997.71, (obtained) 1020.6 (M+Na). Synthesis of 1-7: bis(4-((1,3-bis(nonanojloxj)propan-2yl)oxy)-4-oxobutyl)ammonium chloride

[00344] In a 500 mL round-bottom flask purged and maintained with an inert nitrogen atmosphere, a solution of 16 (12 g, 1.00 equiv) was placed in EtOAc (68 mL). EtOAc / HCl (15 mL, 5.00 equiv, 4M) was added dropwise at 0-10 °C. The resulting solution was stirred for 5 hours at room temperature. The resulting mixture was concentrated under vacuum. The residue was diluted with CH2Cl2 Petition 870250102289, dated 07 / 11 / 2025, p. 102 / 408 98 / 379 (100 mL) and 25 g of silica gel (type: ZCX-2, 100-200 mesh) were added (Note: ZCX-2 is sold by Sincem Silica Gel Co. Ltd.). The mixture was concentrated under vacuum and then applied to an atmospheric silica gel column with a CH2Cb / MeOH gradient of 1:0 to 15:1. The eluent product was collected from 20:1 to 15:1 and concentrated under vacuum. This resulted in 4.2 g of 1-7 as a light yellow oil. ELSD A: water / 0.05% TFA; B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., hold 0.7 min): RT 1.50 min, m / z (Calc.) 897.65, (obtained) 898.6 (M+H). Synthesis of LIPID 1: ((4,4'-(((3-(Dimethylamino)propyl)thio)carbonyl)azanodiyl)bis(butanoyl))bis(oxy))bis(propane-2,1,3-triyl) tetranonanoate 1. triphosgene CH2CI2, pyridine 2. concentrate dissolved in pyridine I 3.

[00345] In a 250 mL round-bottom, three-necked flask, purged and maintained with an inert nitrogen atmosphere, a solution of 1-7 (4.2 g, 1 eq) was placed in CH2Cl2 (150 mL). Tryphosgene (1.33 g, 1 equiv) was added to the mixture at room temperature. This was followed by the dropwise addition of pyridine (1.78 g, 5.00 equiv) with stirring at 0°C. The mixture was stirred for 4 h at room temperature and then concentrated under vacuum. The residue was dissolved with pyridine (600 mL). To this solution, 3-(dimethylamino)propane-1-thiol (0.92 g, 1.20 equiv) was added dropwise with stirring at 0°C over 10 minutes. The resulting solution was stirred overnight at room temperature. Petition 870250102289, dated 07 / 11 / 2025, p. 103 / 408 99 / 379 The resulting mixture was concentrated under vacuum. The residue was diluted with 100 mL of EtOAc. The mixture was washed with 2 x 100 mL of 10% citric acid and 2 x 100 mL of NaHCO3. The mixture was washed with 100 mL of brine and dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was dissolved in 100 mL of CH2Cl and 12 g of silica gel (type: ZCX-2, mesh 100-200) were added. The mixture was concentrated under vacuum and then applied to an atmospheric silica gel column with a CH2Cb / MeOH gradient from 1:0 to 15:1. The eluent product was collected at a 20:1 to 15:1 gradient and concentrated under vacuum. The product was dissolved in 36 mL of n-heptane (20V) and 0.09 g of powdered activated charcoal were added. The mixture was stirred for 4 hours at room temperature and then filtered. 0.09 g of activated charcoal powder was added to the filtrate and the mixture was stirred for another 4 hours at room temperature. The mixture was then filtered.0.045 g of activated charcoal powder was added to the filtrate and the mixture was stirred overnight at room temperature. The mixture was filtered. A mixture of methanol (60 mL) and water (20 mL) was loaded into the filtrate. The mixture was stirred for 30 min at room temperature, held for phase separation, and the upper phase was collected. A mixture of methanol (60 mL) and water (20 mL) was loaded into the n-heptane phase. The mixture was stirred for 30 min at room temperature, held for phase separation, and the upper phase was collected and concentrated to yield 1.5 g (31.9%) of LIPID 1 (HPLC Purity: 96.7%, 205 nm). ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 8 min, wait 0.7 min): RT 7.07 min, m / z (Calcd.) 1042.71, (obtained) 1043.8 (M+H);1H NMR (300 MHz, CDCh): δ 5.27 (m, 2H), 4.33 (dd, J = 11.9, 4.4 Hz, 4H), 4.17 (dd, J = 11.9, 5.7 Hz, 4H), 3.41 (brm, 4H), 2.94 (t, J = 7.3 Hz, 2H), 2.10-2.35 (20H), 1.92 (s, 6H), 1.65 (m, 8H), 1.10-1.57 (40H), 0.96 - 0.85 (12H). Petition 870250102289, dated 07 / 11 / 2025, page 104 / 408 100 / 379 Example 2. Synthesis of LIPID 2: ((4,4'-(((3-(Dimethylamino)propyl)thio)carbonyl) azanediyl)bis (butanoyl))bis(oxy))bis(propane-2,1,3triyl) tetraoctanoate \ 1 c 0 0 c ' General Scheme: 0 ' ο HO^ θ' CH2Cl2, pyridine ' \ \_y> O—, 1-5 °F EDCI, DMAP o . CH2CI2 ^^Χ^χ Ji °χ__ / °-y0^ o-^ / --' 0 — / 2-3 1. triphosgene CH2CI2, pyridine 2. concentrated dissolved / \Z in pyridine 1 3· HS^^^Nx 0 -Χ~Ό θA—\ 0 yy—7 s-^\ A0ZN— 1— 1 LIPID 2 ^X / ° 0 ' \ NaBH3CN λ ---—* “Λ Οχ >=O HOAc, THF ' . ΧΟH o^ 0 \ O 2-1 \ 2-2 / 0 °X \ HCI in EtOAc O 0 ' \ H N-Boc ----------*- Nt — / E,OAc 0 0 / —Zci- o-7 \ / 0 ' 2-4 °X 0 Nχ; x^ í VA °yo / - o-7 / —7 ° -- / LIPID 2 Petition 870250102289, dated 07 / 11 / 2025, page 105 / 408 101 / 379 2-1 synthesis: 2-Oxopropane-1,3-diyl dioctanoate CH2CI2, pyridine

[00346] In a 2 L three-necked round-bottom flask, purged and maintained with an inert nitrogen atmosphere, a solution of 1,3-dihydroxyacetone (50 g, 1.0 eq) and octanoyl chloride (225.8 g, 2.5 eq) in CHCh (900 mL) was placed. Pyridine (175.8 g, 4.0 eq) was added to the reactor while maintaining the temperature at 0°C for 40 minutes. The mixture was stirred at room temperature under nitrogen overnight. The pyridine hydrochloride formed was removed by filtration and washed with CH2O2. The combined filtrate and washes were then washed with 200 mL of 5% aqueous NaHCO3 and brine (200 mL). The solution was then dried over Na2SO4 and concentrated under vacuum. The crude product was mixed with n-heptane (125 mL) for 30 minutes and filtered. This resulted in 98 g (52% yield) 2-1 as a colorless oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., hold 0.7 min): RT 2.09 min, m / z (Calc.) 342.24, (obtained) 343.45 (M+H+). Synthesis of 2-2: 2-Hydroxypropane-1,3-diyl dioctanoate

[00347] In a 3-neck round-bottom balloon with capacity Petition 870250102289, dated 07 / 11 / 2025, page 106 / 408 102 / 379 A solution of 2-1 (20 g, 1.0 eq) was placed in 200 mL of THF, purged, and maintained under an inert nitrogen atmosphere. AcOH (4.56 g, 1.3 eq) was added to the solution at 0°C, and then NaBH3CN (4.3 g, 1.2 eq) at 0°C was added to the mixture. The mixture was stirred for 4 hours at room temperature. The reaction mixture was quenched with 200 mL of water. The mixture was extracted with CH2Cl2 (3 x 200 mL) and the combined organic phases were washed with 5% NaHCO3 (500 mL), brine (500 mL), then dried with Na2SO4. Filtration and concentration under vacuum yielded the crude product 2-2 (19.5 g) which was used in the next step without purification. Synthesis of 2-3: ((4,4'-((tert-Butoxycarbonyl)azanediyl)bis(butanoyl)) bis(oxy))bis(propane-2,1,3-triyl) tetraoctanoate

[00348] In a 500 mL round-bottom, three-necked flask that had been purged and maintained with an inert nitrogen atmosphere, 15 (8.4 g, 1.0 eq) was added and flowed through a 2-inch 2Cl2 solution (175 mL) and the solution was cooled in an ice water bath. DMAP (3.55 g, 1.0 equiv) and EDCI (22.3 g, 4.0 equiv) were added to the solution at 0°C. The reaction mixture was stirred overnight at 25°C. The reaction was then quenched with 200 mL of 10% aqueous citric acid solution. The organic layer was separated, washed with brine (200 mL), and dried over anhydrous sodium sulfate. Vacuum filtration and concentration yielded crude 2Petition 870250102289, dated 07 / 11 / 2025, page 107 / 408 103 / 379 which was dissolved in CH2CI2 and the solution adsorbed onto 54 g of silica gel (type: ZCX-2, 100-200 mesh, 6.43 w / w) and purified on a silica gel column (270 g of silica gel, type: ZCX-2, 100-200 mesh, 32.14 w / w) using a petroleum ether / ethyl acetate gradient from 100:0 to 90:10. The fractions containing the product were pooled, combined and concentrated under reduced pressure to obtain 15 g (55% for 2 steps) of 2-3 as a light yellow oil. Synthesis of 2-4: bis(4-((1,3-bis(octanoyloxy)propan-2-yl)oxy)-4-oxobutyl)ammonium chloride

[00349] In a purged 500 mL round-bottom flask maintained with an inert nitrogen atmosphere, a solution of 23 (15 g, 1.0 equiv) in EtOAc (85.5 mL) was placed, and the mixture was cooled in an ice-water bath. HCl in EtOAc (80 mL, 10.0 equiv, 2 mol / L) was added dropwise at 0-10°C. The resulting solution was stirred overnight at room temperature. The mixture was concentrated under vacuum. This resulted in 13 g (93% yield) of 2-4 as a light yellow oil which was used in the following reaction without further purification. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., wait 0.7 min): RT 0.746 min, m / z (Calc.) 842.60, (obtained) 842.71 (M+H+). Synthesis of LIPID 2: ((4,4'-(((3-(Dimethylamino)propyl)thio) carbonyl) Petition 870250102289, dated 07 / 11 / 2025, pp. 108 / 408 104 / 379 azanediyl)bis (butanoyl))bis(oxy))bis(propane-2,1,3-triyl) tetraoctanoate concentrate dissolved in pyridine 1. triphosgene CH2CI2, pyridine

[00350] In a 500 mL round-bottom, three-necked flask, purged and maintained with an inert nitrogen atmosphere, 2-4 (8 g, 1 eq) dissolved in CH2O2 (280 mL) was placed, and the solution was cooled in an ice bath. Tryphosgene (2.82 g, 1 equiv.) was added to the mixture, followed by the addition of pyridine (3.76 g, 5.00 equiv.), dropwise, with stirring at 0°C. The mixture was stirred for 4 h at room temperature and then concentrated under vacuum. The residue was dissolved with pyridine (160 mL) and the solution was cooled in an ice-water bath under nitrogen. To this solution, 3-(dimethylamino)propane-1-thiol (1.356 g, 1.20 equiv.) was added dropwise with stirring at 0°C for 10 min. The resulting solution was stirred overnight at room temperature. The mixture was concentrated under vacuum and the residue was dissolved in CH2Cl2 (200 mL). The mixture was washed with aqueous citric acid solution (2 x 100 mL), 10% aqueous NaHCO3 (2 x 100 mL) and brine (100 mL).The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product was dissolved in CH2U2 (25 mL) and adsorbed onto 12 g of silica gel (type: ZCX-2, mesh 100-200, 6.43 w / w), and purified on a silica gel column (80 g of silica gel, type: ZCX-2, mesh 100-200, 32.14 w / w) using a CH2Cb / MeOH gradient from 100:0 to 97:3. The fractions containing pure products were analyzed, pooled, combined, and concentrated under reduced pressure. The product thus obtained was dissolved. Petition 870250102289, dated 07 / 11 / 2025, page 109 / 408 105 / 379 in 36 mL of n-heptane and 0.22 g of powdered activated charcoal were added. The mixture was stirred for 4 h at room temperature and then filtered. The filtrate was concentrated under vacuum. This resulted in 3.8 g (42%) of 2 as a pale yellow, viscous oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 2 min., hold 0.7 min): RT 1.48 min, m / z (Calc.) 986.65, (obtained) 987.4 (M+H); 1H NMR (300 MHz, CDCh) δ 5.26 (m, 2H), 4.32 (dd, J = 11.9, 4.4 Hz, 4H), 4.16 (dd, J = 11.9, 5.7 Hz, 4H), 3.40 (brm, 4H), 2.93 (t, J = 7.3 Hz, 2H), 2.39 - 2.25 (18H), 1.91-1.59 (16H), 1.06-1.45 (32H), 0.913 - 0.869 (12H). Example 3. Synthesis LIPID 3: HCl salt bis(1,3-bis(nonanoilóχ1)pr0pan-2:1l)_5-((4-(d1meíilamiΠ0)by1an01l1óχ11nθnan0d10aÍ0 General Outline: 1-2 3-1 Lipid 3 EDCI, DMAP ch2ci2 HCl Petition 870250102289, of 07 / 11 / 2025, p. 110 / 408 106 / 379 Synthesis of 3-2: bis(1,3-bis(nonanoyloxy)propan-2-yl) 5-oxonanodioate

[00351] In a purged 250 mL round-bottom 3-neck flask maintained with an inert nitrogen atmosphere, 3-1 (7.04 g, 1.0 eq, Chemistry - A European Journal 2017, 23, 1274412748) was placed in CH2Cl2 (100 mL), cooled in an ice-water bath under nitrogen. This was followed by the addition of 1-2 (25.95 g, 2.0 eq), DMAP (4.26 g, 1.0 eq) and EDCI (20.09 g, 3.0 eq) at 0 °C. The resulting solution was stirred for 16 hours at room temperature. The reaction mixture was adsorbed onto 90 g of silica gel (type: ZCX-2, mesh 100-200, 6.43 w / w) and purified on a silica gel column (900 g, type: ZCX-2, mesh 100-200) with PE / EA, gradient from 100:0 to 90:10. The fractions containing pure product were pooled, concentrated under vacuum and dried over P2O5 to obtain 19.7 g (62.2%) of 3-2 as a yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., hold 0.7 min): RT 0.87 min, m / z (Calc.) 910.63, (obtained) 933.35 (M+Na). Synthesis of 3-3: bis(1,3-bis(nonanoyloxy)propan-2-yl) 5-hydroxynonodioate Petition 870250102289, of 07 / 11 / 2025, p. 111 / 408 107 / 379

[00352] In a 250 mL round-bottom, three-necked flask, purged and maintained with an inert nitrogen atmosphere, 3-2 (10.7 g, 1.0 eq) was placed in THF (100 mL, 10 V) and cooled in an ice-water bath. This was followed by the addition of HOAc (7.96 g, 11.3 eq) and NaBH3CN (8.88 g, 12.0 eq) at 0°C. The resulting solution was stirred for 16 hours at room temperature. The reaction was then quenched by the addition of water (100 mL, 10 V). The resulting solution was extracted with ethyl acetate (3 x 100 mL) and the organic layers were combined. The resulting mixture was washed with brine (2 x 100 mL). The mixture was dried over anhydrous sodium sulfate and the organic layers were concentrated under vacuum. The reaction mixture was adsorbed onto 40 g of silica gel (type: ZCX-2, mesh 100-200, 6.43 w / w) and purified on a silica gel column (400 g, type: ZCX-2, mesh 100-200) with PE / EA, gradient from 100:0 to 80:20.The fractions containing pure product were combined, concentrated under vacuum and dried over P2O5 to obtain 7.42 g (69.2%) of 3-3 as a yellow ELSD oil A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., hold 0.7 min): RT 0.87 min, m / z (Calc.) 913.27, (obtained) 935.35 (M+Na). Synthesis of LIPID 3: HCl salt bis(1,3-bis(nonanoyloxy)propan-2-yl) 5-((4-(dimethylamino)butanoyl)oxy)nonanedioate

[00353] In a 250 mL round-bottom, three-necked flask, purged and maintained with an inert nitrogen atmosphere, a 3-3 solution (7.42 g, 1.0 eq) was placed in CH2Cl2 (110 mL), cooled in a water bath. Petition 870250102289, dated 07 / 11 / 2025, p. 112 / 408 108 / 379 of ice water. HCl salt of 4-(dimethylamino)butanoic acid (1.63 g, 1.2 eq), DMAP (0.4 g, 0.4 eq) were added, followed by the addition of EDCI (3.74 g, 2.4 eq) in portions at 0°C. The resulting solution was stirred for 16 hours at room temperature. Silica gel (40 g, type: ZCX-2, mesh 100-200, 6.43 wt / wt) was added to the reaction and adsorbed onto the silica gel. It was purified on a silica gel column (300 g, type: ZCX-2, mesh 100-200) with EtOAc / THF, gradient from 100:0 to 75:25. The fractions containing pure product were combined and concentrated under vacuum to obtain 1.9 g (26.3%) of 3 as a yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min, wait 0.7 min): RT 1.89 min, m / z (Calcd.) 1025.74, (obtained) 1026.55 (M+H);1H NMR (300 MHz, CDCh): δ 5.21 (m, 2H), 4.89 (brs, 1H), 4.34 (m, 4H), 4.13 (m, 4H), 2.27-2.37 (16H), 2.22 (s, 6H), 2.04 (brm, 2H), 1.80 (m, 2H), 1.59-1.74 (14H), 1.15-1.28 (40H), 0.85-0.96 (12H). Example 4. Synthesis of LIPID 4: bis(1,3-bis(Octanoyloxy)propan2-yl) 5-((4-(dimethylamino)butanoyl)thio)nonanedioate General Outline: Petition 870250102289, dated 07 / 11 / 2025, p. 113 / 408 109 / 379 Petition 870250102289, dated 07 / 11 / 2025, p. 114 / 408 110 / 379 Synthesis of 4-1: bis(1,3-bis(octanoyloxy)propan-2-yl) 5-oxononanedioate

[00354] In a 1 L round-bottom, 3-necked flask, 3-1 (20.0 g, 98.909 mmol, 1.00 equiv), 2-2 (68.2 g, 197.818 mmol, 2 equiv) and DMAP (36.3 g, 296.727 mmol, 3 equiv) were placed in CH2Cl2 (600 mL), cooled in an ice-cold water bath under nitrogen. This was followed by the addition of EDCI (56.9 g, 296.727 mmol, 3 equiv) in several batches at 0 °C. The resulting solution was stirred for 16 hours at room temperature. The reaction was then quenched by the addition of aqueous HCl (1 mol / L, 75 mL). The resulting solution was extracted with CH2Cl2 (200 mL). The combined organic phases were washed with brine (2 x 200 mL). The mixture was dried over anhydrous sodium sulfate and concentrated. The crude material was dissolved in CH2Cl2 (200 mL) and adsorbed onto silica gel (108 g, type: ZCX-2, mesh 100-200) and purified on a silica gel column (720 g, type: ZCX-2, mesh 100-200) with a PE / EA gradient of 100:0 to 90:10.The fractions containing the pure product were combined and concentrated under vacuum to obtain 50 g (53.2%) 4-1 as a yellow oil. ELSD A: water / 0.05% TFA: B: CHaCN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., hold 0.7 min): RT 1.74 min, m / z 854.58 (Calc.), (obtained) 877.75 (M+Na). Petition 870250102289, dated 07 / 11 / 2025, p. 115 / 408 111 / 379 Synthesis of 4-2: bis(1,3-bis(octanoyloxy)propan-2-yl) 5-hydroxynonanedioate

[00355] In a 1 L round-bottom, 3-necked flask, 4-1 (50.0 g, 58.469 mmol, 1.00 equiv) was placed in THF (500 mL). This solution was cooled in an ice-water bath under nitrogen, and HOAc (35.1 g, 584.686 mmol, 10 equiv) was added at 0 °C. To this, NaBH3CN (36.7 g, 584.686 mmol, 10 equiv) was added in several portions at 0 °C. The resulting solution was stirred for 3 hours at room temperature. The reaction was then quenched by the addition of water (200 mL). The resulting solution was extracted with dichloromethane (1000 mL). The organic phase was dried over anhydrous Na2SO4 and concentrated. The crude material was adsorbed onto silica gel (160 g, type: ZCX-2, mesh 100-200) and purified on a silica gel column (400 g, type: ZCX-2, mesh 100-200) with a PE / EA gradient of 100:0 to 90:10. The fractions containing the pure product were pooled and concentrated under vacuum to obtain 20 g (40%) 4-2 as a yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B for 3 min., wait 0.7 min): RT 1.00 min, m / z 856.59 (Calc.), (obtained) 879.70 (M+Na). Petition 870250102289, dated 07 / 11 / 2025, page 116 / 408 112 / 379 Synthesis of 4-3: bis(1,3-bis(octanoyloxy)propan-2-yl) 5-((methylsulfonyl)oxy)nonanedioate

[00356] In a 500 mL three-necked round-bottom flask, 4-2 (25.0 g, 29.166 mmol, 1.00 equiv) and EtaN (5.9 g, 58.331 mmol, 2 equiv) were placed in CH2O2 (250 mL) and cooled in an ice-water nitrogen bath. This was followed by the dropwise addition of MsCl (5.0 g, 43.748 mmol, 1.5 equiv) with stirring at 0 °C for 20 min. The resulting solution was stirred for 3 hours at room temperature. The reaction was then quenched by the addition of water / ice (100 mL). The resulting solution was extracted with CH2Cl2 (2 x 100 mL). The combined organic phases were washed with brine (100 mL) and dried over Na2SO4. After concentration, this resulted in 24 g (crude) 4-3 as light yellow oil which was used as such in the following reaction. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 2 min., wait 0.7 min): RT 1.71 min, m / z 934.57 (Calc.), (obtained) 957.65 (M+Na). 4-4 synthesis: bis(1,3-bis(octanoyloxy)propan-2-yl) 5-mercaptononanedioate Petition 870250102289, dated 07 / 11 / 2025, page 117 / 408 113 / 379

[00357] In a 500 mL three-necked round-bottom flask, 4-3 (30.0 g, 32.077 mmol, 1.00 equiv) was placed in DMF (300, 10 V), and the mixture was cooled in an ice-water bath under nitrogen. This was followed by the addition of NaSH (9.0 g, 160.383 mmol, 5.00 equiv) in three portions over 1.5 hours at 0 °C. The resulting solution was stirred for 5 hours at room temperature. The reaction was then quenched by the addition of water / ice (100 mL). The mixture was extracted with EtOAc (3 x 100 mL). The combined organic phases were washed with brine (2 x 100 mL). The mixture was dried over anhydrous sodium sulfate and concentrated. This resulted in 10 g (crude) of 4-4 as a light yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 2 min., wait 0.7 min): RT 1.17 min, m / z 872.57 (Calc.), (obtained) 895.70 (M+Na). Synthesis of LIPID 4: bis(1,3-bis(Octanoyloxy)propan-2-yl) 5-((4-(dimethylamino)butanoyl)thio)nonanedioate

[00358] In a 250 mL three-necked round-bottom flask, 4-4 (12.0 g, 13.742 mmol, 1.00 equiv), 4-(dimethylamino)butanoic acid (2.2 g, 16.490 mmol, 1.2 equiv) and DMAP (2.0 g, 16.490 mmol, 1.2 equiv) were mixed in DCM (120 mL), and the solution was cooled in an ice-water bath under nitrogen. This was followed by the addition of EDCI (3.16 g, 16.490 mmol, 1.2 equiv) in several batches at 0°C. The resulting solution was stirred for 16 hours at room temperature. The reaction was then quenched by the addition of aqueous HCl (1 mol / L, 50 mL). The solution Petition 870250102289, dated 07 / 11 / 2025, p. 118 / 408 The resulting 114 / 379 was extracted with dichloromethane (2 x 100 mL). The combined organic phases were washed with brine (2 x 100 mL) and dried over anhydrous sodium sulfate and then concentrated. The crude material was adsorbed onto silica gel (25 g, type: ZCX-2, mesh 100-200) and purified on a silica gel column (200 g, type: ZCX-2, mesh 100-200) with a CH2Cl2 / MeOH gradient from 100:0 to 25:1. The fractions containing the pure product were pooled and concentrated under vacuum to obtain 1.5 g (three-step yield of 6.5%) of LIPID 4 as a light yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 2 min., wait 0.7 min): RT 1.15 min, m / z 985.66 (Calc.), (obtained) 986.55 (M+Na); 1H-NMR (400 MHz, CDCh): δ 5.26 (m, 2H), 4.31 (m, 4H), 4.15 (m, 4H), 3.53 (brs, 1H), 2.61 (t, J = 7.5 Hz, 2H), 2.39-2.28 (14H), 2.24 (s, 6H), 1.85 (m, 2H), 1.787-1.512 (16H), 1.34-1.29 (32H), 0.98-0.80 (12H). Example 5.Synthesis of LIPID 5: bis(1,3-bis(Nonanoyloxy)propan-2yl) 4-((4-(dimethylamino)butanoyl)oxy)heptanedioate. Petition 870250102289, dated 07 / 11 / 2025, page 119 / 408 115 / 379 General Outline: EDCI, DMAP, CH2CI2 HS. EtO2C HO2C ho2c 'SH BF2-OEt2 6N aq. NaOH EtOH CH2CI EtO2C HO2C ho2c OH HOAc.THF acetone CH2CI Lipid 5 Synthesis of 5-1: 4-oxoheptanedioic acid NBS NaBH3CN EDCI, DMAP EtO2C 6N aq. NaOH EtOH HO2C 5-1

[00359] EtOH (25 mL, 5 V) and diethyl-4-oxo-heptanesioate (5 g, 1 eq) were added to a three-necked round-bottom flask at room temperature under nitrogen. The mixture was cooled in an ice-water bath, and then aqueous sodium hydroxide (6 N, 25 mL) was slowly added to the mixture at 0 °C. The resulting solution was then heated and stirred for 2 h at 60 °C. After cooling to room temperature, brine (50 mL) and CH2Cl2 (50 mL) were added to the mixture and stirred for 10 minutes, then the aqueous phase was separated. The pH of the aqueous phase was adjusted to 3-4 with 3 N HCl. The mixture was extracted with CH2Cl2 (100 mL). The organic phase was dried with anhydrous MgSO4 and then filtered. Concentration under vacuum provided Petition 870250102289, dated 07 / 11 / 2025, page 120 / 408 116 / 379 5-1 (3.2 g, 84.6% yield) as a light yellow solid. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 2 min., hold 0.7 min): RT 0.81 min, m / z 174.05 (Calc.), (obtained) 197.06 (M+Na). Synthesis of 5-2: 3,3'-(1,3-dithiolane-2,2-diyl)dipropionic acid

[00360] To a round-bottom flask with three necks, CH2Cl2 (32 ml), 5-1 (3.2 g, 1 eq) and ethane-1,2-dithiol (2.1 g, 1.2 eq) were added one portion at room temperature. The mixture was cooled in an ice-water bath under nitrogen and BF3.Et2O (6.48 g, 2.5 eq) was slowly added to the mixture at 0 °C. The resulting solution was stirred for 16 hours at 20 °C. The solid was collected by filtration. The solid was dried under vacuum to give 5-2 (4 g, 88% yield) as a light yellow solid. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 2 min., wait 0.7 min): RT 0.20 min, m / z 250.03 (Calc.), (obtained) 268.2 (M+Na). Synthesis of 5-3: ((3,3'-(1,3-Dithiolane-2,2-diyl)bis(propanoyl)) bis(oxy)) bis(propane-2,1,3-triyl) tetranonanoate Petition 870250102289, dated 07 / 11 / 2025, page 121 / 408 117 / 379

[00361] To a round-bottom flask with three necks, CH2Cl2 (100 mL), 5-2 (5 g, 1.0 eq), 1-2 (16.37 g, 2.2 eq), and DMAP (2.44 g, 1 eq) were successively added. The mixture was cooled in an ice-water bath under nitrogen, then EDCI (8.42 g, 2.2 eq) was added to the reaction mixture at 0 °C in portions. The resulting solution was stirred for 16 hours at 20 °C. The reaction system was quenched with 10% aqueous citric acid (50 mL). The organic phase was separated, washed with 10% aqueous citric acid solution (50 mL), brine (50 mL), and dried with anhydrous MgSO4, then filtered. Vacuum concentration yielded crude 5-3 which was dissolved in CH2Cl2 (50 mL) and the solution was adsorbed onto silica gel (50 g, type: ZCX-2, mesh 100-200) and purified on a silica gel column (200 g, type: ZCX-2, mesh 100-200) with a PE / EA gradient of 100:0 to 98:2. The fractions containing pure product were pooled and concentrated under vacuum to yield 5-3 (16.1 g, 84% yield) as a colorless oil.(Due to weak ionization, no mass was observed. Thus, without further characterization, the molecule was used in the next step.) Synthesis of 5-4: bis(1,3-bis(nonanoyloxy)propan-2-yl) 4-oxoheptanedioate

[00362] Acetone (400 mL) and 5-3 (16 g, 1.0 eq) were added to a round-bottom flask with three necks and the solution was cooled. Petition 870250102289, dated 07 / 11 / 2025, page 122 / 408 118 / 379 At -20°C under nitrogen, NBS (11.87 g, 4 eq) in acetone (80 mL) was added dropwise to the reaction mixture over a period of 15 minutes. The resulting solution was stirred for 1 h at -20°C. The reaction was quenched with H2O (320 mL) and heated to room temperature. The acetone was removed by concentration under vacuum and the mixture was extracted with EtOAc (160 mL). The organic phase was dried over Na2SO4, filtered, and the solvent was removed under reduced pressure. The crude material was dissolved in CH2Cl2 (75 mL), and adsorbed onto silica gel (30 g, type: ZCX-2, mesh 100-200) and purified on a silica gel column (200 g, type: ZCX-2, mesh 100-200) with a PE / EA gradient of 100:0 to 97:3. The fractions containing the pure product were pooled and concentrated under vacuum to obtain 5-4 (10.3 g, 70% yield) as a colorless oil. 1H NMR (300 MHz, CDCh) δ 5.23 (q, J = 5.0 Hz, 2H), 4.30 (dd, J = 11.9, 4.4 Hz, 4H), 4.16 (dd, J = 12.0, 5.7 Hz, 4H), 2.78 (t, J = 6.5 Hz, 4H), 2.63 (t, J = 6.6 Hz, 4H), 2.33 (t, J = 7.5 Hz, 8H), 1.67 - 1.53 (10H), 1.37 - 1.24 (38H), 0.94 - 0.84 (m, 12H). Synthesis of 5-5: bis(1,3-bis(nonanoyloxy)propan-2-yl) 4-hydroxyheptanodioate

[00363] In a 500 mL round-bottom, four-necked flask, purged and maintained with an inert nitrogen atmosphere, 5-4 (10.3 g, 1 eq) and THF (100 mL) were placed. AcOH (7.0 g, 10 eq) was added to this and the solution was cooled in an ice-water bath. This was followed Petition 870250102289, dated 07 / 11 / 2025, p. 123 / 408 119 / 379 by adding NaBHaCN (7.32 g, 10 eq) in several batches at 0°C. The resulting solution was stirred for 18 hours at 25°C. The reaction system was quenched with H2O (400 mL). The mixture was extracted with EtOAc (100 mL), the organic phase was separated, dried over Na2SO4, filtered, and concentrated under vacuum. Crude 5-5 was dissolved in CH2Cl2 and adsorbed onto silica gel (30 g, type: ZCX-2, mesh 100-200) and purified on a silica gel column (150 g, type: ZCX-2, mesh 100-200) with a PE / EA gradient of 100:0 to 95:5. The fractions containing pure product were pooled and concentrated under vacuum to obtain 5-5 (6 g, 70% yield) as a colorless oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 5 min., wait 0.7 min): RT 3.48 min, m / z 884.62 (Calc.), (obtained) 907.35 (M+Na). Synthesis of LIPID 5: bis(1,3-bis(Nonanoyloxy)propan-2-yl) 4-((4-(dimethylamino)butanoyl)oxy)heptanedioate

[00364] To a round-bottom flask with three necks, 5-5 (4 g, 1 eq), 4-(dimethylamino)butanoic acid (0.99 g, 1.3 eq), DMAP (0.39 g, 0.7 eq), and CH2Cl2 (60 mL) were successively added. The mixture was cooled in an ice-water bath under nitrogen, then EDCI (1.21 g, 1.4 eq) was added to the reaction mixture at 0 °C in portions. The resulting solution was stirred for 16 hours at 20 °C. The reaction system was quenched with 10% aqueous citric acid solution (40 mL). The organic phase was separated, washed with 10% citric acid solution (40 mL), brine (40 mL), dried with anhydrous MgSO4, and then filtered. The solvent was removed under vacuum, and the residue was dissolved in CH2Cl2. Petition 870250102289, dated 07 / 11 / 2025, page 124 / 408 120 / 379 (25 mL), the crude material was adsorbed onto silica gel (10 g, type: ZCX-2, mesh 100-200) and purified on a silica gel column (50 g, type: ZCX-2, mesh 100-200) with a CH2Cb / MeOH gradient from 100:0 to 80:1. The fractions containing pure product were pooled and concentrated under vacuum to yield 5 (1.2 g, 27% yield) as a light yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 2 min, wait 0.7 min): RT 1.82 min, m / z 997.71 (Calcd.), (obtained) 998.56 (M+H);1H-NMR (300 MHz, CDCh): δ 5.24 (m, 2H), 4.96 (dd, J = 8.1,4.2 Hz, 1H), 4.30 (m, 4H), 4.15 (m, 4H), 2.41-2.25 (20H), 1.80-1.92 (6H), 1.67-1.54 (10H), 1.02-1.49 (40H), 0.94 - 0.84 (12H). Example 6. Lipid Synthesis 6a General Outline: ho2c OCH2Ph ​​H2, Pd / C N-Boc HO y OCH2Ph ​​​​ÕH HO2C EDCI, DMAP, CH2CI2 OH ChoClo, pyridine MeOH NH CH.CI Lipid 6a 3.HS 1. triiogeneum CH2Cl2, pyridine 2. concentrated, dissolved in pyridine TFA Petition 870250102289, dated 07 / 11 / 2025, page 125 / 408 121 / 379 Synthesis of 6-1: (S)-3-(benzyloxy)propane-1,2-diyl dinonanoate

[00365] To a three-necked flask, CH2Cl2 (60 mL), (R)3-(benzyloxy)propane-1,2-diol (3 g, 1 eq), and nonanoyl chloride (6.4 g, 2.2 eq) were added as a portion at room temperature. The mixture was cooled in an ice-water bath under nitrogen. Pyridine (3.90 g, 3 eq) was added to the reaction mixture at 0°C over a period of 10 minutes. The resulting solution was stirred for 16 hours at 20°C. The reaction was then quenched by the addition of 30 mL of water and stirred for 10 min. The organic phase was separated. The aqueous layer was extracted with CH2Cl2 (75 mL). The combined organic layers were dried over anhydrous sodium sulfate and then filtered. Concentration under vacuum yielded crude 6-1 which was dissolved in CH2Cl2 (50 mL) which was adsorbed onto 20 g of silica gel (type: ZCX-2, mesh 100-200, 6.43 w / w) and purified on a silica gel column (100 g of silica gel, type: ZCX-2, mesh 100-200, 32.14 w / w) using a petroleum ether / EtOAc gradient from 100:0 to 50:1.The fractions containing pure products were analyzed, combined, and concentrated under reduced pressure to provide the 6-1 (6.0 g, 80% yield) as a colorless oil. ELSD A: water / 0.05%. TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 2 min., wait 0.7 min): RT 1.1 min, m / z (Calc.) 462.33, (obtained) 485.2 (M+Na). Synthesis of 6-2: (S)-3-hydroxypropane-1,2-diyl dinonanoate

[00366] MeOH (60 mL), 6-1 (6 g, 1 eq), Pd / C (0.6 g, 10% by weight) were added to a three-necked flask under a nitrogen atmosphere. Petition 870250102289, dated 07 / 11 / 2025, page 126 / 408 122 / 379 at room temperature. The flask was evacuated and washed three times with hydrogen. The mixture was stirred for 16 hours at room temperature under a hydrogen atmosphere (flask). It was filtered, and the filtrate was concentrated to dryness under vacuum to provide 6-2 (3.1 g, 64% yield) as a colorless oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 2 min., hold 0.7 min): RT 0.89 min, m / z (Calc.) 3722.29, (obtained) 395.3 (M+Na). Synthesis of 6-3: (2R,2'R)-((3,3'-((tert-Butoxycarbonyl)azanodiyl)bis(propanoyl))bis(oxy))bis(propane-3,1,2-triyl)tetranonanoate

[00367] To a round-bottom flask with three necks, CH2Cl2 (20 mL), 3,3'-((tert-butoxycarbonyl)azanodiyl)dipropionic acid (commercially available, 1 g, 1.0 eq), 6-2 (3.10 g, 2.2 eq) and DMAP (0.47 g, 1 eq) were successively added, and the mixture was cooled in an ice-cold water bath under nitrogen. EDCI (1.60 g, 2.2 eq) was added to the reaction mixture at 0 °C in portions over 10 minutes. The resulting solution was stirred for 16 hours at 20 °C and the reaction was quenched with 10% citric acid solution (10 mL). The organic phase was separated and washed with aqueous solution. 10% citric acid (10 mL), brine (10 mL) and dried with anhydrous MgSO4 and then filtered. Concentration under vacuum yielded crude product 6-3 which was dissolved in CH2Cl2 (10 mL) and adsorbed onto 5 g of silica gel (type: ZCX-2, mesh 100-200, 6.43 w / w), and purified on a silica gel column (25 g of silica gel, type: ZCX). Petition 870250102289, dated 07 / 11 / 2025, page 127 / 408 123 / 379 2, mesh 100-200, 32.14 p / p) using a petroleum ether / EtOAc gradient of 100:0 to 50:1. The fractions containing pure products were analyzed, pooled, combined and concentrated under reduced pressure to provide 6-3 (3 g, 81% yield) as a yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., hold 0.7 min): RT 2.35 min, m / z (Calc.) 969.68, (obtained) 992.5 (M+Na). Synthesis of 6-4: (2R,2'R)-((3,3'-Azanediylbis(propanoyl))bis(oxy))bis(propane-3,1,2-triyl) tetranonanoate

[00368] To a three-necked flask, CH2Cl2 (60 mL) was added, 6-3 (3 g, 1 eq) as a portion at room temperature. The mixture was cooled in an ice-water bath under nitrogen, then TFA (4.5 mL) was slowly added to the reaction mixture at 0-5°C. The reaction mixture was stirred for 2 hours at 25°C. The reaction was then quenched by the addition of 5% sodium carbonate solution (10% by weight, 30 mL). The organic phase was separated. The organic phase was washed with brine (2 x 30 mL), dried with anhydrous MgSO4, and then filtered and concentrated to dryness under vacuum to provide 6-4 (2.5 g, 94% yield) as a yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., wait 0.7 min): RT 0.87 min, m / z (Calc.) 869.62, (obtained) 892.40 (M+Na). Petition 870250102289, dated 07 / 11 / 2025, page 128 / 408 124 / 379 Lipid Synthesis 6a

[00369] To a three-necked flask, CH2Cl2 (50 mL, 20 V), 6-4 (2.50 g, 1 eq) was added as a portion at room temperature. The mixture was then cooled in an ice-water bath under nitrogen, and then tryphosgene (0.85 g, 1 eq) was added to the reaction mixture at 0–5°C in portions. Pyridine (1.13 g, 5 eq) was added slowly to the reaction mixture over 2 ± 0.5 hours. After the addition, the reaction mixture was stirred for 2 hours at room temperature. The solvent was evaporated under reduced pressure, and the residue was dissolved in anhydrous pyridine (50 mL, 20 V) and cooled in an ice-water bath under nitrogen. To this was added 3-(dimethylamino)-1-propanethiol hydrochloride (0.41 g, 1.2 eq) at 0°C. After the addition, the above mixture was stirred for 18 hours at room temperature. The solvent was removed by rotary evaporation under vacuum. The mixture was diluted with CH2Cl2 (50 mL). The organic phase was washed with aqueous solution of 10% citric acid (3 x 25 mL).The organic phase was dried with anhydrous MgSO4 and then filtered. Concentration under vacuum gave crude LIPID 6a which was adsorbed onto 10 g of silica gel (type: ZCX-2, mesh 100-200, 6.43 w / w) and purified on a silica gel column (50 g silica gel, type: ZCX-2, mesh 100-200, 32.14 w / w) using a CH2Cl2 / MeOH gradient from 100:0 to 98:2. The fractions containing pure products were analyzed, pooled, combined and concentrated under reduced pressure to yield 6 (1.2 g, 41% yield) as a yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 2 min., wait 0.7 min): RT 1.1 min, m / z (Calc.) 1014.68, (obtained) 1015.68 (M+H);1H NMR (300 MHz, CDCh) δ. Petition 870250102289, dated 07 / 11 / 2025, p. 129 / 408 125 / 379 5.26 (m, 2H), 4.31 (m, 4H), 4.15 (m, 4H), 3.65 (t, J = 7.2 Hz, 4H), 2.93 (t, J = 7.3 Hz, 2H), 2.65 (t, J = 7.1 Hz, 4H), 2.50-2.19 (16H), 1.52-1.70 (10H), 1.36-1.23 (40H), 0.93-0.83 (12H). Example 7. Lipid Synthesis 7: bis(1,3-bis(octanoyloxy)propan-2-yl) 4-((4-(dimethylamino)butanoyl)thio)heptanedioate General Scheme \'yso ——o HO2C 2.20 θ4 EDCI, DMAP, CH2CI2 HO2C '—. 52 0 0 o? \ \ 7-1 °\ °\ rJ ο o ° 0 \ \ MsCI \___ )— OH --------► ' \ x___ / Et3N, CH2CI2 - Αό \ Λο \ 0 / 0 2 O 0 \__ 7-3 7-4 HCU^A0H EDCI, DMAP CH2CI2 —V—. °\ rJ o S', NBS \__ '--·. NaBH3CN J --:--- \ F° 3 acetone S H0Ac'THF00 o? \ 7-2 \ 0 o ° o^; NaSH \___ \ VoMs ------► ' λ )—SH _ / DMF V____ / λο-^ 00 o; \ x7-5 ^^yo —y O V0'__ / O \l— 0 °F / —' mF 00 o; \ \ LIPID-7 Petition 870250102289, dated 07 / 11 / 2025, page 130 / 408 126 / 379 Synthesis of 7-1: ((3,3'-(1,3-Dithiolane-2,2-diyl)bis(propanoyl))bis(oxy)) bis(propane-2,1,3-triyl) tetraoctanoate

[00370] In a purged 500 mL three-necked round-bottom flask maintained with an inert nitrogen atmosphere, 5-2 (16 g, 1.0 equiv) was placed in CH2O2 (240 mL). This was followed by the addition of 2-2 (48 g, 2.0 equiv) DMAP (23 g, 1.0 equiv) and the mixture was cooled in an ice-water bath under nitrogen. To this cooled solution, EDCI (36.8 g, 3.0 equiv) was added at 0 °C in portions over 45 minutes. The resulting solution was stirred for 16 hours at room temperature. This reaction mixture was adsorbed onto silica gel (110 g, type: ZCX-2, mesh 100200) and purified on a silica gel column (800 g, type: ZCX-2, mesh 100200) with petroleum ether / EtOAc gradient from 100:0 to 90:10. The fractions containing pure product were pooled and concentrated under vacuum to yield 7-1 (60 g, 95% yield) as a yellow oil. ELSD A: water / 0.05% TFA; B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 2 min., hold 0.7 min): RT 1.60 min, m / z 902.52 (Calc.), (obtained) 925.50 (M+Na). Synthesis of 7-2: bis(1,3-bis(octanoyloxy)propan-2-yl) 4-oxo-heptanedioate Petition 870250102289, dated 07 / 11 / 2025, p. 131 / 408 127 / 379

[00371] Acetone (1.5 L) and 7-1 (60 g, 1.0 equiv.) were added to a 3 L three-necked round-bottom flask. The mixture was cooled to 20°C under nitrogen, then a solution of NBS (47.3 g, 4.0 equiv.) in acetone (300 mL) was added dropwise to the reaction mixture over 15 minutes. The resulting solution was stirred for 1 h at -20°C. The reaction was quenched with water (300 mL), heated to room temperature, and concentrated under vacuum to remove the acetone. The mixture was extracted with EtOAc (600 mL), the organic phase (Na2SO4) was dried, filtered, and concentrated under vacuum to obtain the crude product 7-2. The solvent was removed under reduced pressure. Crude 7-2 was dissolved in CH2Cl2 (200 mL) and adsorbed onto silica gel (120 g, type: ZCX-2, 100-200 mesh) and purified on a silica gel column (800 g, type: ZCX-2, 100-200 mesh) with petroleum ether / EtOAc gradient from 100:0 to 90:10.The fractions containing pure product were combined and concentrated under vacuum to generate 7-2 (44 g, 80% yield) as a colorless oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 2 min., hold 0.7 min): RT 1.36 min, m / z 826.54 (Calc.), (obtained) 849.50 (M+Na). Synthesis of 7-3: bis(1,3-bis(octanoyloxy)propan-2-yl) 4-hydroxyheptanedioate

[00372] In a 1 L round-bottom, 4-necked flask, purged and maintained with an inert nitrogen atmosphere, 7-2 (44 g, 1.0 equiv) was placed in THF (400 mL). To this was added HOAc (37 g, 12.0 Petition 870250102289, dated 07 / 11 / 2025, p. 132 / 408 128 / 379 equiv) at 0°C. This was followed by the addition of NaBH3CN (39 g, 12.0 equiv) in several batches at 0°C. The resulting solution was stirred for 18 hours at 25°C. The reaction was quenched with water (800 mL). The mixture was extracted with EA (800 mL). The organic phase was separated, dried over Na2SO4, filtered, and concentrated under vacuum to yield crude product 7-3. Crude 7-3 was dissolved in CH2Cl2 (150 mL) and adsorbed onto silica gel (80 g, type: ZCX-2, mesh 100-200) and purified on a silica gel column (800 g, type: ZCX-2, mesh 100-200) with petroleum ether / EtOAc gradient from 100:0 to 80:20. The fractions containing pure product were combined and concentrated under vacuum to yield 7-3 (16 g, 36% yield) as a colorless oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 2 min., hold 0.7 min): RT 1.32 min, m / z 828.56 (Calc.), (obtained) 851.50 (M+Na). Synthesis of 7-4: bis(1,3-bis(octanoyloxy)propan-2-yl) 4-((methylsulfonyl)oxy)heptanedioate

[00373] In a 500 mL three-necked round-bottom flask, 7-3 (16 g, 1.0 equiv) and Et3N (2.4 g, 1.2 equiv) were placed in DCM (160 mL) and the solution was cooled in an ice-water bath under nitrogen. MsCl (2.42 g, 1.1 equiv) was added dropwise to this cooled solution with stirring at 0 °C for 20 min. The resulting solution was stirred for 3 hours at room temperature. The reaction was then quenched by the addition of water / ice (100 mL). The resulting solution was extracted with Petition 870250102289, dated 07 / 11 / 2025, p. 133 / 408 129 / 379 dichloromethane (2 x 00 mL). The combined organic phases were washed with brine (100 mL). The organic phase was separated, dried over Na2SO4, filtered, and the solvent was removed under reduced pressure to yield crude product 7-4. Crude 7-4 was dissolved in CH2Cl2 (75 mL) and adsorbed onto silica gel (32 g, type: ZCX-2, mesh 100-200) and purified on a silica gel column (500 g, type: ZCX-2, mesh 100-200) with petroleum ether / EtOAc gradient from 100:0 to 80:20. The fractions containing pure product were pooled and concentrated under vacuum to yield 7-4 (10 g, 60% yield) as a colorless oil. ELSD A: water / 0.05% TFA: B: CHaCN / 0.05% TFA 95:5 to 5:95 A / B at 2 min, wait 0.7 min): RT 1.26 min, m / z 906.54 (Calc.), (obtained) 929.50 (M+Na). Synthesis of 7-5: bis(1,3-bis(octanoyloxy)propan-2-yl) 4-((methylsulfonyl)oxy)heptanedioate

[00374] In a 500 mL three-necked round-bottom flask, 7-4 (200 mg, 1.0 equiv) was placed in DMF (4 mL) and the solution was cooled in an ice-water bath under nitrogen. This was followed by the addition of NaSH (37.5 mg, 3.0 equiv.) at 0 °C. The resulting solution was stirred for 3 hours at 0 °C. The reaction was then quenched by the addition of water / ice (20 mL). The resulting solution was extracted with ethyl acetate (40 mL). The organic phase was separated and washed with brine (2 x 30 mL). Petition 870250102289, dated 07 / 11 / 2025, page 134 / 408 (130 / 379 mL). The same scale reaction process was repeated 50 times. The combined mixture (from the repeated reactions) was dried over anhydrous sodium sulfate and concentrated under vacuum to yield crude product 7-5. Crude 7-5 was dissolved in THF (75 mL) and adsorbed onto silica gel (20 g, type: ZCX-2, 100-200 mesh) and purified on a silica gel column (200 g, type: ZCX-2, 100-200 mesh) with petroleum ether / EtOAc gradient from 100:0 to 80:20. The fractions containing pure product were pooled and concentrated under vacuum to yield 7-5 (3 g, 32% yield) as a light yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 2 min., wait 0.7 min): RT 1.26 min, m / z 844.54 (Calc.), (obtained) 845.65 (M+H). Synthesis of LIPID 7: bis(1,3-bis(Octanoyloxy)propan-2-yl) 4-((4-(dimethylamino)butanoyl)thio)heptanedioate

[00375] In a 100 mL round-bottom, three-necked flask, purged and maintained with an inert nitrogen atmosphere, a solution of 7-5 (3 g, 1.0 equiv) was placed in CH2U2 (30 mL). HCl salt of 4-(dimethylamino)butanoic acid (0.71 g, 1.2 equiv), DMAP (0.43 g, 1.0 equiv) were added and the mixture was cooled in an ice-water bath. This was followed by the addition of EDCI (1.02 g, 1.5 equiv) in portions at 0 °C. The resulting solution was stirred for 16 hours at room temperature. The reaction mixture was adsorbed onto silica gel (250 g, type: ZCX2, mesh 100-200) and purified on a silica gel column (250 g, type: ZCX2). Petition 870250102289, dated 07 / 11 / 2025, page 135 / 408 131 / 379 2, mesh 100-200) with n-heptane / acetone gradient from 100:0 to 50:50. The fractions containing pure product were pooled and concentrated under vacuum to give LIPID 7 (1.1 g, 32% yield) as a yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 2 min., hold 0.7 min): RT 0.75 min, m / z 957.52 (Calc.), (obtained) 958.50 (M+H). 1H-NMR (300 MHz, CDCh): δ 5.25 (m, 2H), 4.29 (m, 4H), 4.15 (m, 4H), 3.54 (brm, 1H), 2.62 (t, J = 7.4 Hz, 2H), 2.52-2.21 (20H), 2.03 (m, 2H), 1.83 (m, 4H), 1.61 (m, 8H), 1.39-1.17 (28H), 0.970.80 (16H). Example 8. Synthesis of LIPID 8: ((2,2'-((((3-(Dimethylamino)propyl)thio)carbonyl)azanediyl)bis(acetyl))bis(oxy))bis(propane-2,1,3-triyl) tetranonanoate General Outline: Petition 870250102289, dated 07 / 11 / 2025, p. 136 / 408 132 / 379 8-1 synthesis: ((2,2'-(( tert- butoxycarbonyl)azanodiyl)bis(acetyl))bis(oxy))bis(propane-2,1,3-triyl) tetranonanoate

[00376] To a round-bottom flask with three necks, 2,2'-((tert-butoxycarbonyl)azanodiyl)diacetic acid (1 g, 1.0 eq), 12 (3.50 g, 2.2 eq) and DMAP (0.52 g, 1 eq) were added in DCM (20 mL) and the solution was cooled in an ice-water bath under nitrogen. To this cooled solution, EDCI (1.80 g, 2.2 eq) at 0 °C was added in several portions. The resulting solution was stirred for 16 hours at 20 °C. The reaction was quenched with 10% aqueous citric acid solution (10 mL). The organic phase was separated, washed with 10% aqueous citric acid solution (10 mL, 10 V), brine (10 mL, 10 V) and dried with anhydrous MgSO4. Filtration and vacuum concentration yielded crude product 81, which was dissolved in CH2Cl2 (15 mL), adsorbed onto 5 g of silica gel (type: ZCX-2, mesh 100-200, 6.43 w / w), and purified on a silica gel column (20 g of silica gel, type: ZCX-2, mesh 100-200, 32.14 w / w). Petition 870250102289, dated 07 / 11 / 2025, p. 137 / 408 133 / 379 using petroleum ether / EtOAc (volume ratio). (gradient from 100:0 to 50:1). The fractions containing pure products were analyzed, pooled, combined and concentrated under reduced pressure to provide 8-1 (3.27 g, 81% yield) as yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., hold 0.7 min): RT 2.2 min, m / z (Calc.) 941.64, (obtained) 964.60 (M+Na). Synthesis of 8-2: ((2,2'-Azanediylbis(acetyl))bis(oxy))bis (propane-

[00377] To a three-necked flask, 8-1 (3 g, 1 eq) was added in CH2Cl2 (60 mL) and the resulting solution was cooled in an ice-water bath under nitrogen, then TFA (4.5 mL) was slowly added at 0-5 °C. The resulting solution was stirred for 2 hours at 20 °C. The reaction was then quenched by the careful addition of 10% aqueous sodium carbonate solution (30 mL). The organic phase was separated and washed with brine (2 x 30 mL), dried with anhydrous MgSO4, and filtered. The solvent was removed under vacuum to provide the 8-2 (2.5 g, 93% yield) as yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., wait 0.7 min): RT 1.15 min, m / z (Calc.) 841.59, (obtained) 842.51 (M+H).

[00378] Synthesis of LIPID 8: ((2,2'-((((3-(Dimethylamino)propyl)thio)carbonyl) azanediyl) bis(acetyl))bis(oxy))bis(propane-2,1,3-triyl) tetranonanoate Petition 870250102289, dated 07 / 11 / 2025, page 138 / 408 134 / 379

[00379] To a three-necked flask, 8-2 (2.50 g, 1 eq) of CH2Cl2 (50 mL) was added as a portion at room temperature. The resulting solution was cooled in an ice-water bath under nitrogen. Then, tryphosgene (0.88 g, 1 eq) was added to the reaction mixture at 0–5 °C for 5 minutes. Pyridine (1.17 g, 5 eq) was slowly added to the reaction mixture over 2 ± 0.5 hours. After the addition, the reaction mixture was stirred for 2 hours at room temperature. The solvent was evaporated under reduced pressure, and the residue was dissolved in anhydrous pyridine (50 mL) and cooled in an ice-water bath. To this was added 3-(dimethylamino)-1-propanethiol hydrochloride (0.42 g, 1.2 eq), and the above mixture was stirred for 18 hours at room temperature. The solvent was removed under vacuum. The residue was dissolved in CH2Cl2 (50 mL) and washed with a 10% aqueous citric acid solution (3 x 25 mL). The organic phase was separated, dried with anhydrous MgSO4, and then filtered.Vacuum concentration yielded crude LIPID 8, the crude product dissolved in CH2Cl2 (15 mL), and adsorbed onto silica gel (5 g, type: ZCX2, mesh 100-200, 6.43 w / w), and purified on a silica gel column (20 g silica gel, type: ZCX-2, mesh 100-200, 32.14 w / w) using a CH2Cl2 / MeOH gradient (volume ratio, gradient from 100:0 to 98:2). The fractions containing LIPID 8 were analyzed, pooled, combined, and concentrated under reduced pressure to yield LIPID 8 (1.2 g, 41% yield) as a yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 2 min., hold 0.7. Petition 870250102289, dated 07 / 11 / 2025, page 139 / 408 LIPID 9 135 / 379 min): RT 0.88 min, m / z (Calcd.) 986.65, (obtained) 987.95 (M+H); 7.3Hz, 2H), 2.340-2.212 (16H), 1.78 (m, 2H), 1.71-1.57 (8H), 1.351.20 (40H), 0.94-0.80 (12H). Example 9. Synthesis of LIPID 9: bis(1,3-bis(Nonanoyloxy)propan2-yl) 4-((4-(dimethylamino)butanoyl)thio)heptanodioate General Outline: LIPID 9 Petition 870250102289, of 07 / 11 / 2025, p. 140 / 408 136 / 379 Synthesis of 9-1: bis(1,3-bis(Nonanoyloxy)propan-2-yl) 4-((methylsulfonyl)oxy) heptanodioate

[00380] To a 250 mL four-necked round flask with mechanical stirring under N2, 5-5 (6 g, 1.0 eq) of CH2Cl2 (90 mL) was added. This was followed by the addition of Et3N (2.06 g, 3.0 eq) and the resulting solution was cooled in an ice-cold water bath under nitrogen. To the cooled solution, MsCl (1.16 g, 1.5 eq) was added dropwise with stirring at 0 °C. The resulting solution was stirred for 12 hours at room temperature. The reaction was then quenched by the addition of H2O (100 mL). The phases were separated and the aqueous layer was extracted with CH2Cl2 (100 mL). Then, the combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. Crude 9-2 was purified by High-Flash-Prep-HPLC under the following conditions: column, XB-C18 silica gel; mobile phase, i-PrOH in 1 mmol NH4HCO3 in water, gradient from 65% to 95% in 30 min; detector, UV ELSD.Concentrated to dryness under vacuum to provide 9-1 (5 g, 44% overall yield in 2 steps) as a colorless oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 2 min., hold 0.7 min): RT 1.66 min, m / z 962.60 (Calc.), (obtained) 985.50 (M+Na). Petition 870250102289, dated 07 / 11 / 2025, p. 141 / 408 137 / 379 Synthesis of 9-2: bis(1,3-bis(nonanoyloxy)propan-2-yl) 4-mercaptoheptanedioate

[00381] In a 100 mL round-bottom, three-necked flask, purged and maintained with an inert nitrogen atmosphere, 9-1 (100 mg, 1.00 equiv) was placed in DMF (0.5 mL), the resulting solution was cooled in an ice-water bath under nitrogen. This was followed by the addition of NaSH (29.1 mg, 5.00 eq) at 0 °C. The resulting solution was stirred for 24 hours at 0 °C. This reaction was repeated for 49 hours and the total mixture was combined for processing. The reaction was then quenched by the addition of water / ice (200 mL). The resulting solution was extracted with EtOAc (3 x 100 mL) and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to yield 9-2 (4.8 g, crude) as a colorless oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., wait 0.7 min): RT 2.08 min, m / z 900.60 (Calc.), (obtained) 923.50 (M+Na). Synthesis of LIPID 9: bis(1,3-bis(Nonanoyloxy)propan-2-yl) 4-((4-(dimethylamino)butanoyl)thio)heptanedioate LIPID 9 Petition 870250102289, dated 07 / 11 / 2025, p. 142 / 408 138 / 379

[00382] To a round-bottom flask with three necks, 9-2 (4.8 g, 1.0 eq), 4-(dimethylamino)butanoic acid (1.16 g, 1.3 eq) and DMAP (0.46 g, 0.7 eq) were added in CH2Cl2 (72 mL). The resulting solution was cooled in an ice-water bath under nitrogen. EDCI (1.84 g, 1.4 eq) was added to the reaction mixture at 0 °C in several portions. The resulting solution was stirred for 12 hours at room temperature. The reaction system was quenched with 10% aqueous citric acid (48 mL). The organic phase was separated, washed with 10% aqueous citric acid (48 mL), brine (48 mL, 10 V), and dried with anhydrous MgSO4. Filtration and vacuum concentration yielded crude product 9, which was dissolved in CH2O2 (25 mL) and adsorbed onto a silica gel column (10 g, type: ZCX-2, mesh 100-200) and purified on a silica gel column (50 g, type: ZCX-2, mesh 100-200) with an n-heptane / acetone gradient from 100:0 to 75:50.The fractions containing pure 9 were combined and concentrated under vacuum to provide 9 (0.9 g, 18% yield) as a yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., wait 0.7 min): RT 1.24 min, m / z 1013.68 (Calcd.), (obtained) 1015.40 (M+H);1H NMR (300 MHz, CDCh): δ 5.27 (q, J = 5.1 Hz, 2H), 4.30 (m, 4H), 4.16 (m, 4H), 3.54 (brm, 1H), 2.64 (t, J = 7.3 Hz, 2H), 2.46-2.23 (18H), 2.04 (m, 2H), 1.84 (m, 4H), 1.35-1.76 (13H), 1.00-1.32 (37H), 0.96-0.83 (12H). Example 10. Synthesis of LIPID 10: ((4,4'-(((3-(Dimethylamino)propyl)thio)carbonyl) azanediyl)bis(butanoyl))bis(oxy))bis(propane-2,1,3triyl) tetrakis(3-cyclohexylpropanoate) Petition 870250102289, dated 07 / 11 / 2025, p. 143 / 408 139 / 379 General Outline: DMF (cat.), CHpCIp CO2h oxalyl chloride NaBH3CN HOAc, THF 1-5 1. triiogeneo CH2CI2, pyridine c concentrate dissolved in pyridine DMAP, EDCI, CH2CI2 OH LIPID 10 3. HS N-Boc -----EtOAc pyridine chci3 HCl-EtOAc Synthesis of 10-1: 3-cyclohexylpropanoyl chloride DMF (cat.), CH2CI2oxalyl chloride

[00383] In a 2000 mL three-necked round-bottom flask, purged and maintained with an inert nitrogen atmosphere, a solution of 3-cyclohexylpropanoic acid (100 g, 1.0 eq) in CH2Cl2 (1 L) was placed and DMF (0.2 mL) was added. Oxalyl chloride (161.00 g, 2.00 eq) was added dropwise at room temperature. The mixture was stirred at room temperature under nitrogen overnight. The mixture was concentrated under vacuum to yield crude 10-1. This was used as such in the following reaction. Synthesis of 10-2: 2-Oxopropane-1,3-diyl bis(3-cyclohexylpropanoate) pyridine, CHCl3 / \— q. 10-1 \\— / or 10-2 Petition 870250102289, dated 07 / 11 / 2025, page 144 / 408 140 / 379

[00384] In a 2000 mL three-necked round-bottom flask, purged and maintained with an inert nitrogen atmosphere, a solution of 10⁻¹ (83.00 g, 2.50 eq) and dihydroxyacetone (17.20 g, 1.00 eq) in CH₃Ch (1600 mL) was placed, and the solution was cooled in an ice-water bath under nitrogen. Pyridine (61.00 g, 4.00 eq) was added to this cooled solution while the temperature was maintained at 0°C for 40 minutes. The mixture was stirred at room temperature under nitrogen overnight. The pyridine hydrochloride formed was removed by filtration and washed with CH₂Cl₂ (200 mL). The combined filtrates were then washed with 5% aq. NaHCO₃ (2000 mL), 5% aq. HCl (2,000 mL), brine (2,000 mL), and dried over Na2SO4. Concentration under vacuum gave 65 g (92.8% yield) of 10-2 as a yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min, hold 0.7 min): RT 2.56 min, m / z 366.24 (Calc.), (obtained) 367.40 (M+H). Synthesis of 10-3: 2-Hydroxypropane-1,3-diyl bis(3-cyclohexylpropanoate)

[00385] In a 2000 mL round-bottom, three-necked flask, purged and maintained with an inert nitrogen atmosphere, a 10⁻² solution (85.00 g, 1.00 eq) was placed in THF (1 L). HOAc (18.00 g, 1.30 eq) was added to the solution, and the solution was cooled in an ice-water bath. NaBHaCN (18.00 g, 1.20 eq) at 0°C was added to this cooled solution. The mixture was stirred overnight at room temperature. The reaction mixture was quenched with brine (1 L). The mixture was extracted with EtOAc (3 x 400 mL). The Petition 870250102289, dated 07 / 11 / 2025, p. 145 / 408 141 / 379 combined organic phases were then washed with 5% aq. NaHCO3 (200 mL), 5% aq. HCl (200 mL), brine (200 mL) and dried over Na2SO4. Filtration and concentration under vacuum yielded crude product 10-3 which was dissolved in CH2Cl2 (500 mL) and adsorbed onto silica gel (240 g, type: ZCX-2, mesh 100-200). The crude material was purified on a silica gel column (800 g, type: ZCX-2, mesh 100-200) with petroleum ether / EtOAc gradient from 100:0 to 90:10. The fractions containing pure product were pooled and concentrated under vacuum to yield 10-3 (61 g (70.1% yield)) as a yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., wait 0.7 min): RT 2.50 min, m / z 368.26 (Calc.), (obtained) 351.2 (MH2O). Synthesis of 10-4: ((4,4'-(( tert- Butoxycarbonyl)azanodiyl)bis(butanoyl)) bis(oxy)) bis(propane-2,1,3-triyl) tetrakis(3-cyclohexylpropanoate)

[00386] In a 250 mL round-bottom, three-necked flask that had been purged and maintained with an inert nitrogen atmosphere, 15 (4.00 g, 1 eq) and 10⁻³ (10.20 g, 2 equiv) were added, and the mixture was dissolved in CH₂Cl₂ (80 mL). The solution was cooled in an ice-cold water bath, and DMAP (1.69 g, 1.00 eq) and EDCI (10.60 g, 4.00 eq) were added sequentially to 0°C. The reaction mixture was stirred overnight at room temperature. The reaction was then quenched with 10% citric acid (200 mL), and the organic phase was separated. The organic phase was washed with 10% aqueous NaHCO₃ solution (200 mL), brine (200 mL), and dried. Petition 870250102289, dated 07 / 11 / 2025, page 146 / 408 142 / 379 on anhydrous sodium sulfate. Filtration and vacuum concentration yielded crude product 10-4, which was dissolved in CH2Cl2 (100 mL) and adsorbed onto silica gel (50 g, type: ZCX-2, mesh 100-200) and purified on a silica gel column (400 g, type: ZCX-2, mesh 100-200) with petroleum ether / EtOAc gradient from 100:0 to 90:10. The fractions containing pure product were pooled and concentrated under vacuum to provide 11 g (77.7% yield) of 10-4 as a light yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min, wait 0.7 min): RT 1.79 min, m / z 989.64 (Calc.), (obtained) 1012.50 (M+Na). Synthesis of 10-5: bis(4-((1,3-bis((3-cyclohexylpropanoyl)oxy)propan-2-yl)oxy)-4-oxobutyl)ammonium chloride N-Boc HCl-EtOAc

[00387] In a 250 mL round-bottom flask, purged and maintained in an inert nitrogen atmosphere, a 10⁴ solution (6.30 g, 1.00 eq) was placed in EtOAc (20 mL) and the solution was cooled in an ice water bath. To the cooled solution, HCl in EtOAc (60 mL, 10 eq, 2M) was added dropwise at 0-10°C. The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. This yielded 6 g (99% yield) of 10⁻⁵ as a light yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min, wait 0.7 min): RT 1.48 min, m / z 889.59 (Calc.), (obtained) 890.50 (M+H). Lipid Synthesis 10: ((4,4'-(((3-(Dimethylamino)propyl)thio)carbo Petition 870250102289, dated 07 / 11 / 2025, page 147 / 408 143 / 379 nyl)azanediyl) bis(butanoyl))bis(oxy))bis(propane-2,1,3-triyl) tetrakis(3-cyclohexylpropanoate) 1. triphosgene CH2CI2, pyridine 2. concentrate dissolved in pyridine 0LIPID 10 10-5

[00388] In a 250 mL round-bottom, three-necked flask, purged and maintained with an inert nitrogen atmosphere, a 10-5 solution (6.00 g, 1.00 eq) was placed in CH2Cl2 (100 mL) and the solution was cooled in an ice-water bath under nitrogen. Tryphosgene (1.91 g, 1.62 eq) was added to the mixture at 0°C. This was followed by the dropwise addition of pyridine (2.56 g, 5.00 eq) with stirring at 0°C. The mixture was stirred for 4 h at room temperature and then concentrated under vacuum. The residue was dissolved with pyridine (100 mL) and cooled in an ice-water bath under nitrogen. To this solution, 3-(dimethylamino)propane-1-thiol (0.92 g, 1.93 eq) was added dropwise with stirring at 0°C for 10 min. The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The residue was diluted with CH2C2 (500 mL) and the solution was washed with 10% aqueous citric acid solution (2 x 200 mL).NaHCO3 (2 x 200 mL), brine (100 mL), dried over anhydrous sodium sulfate and concentrated under vacuum to yield crude LIPID 10. The residue was dissolved in CH2Cl2 (100 mL) and adsorbed onto silica gel (50 g, type: ZCX-2, mesh 100-200) and purified on a silica gel column (250 g, type: ZCX2, mesh 100-200) with a CHaCb / MeOH gradient from 100:0 to 97:3. The fractions containing pure product were pooled and concentrated under vacuum. The product was dissolved in n-heptane (40 mL) and 0.22 g of powdered activated charcoal was added. The mixture was stirred for 4 h. Petition 870250102289, dated 07 / 11 / 2025, pp. 148 / 408 144 / 379 room temperature and then filtered. The filtrate was concentrated under vacuum to produce 2 g (48% yield) of LIPID 10 as a light yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., hold 0.7 min): RT 0.68 min, m / z 1034.65 (Calc.), (obtained) 1035.65 (M+H); 1H NMR (300 MHz, CDCb): δ 5.25 (m, 2H), 4.31 (m, 4H), 4.14 (dd, J = 11.9, 5.7 Hz, 4H), 3.38 (brm, 4H), 2.94 (t, J = 7.3 Hz, 2H), 2.44 - 2.22 (20H), 1.99-1.47 (26H), 1.39-1.17 (20H), 0.95 - 0.79 (12H). Example 11. Synthesis of LIPID 11: ((4,4'-((((3-(Dimethylamino)propyl)thio)carbonyl)azanediyl)bis(butanoyl))bis(oxy))bis(propane-2,1,3triyl)_tetraguis(4:çiçlozhexjlbutanoatol LIPID 11 General Diagram: oxalyl chloride DMF (cat.), OH2OI2 11 ( \ \ NaBH3CN V / > HOAc, THF 11-2 0 O HO^OH O pyridine, CHCI3 1-1 v_ / 0^ V / ~OH 11-3° Petition 870250102289, dated 07 / 11 / 2025, p. 149 / 408 145 / 379 O 3. HS 1. triphosgene CH2CI2, pyridine ρ s 2. Concentrate dissolves in pyridine. LIPID 11 N— / Synthesis of 11-1: 4-cyclohexylbutanoyl chloride DMF (cat.), CH2CI2oxalyl chloride 11-1

[00389] In a 1 L round-bottom, 3-necked flask, purged and maintained with an inert nitrogen atmosphere, a solution of 4-cyclohexylbutanoic acid (50 g, 1.0 eq) was placed in CHCh (500 Petition 870250102289, dated 07 / 11 / 2025, p. 150 / 408 146 / 379 ml) and then DMF (0.25 ml) was added. The solution was cooled in an ice water bath and then oxalyl chloride (74.1 g, 2.0 eq) was added dropwise over a period of 30 minutes. The mixture was stirred at room temperature under nitrogen overnight. The mixture was concentrated under vacuum. This resulted in 55.7 g (99.9% yield) of yellow oil, which was used as such in the next step. Synthesis of 11-2: 2-Oxopropane-1,3-diyl bis(4-cyclohexylbutanoate)

[00390] In a 2 L round-bottom, 3-necked flask, purged and maintained with an inert nitrogen atmosphere, a solution of 11-1 (55.7 g, 2.5 eq) was placed, the solution was cooled in an ice water bath, and 1,3-dihydroxyacetone (10.6 g, 1.0 eq) in CHCh (1114 mL) was then added over a period of 1 hour. Pyridine (37.3 g, 4.0 eq) was added to the mixture while maintaining the temperature at 0°C for 40 minutes. The mixture was stirred at room temperature overnight under nitrogen. The reaction mixture was quenched with water (1 L). The organic phase was separated, and the aqueous layer was extracted with CH2Cl2 (3 x 200 mL). The organic phases were combined and washed with 5% aqueous NaHCO3 solution (300 mL), 5% aqueous HCl (300 mL), and brine (300 mL). The solution was then dried over anhydrous Na2SO4, and the product was obtained by evaporation. This resulted in 56.4 g of crude 11-2 as yellow oil, which was used as such in the following reaction. Petition 870250102289, dated 07 / 11 / 2025, page 151 / 408 147 / 379 Synthesis of 11-3: 2-hydroxypropane-1,3-diyl bis(4-cyclohexylbutanoate)

[00391] In a 1 L round-bottom, 3-necked flask, purged and maintained with an inert nitrogen atmosphere, a solution of 11-2 (56.4 g, 1.0 eq) in THF (550 mL) was placed, and the mixture was cooled in an ice-water bath. HOAc (11.13 g, 1.3 eq) at 0 °C was added to the cooled solution. Then NaBH3CN (10.79 g, 1.2 eq) was added to the mixture at 0 °C. The mixture was stirred overnight at room temperature. The reaction mixture was quenched with water (500 mL). The mixture was extracted with CH2Cl2 (3 x 200 mL). The organic layers were combined and washed with 5% aqueous NaHCO3 solution (200 mL), 5% aqueous HCl (200 mL), and brine (200 mL). The solution was then dried over Na2SO4 and concentrated under vacuum.The residue was dissolved in CH2Cl2 (150 mL), silica gel (60 g, type: ZCX-2, mesh 100-200) was added, and the crude product was adsorbed onto the silica gel and purified on a silica gel column (240 g, type: ZCX-2, mesh 100-200) with a petroleum ether / EtOAc gradient from 100:0 to 80:20. The fractions containing 11-3 were pooled, concentrated, and dried under vacuum to obtain 30.3 g (65.0% overall yield in 2 steps) of 11-3 as yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min, wait 0.7 min): RT 0.76 min, m / z 396.29 (Calc.), (obtained) 419.29 (M+Na). Synthesis of 11-4: ((4,4'-((tert-butoxycarbonyl)azanediyl)bis(butanoyl)) bis(oxy)) bis(propane-2,1,3-triyl) tetrakis(4-cyclohexylbutanoate) Petition 870250102289, dated 07 / 11 / 2025, page 152 / 408 148 / 379

[00392] In a 250 mL round-bottom, three-necked flask, purged and maintained with an inert nitrogen atmosphere, 11-3 (5.46 g, 2.0 eq) was added to the 1-5 (2.05 g, 1.0 eq) solution in CH2Cl2 (100 mL), and the mixture was cooled in an ice-water bath. DMAP (2.3 g, 1.0 eq) followed by EDCI (14.51 g, 4.0 eq) at 0 °C were added to the solution. The reaction mixture was stirred overnight at room temperature. The reaction was then quenched with 10% aqueous citric acid (200 mL), the organic phase was separated and washed with 10% aqueous NaHCO3 (200 mL) and brine (200 mL). The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This material was combined with another reaction on a 7.05 g scale (based on 11-3) and the combined material was adsorbed onto silica gel (30 g, type: ZCX-2, mesh 100200) and purified on a silica gel column (90 g, type: ZCX-2, mesh 100200) with a petroleum ether / EtOAc gradient from 100:0 to 65:35.The fractions containing 11-4 were combined and concentrated and dried under vacuum to obtain 14.2g (43.0%) 11-4 as yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min, hold 0.7 min): RT 2.77 min, m / z 1045.71 (Calc.), (obtained) 1068.55 (M+Na). Synthesis of 11-5: bis(4-((1,3-bis((4-cyclohexylbutanoyl)oxy)propan-2-yl)oxy)-4-oxobutyl)ammonium chloride Petition 870250102289, dated 07 / 11 / 2025, p. 153 / 408 149 / 379

[00393] In a purged 250 mL round-bottom flask maintained with an inert nitrogen atmosphere, a solution of 11-4 (14.17 g, 1.0 eq) in EtOAc (71 mL) was placed, and the solution was cooled in an ice-water bath. HCl in EtOAc (142 mL, 2 mol / L) was added dropwise at 0-10 °C. The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. This yielded 13.6 g (99.9% yield) of 11-5 as a light yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min, wait 0.7 min): RT 0.94 min, m / z 945.65 (Calc.), (obtained) 946.60 (M+H). Synthesis of LIPID 11: ((4,4'-((((3-(Dimethylamino)propyl)thio)carbonyl) azanediyl)bis (butanoyl))bis(oxy))bis(propane-2,1,3-triyl) tetrakis(4-cyclohexylbutanoate) Triphosgene CH2CI2, pyridine 2. concentrate dissolved in pyridine

[00394] In a 1 L round-bottom, 3-necked flask, purged and maintained with an inert nitrogen atmosphere, a solution Petition 870250102289, dated 07 / 11 / 2025, p. 154 / 408 150 / 379 of 11-5 (12.0 g, 1.0 eq) in CH2Cl2 (420 mL) and the solution was cooled in an ice water bath. Triphosgene (5.44 g, 1.5 eq) was added to the solution at 0°C. This was followed by the dropwise addition of pyridine (4.82 g, 5.0 eq) with stirring at 0°C. The mixture was stirred for 4 h at room temperature and then concentrated under vacuum. The residue was dissolved in pyridine (240 mL) and the resulting solution was cooled in an ice water bath. To this solution, 3-(dimethylamino)propane-1-thiol (2.91 g, 2.0 eq) was added dropwise with stirring at 0°C for 10 min. The resulting solution was stirred overnight at room temperature. The reaction mixture was concentrated under vacuum. The residue was diluted with DCM (200 mL). The mixture was washed with 10% aqueous NaHCO3 (2 x 200 mL), brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum.The crude product was adsorbed onto silica gel (20 g, type: ZCX-2, 100-200 mesh) and purified on a silica gel column (80 g, type: ZCX-2, 100-200 mesh) with an n-heptane / acetone gradient from 100:0 to 65:35. The fractions containing pure product were pooled, concentrated, and dried under vacuum to obtain 2 g of 11, which was dissolved in n-heptane (40 ml, 20 V) and activated carbon powder (0.22 g) was added. The mixture was stirred for 4 h at room temperature and then filtered. The filtrate was concentrated under vacuum. This resulted in 2 g (14.4% yield) of 11 as a light yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min, wait 0.7 min): RT 1.00 min, m / z 1090.71 (Calcd.), (obtained) 1091.60 (M+H);1H NMR (300 MHz, CDCh): δ 5.24 (m, 2H), 4.32 (dd, J = 11.9, 4.4 Hz, 4H), 4.15 (dd, J = 11.9, 5.7 Hz, 4H), 3.39 (brm, 4H), 2.92 (t, J = 7.3 Hz, 2H), 2.27-2.38 (14H), 2.05 (s, 6H), 1.85-2.00 (6H), 1.57-1.83 (29H), 1.11-1.28 (23H), 1.06-1.08 (8H). Example 12. Synthesis of LIPID 12: ((6,6'-(((3-(Dimethylamino)propyl)thio)carbonyl) azanediyl)bis(hexanoyl))bis(oxy))bis(propane-2,1,3triyl) tetrakis(3-cyclohexylpropanoate) Petition 870250102289, dated 07 / 11 / 2025, page 155 / 408 151 / 379 Lipid 12 General Outline: THE 1. triphosgene CH2CI2, pyridine 2. concentrate dissolved in pyridine 3· HS, / x N LIPID 12 Synthesis of 12-1: 6,6'-(benzylazanodiyl)dihexanoate dimethyl

[00395] Loaded K2CO3 (9.5 g, 2.3 eq), benzylamine (3.2 g, 1.0 eq) and methyl 4-bromobutyrate (15.2 g, 2.3 eq) in CH3CN (64 mL) to Petition 870250102289, dated 07 / 11 / 2025, page 156 / 408 152 / 379 a 250 ml round four-necked flask at 25 °C with mechanical stirring under N2. The mixture was then heated (80 °C) and stirred for 15 h. The mixture was then cooled to 25 °C and the mixture was dropped into water (65 mL) and the mixture was extracted with EtOAc (2 x 65 ml). The combined organic phases were dried (Na2SO4), filtered and concentrated under vacuum to obtain the crude product 12-1 (10 g, crude) as a yellow oil which was used as such in the following reaction. Synthesis of 12-2: Dimethyl 6,6'-((tert-butoxycarbonyl)azanediyl)dihexanoate H3CO2C—ξ H3CO2C—ξ ' \ \_ / H2, Pd / C \ / (Boc)2O' \ ►N-Boc ,--- / EtOH, H3CO2C^ H3CO2C^ 12-112-2

[00396] 12-1 (10 g, 1.0 eq), (Boc)2O (6.6 g, 1.1 eq) and Pd / C (1 g, 10% w / w) were loaded into EtOH (100 mL) in a 250 mL hydrogenation autoclave at room temperature. The mixture was stirred for 16 hours at room temperature under a 5 atm hydrogen atmosphere. The reaction mixture was filtered and concentrated under vacuum at 40°C. This resulted in 12-2 (11 g, crude) as a light brown oil. This was used as such in the following reaction. Synthesis of 12-3: 6,6'-((tert-Butoxycarbonyl)azanodiyl)dihexanoic acid H3CO2C—ξ HO2C—ξ '—\ 6N aq. NaOH'—\ N-Boc ---------►N-Boc __ / EtOH / h3co2c^ho 12-212-3

[00397] A solution of 12-2 (11 g, 1.0 eq) in ethanol (55 mL) at room temperature was charged into a round-bottom flask under Petition 870250102289, dated 07 / 11 / 2025, p. 157 / 408 153 / 379 nitrogen. Aqueous 6 M NaOH (55 mL) was added at room temperature. After the addition was complete, the mixture was heated to 60°C for 2 hours. The mixture was cooled to room temperature and poured into brine (110 mL). The solution was extracted twice with n-BuOH / n-heptane (2:1, 110 mL) to remove organic impurities. The aqueous phase was acidified by the addition of 3 mol / L aqueous HCl to approximately pH=3 and then extracted with t-BuOH:n-heptane (2:1) (110 mL, 2x). The combined organic phases were concentrated under reduced pressure to yield a sticky solid. The residue was suspended with diethyl ether (22 mL) and filtered. The filter cake was collected to yield 12-3 (5.6 g, 66% overall yield in three steps) as a white solid. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., wait 0.7 min): RT 1.64 min, m / z 345.22 (Calc.), (obtained) 368.10 (M+Na). Synthesis of 12-4: ((6,6'-(( tert- Butoxycarbonyl)azanodiyl)bis(hexanoyl)) bis(oxy))bis(propane-2,1,3-triyl) tetrakis(3-cyclohexylpropanoate)

[00398] In a 250 mL round-bottom flask with three necks, 12-3 (5.6 g, 1.0 eq), 10-3 (10 g, 2.0 eq) and DMAP (1.65 g, 1.0 eq) were placed in CH2Cl2 (85 mL), and the solution was cooled in an ice-water bath under nitrogen. EDCI (7.5 g, 2.2 eq) was added to the reaction mixture at 0 °C, in portions over 15 minutes. After the Petition 870250102289, dated 07 / 11 / 2025, page 158 / 408 154 / 379 addition complete, the reaction was heated to room temperature and stirred for 16 hours at 20 °C. The reaction mixture was molded in 10% aqueous citric acid (112 mL). The organic phase was separated, rinsed with 10% aqueous citric acid (112 mL), brine (112 mL), dried with anhydrous MgSO4, and then filtered. The solvent was removed under vacuum to yield the crude product 12-4, which was dissolved with CH2Cl2 (65 mL). The crude product was adsorbed onto silica gel (30 g, type: ZCX-2, 100-200 mesh) and purified on a silica gel column (150 g, type: ZCX-2, 100-200 mesh) with a petroleum ether / EtOAc gradient from 100:0 to 88:12. The fractions containing pure product were pooled, concentrated, and dried under vacuum to obtain 10.1 g (60%) of 12-4 as a colorless oil. ELSD A: water / 0.05% TFA; B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., wait 0.7 min): RT 2.2 min, m / z 1045.71 (Calc.), (obtained) 1068.65 (M+Na). Synthesis of 12-5: ((6,6'-Azanediylbis(hexanoyl))bis(oxy))bis(propane2,1,3-triyl) tetrakis(3-cyclohexylpropanoate)

[00399] In a 100 mL round-bottom flask with three necks, 12-4 (5 g, 1.0 eq) was placed in CH2Cl2 (50 mL) and the solution was cooled in an ice-water bath under nitrogen. Then, TFA (7.5 mL) was added to the reaction mixture at 0-15 °C. After the addition was complete, the solution was allowed to warm to room temperature and stirred for 2 h. The mixture was concentrated. Petition 870250102289, dated 07 / 11 / 2025, p. 159 / 408 155 / 379 under vacuum at 30°C and then n-heptane (100 mL) was added to the reaction mixture. The resulting turbid mixture was washed with 17% aqueous sodium carbonate solution (500 mL), brine (250 mL, 3 times) and dried over anhydrous MgSO4. Filtration and concentration under vacuum yielded 12-5 (4.5 g, 90% yield) as yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., hold 0.7 min): RT 0.94 min, m / z 945.65 (Calc.), (obtained) 946.60 (M+H). Synthesis of LIPID 12: ((6,6'-(((3(dimethylamino)propyl)thio)carbonyl)azanediyl) bis(hexanoyl))bis(oxy))bis(propane-2,1,3-triyl) tetrakis(3-cyclohexylpropanoate) 2. concentrate dissolved in pyridine 3. 1. triphosgene CH2CI2, pyridine

[00400] In a 250 mL three-necked round-bottom flask, 12-5 (4.5 g, 1.0 eq) and CH2Cl2 (68 mL) were added, and the solution was cooled in an ice-water bath under nitrogen. Then, tryphosgene (1.4 g, 1.0 eq) was added to the cooled solution, followed by the addition of pyridine (1.88 g, 5.0 eq) over a period of 30 minutes. After the addition was complete, the reaction mixture was heated to room temperature and then stirred for 4 hours. The solvent was removed under vacuum, and the residue was dissolved in pyridine (90 mL), and the mixture was cooled in an ice-water bath under nitrogen. To this cooled solution, 3-(dimethylamino)-1-propanethiol hydrochloride (0.57 g, 1.1 eq) was added. After the addition was complete, the reaction mixture was heated to room temperature and stirred for 18 hours. The mixture was concentrated under vacuum, the temperature was maintained at or below 20 °C to provide crude LIPID 12 which was dissolved in Petition 870250102289, dated 07 / 11 / 2025, p. 160 / 408 156 / 379 CH2Cl2 (90 mL) and the resulting solution was washed with 10% aqueous citric acid solution (45 mL), brine (45 mL, 3 times), 10% aqueous sodium bicarbonate solution (45 mL), and brine (45 mL, 2 times). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced vacuum to yield crude LIPID 12. Crude LIPID 12 was dissolved in CH2Cl2 (30 mL) and adsorbed onto silica gel (15 g, type: ZCX-2, mesh 100-200) and purified on a silica gel column (60 g, type: ZCX-2, mesh 100-200) with a heptane / acetone n-gradient from 100:0 to 80:20. The fractions containing pure product were combined and concentrated and dried under vacuum to obtain 1.5 g (29%) of LIPID 12 as a light yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., wait 0.7 min): RT 0.87 min, m / z 1090.71 (Calcd.), (obtained) 1091.60 (M+H);1H NMR (300 MHz, CDCh): δ 5.27 (m, 2H), 4.30 (dd, J = 11.9, 4.4 Hz, 4H), 4.1 (dd, J = 11.9, 5.8 Hz, 4H), 3.27 (brm, 4H), 2.90 (t, J = 7.2Hz, 2H), 2.45-2.20 (20H), 1.81 (m, 2H), 1.711.63 (22H), 1.55-1.47 (12H), 1.34-1.07 (22H), 0.94-0.77 (8H). Example 13. Lipid Synthesis 13: 2-(3-{(3-dimethylaminopropylsulfanylcarbonyl)-[2-(2-nonanoyloxy-1-nonanoyloxymethyl-ethoxycarbonyl)-ethyl-1-amino}-propionyloxy)-3-octanoyloxypropyl ester of nonanoic acid Petition 870250102289, dated 07 / 11 / 2025, page 161 / 408 157 / 379 General Outline: 1-2 2. Concentrate dissolves in pyridine. 1. triphosgene CH2CI2, pyridine

[00401] Synthesis of 13-1: ((3,3'-(( tert- butoxycarbonyl)azanodiyl)bis(propanoyl)) bis(oxy))bis(propane-2,1,3-triyl) tetranonanoate

[00402] 1-5 (7.3 g, 28.0 mmol) and 1-2 (18.8 g, 56.0 mmol) were dissolved in CH2Cl2 (110 mL) in a 500 mL round-bottom flask with 3 necks under nitrogen. The solution was cooled in an ice-water bath and DMAP (3.4 g, 28.0 mmol) and EDCl (21.5 g, 0.112 mol) were added in order. After the addition was complete, the mixture was heated to room temperature and stirred for 16 Petition 870250102289, dated 07 / 11 / 2025, page 162 / 408 158 / 379 hours. The mixture was molded in 10% aqueous citric acid (200 mL), the organic phase was separated, washed with brine (200 mL) and dried over anhydrous Na2SO4. The desiccant was removed by filtration through a sintered glass funnel and 50 g of silica gel (type: ZCX-2, mesh 100-200) was added to the filtrate. The solvent was removed under vacuum with the temperature of the rotary evaporator bath at 35°C. Silica gel containing adsorbed 13-1 was placed on a silica gel column (50 mm outer diameter, 200 g silica gel, type: ZCX-2, mesh 100200). The column was eluted with a petroleum ether gradient: EtOAc 100:0 to 97:3, 200 mL. TLC analysis indicated fractions containing 13-1 which were combined and concentrated in vacuum to yield 13-1 (12.8 g, 13.2 mmol, 47%) as a pale yellow, viscous oil. 1H-NMR (300 mHz, DMSO-d6): δ 5.18 (br m, 2H), 4.26 (m, 4H), 4.13 (m, 4), 2.29 (t, J = 7.2 Hz, 8H), 1.40-1.60 (14H), 1.38 (s, 9H), 1.18-1.32 (42H), 0.86 (m, 12H). Synthesis of 13-2: Hydrochloride salt of ((3,3'-azanediylbis(propanoyl))bis(oxy))bis(propane-2,1,3-triyl)tetranonanoate

[00403] To a solution of 13-1 (12.8 g, 13.2 mmol) in EtOAc (75 mL), cooled in a water bath under nitrogen, a solution of HCl in EtOAc (2 M, 80 mL, 0.160 mol) was added at a rate such that the internal temperature remained between 0-10 °C. After the addition was complete, the mixture was allowed to warm to room temperature and Petition 870250102289, dated 07 / 11 / 2025, p. 163 / 408 159 / 379 was stirred for 14 hours. Concentration in vacuum yielded the salt HCl 13-2 (8.1 g, 9.37 mmol, 71%) as a clear yellow, viscous oil. 1H-NMR (300 mHz, DMSO-d6): δ 5.19 (br m, 2H), 4.25 (m, 4H), 4.14 (m, 4H), 2.73 (br t, J = 6.9Hz, 4H), 2.40 (br t, J = 6.9Hz, 4H), 2.29 (br t, J = 7.2Hz, 8H), 1.38-1.58 (8H), 1.16-1.32 (40H), 0.87 (m, 12H). Lipid Synthesis 13: 2-((3-(((3-(Dimethylamino)propyl)thio)carbonyl)(3-((1-(nonanoyloxy)-3-(octanoyloxy)propan-2-yl)oxy)-3-oxopropyl)amino)propanoyl)oxy)propane-1,3-diyl dinonanoate

[00404] To a solution of 13-2 (8.1 g, 9.37 mmol) in CH2Cl2 (280 mL), cooled in an ice-water bath under nitrogen, triphosgene (2.77 g, 9.33 mmol) was added in one portion, followed by the dropwise addition of pyridine (3.68 g, 46.52 mmol). After the addition was complete, the reaction mixture was allowed to warm to room temperature and stirred for 4 hours. The solvent was removed under vacuum (bath temperature 25 °C) and the residue was dissolved in pyridine (160 mL). The solution was cooled in an ice-water bath under nitrogen and 3-dimethylaminopropane-1-thiol (1.32 g, 11.1 mmol) was added dropwise over 10 minutes. After the addition was complete, the mixture was allowed to warm to room temperature and stirred for 14 hours. The solvent was removed under vacuum and the residue was dissolved in CH2Cl2 (200 mL). The solution was washed with 10% aqueous citric acid solution (100 mL), 5% aqueous NaHCO3 (100 mL), brine (100 mL) and dried over anhydrous Na2SO4. The drying agent was removed by filtration in a sintered glass funnel and silica gel (16 g, type ZCX02, mesh 100-200). Petition 870250102289, dated 07 / 11 / 2025, p. 164 / 408 160 / 379 was added to the filtrate. The solvent was removed under vacuum (bath temperature 25 °C) and the silica gel containing adsorbed 13 was placed on a silica gel column (81 g of ZCX02 type silica gel, 100-200 mesh) using a combi-flash. The column was eluted with an n-heptane / acetone gradient from 100:0 to 90:10, 100 mL fractions. TLC was used to locate qualified fractions which were combined and concentrated under vacuum to yield 13 (1.9 g) which was considered 90% pure by HPLC. 13 was further purified by preparative reversed-phase HPLC (C18, A: water with 0.1% formic acid, B: acetonitrile, gradient from 41% B to 58% B for 8 minutes). The qualified fractions were combined and concentrated in vacuum to yield 13 (1.01 g, 1.00 mmol, 10.6%) as a clear, pale yellow viscous oil. Purity by HPLC: 99.65%; ES-MS (+ mode): Calc.68 (br t, J = 7.2Hz, 4H), 2.94 (t, J = 7.2Hz, 2H), 2.68 (br t, J = 7.2Hz, 4H), 2.20-2.40 (16H), 1.81 (m, 2H), 1.52-1.66 (8H), 1.161.38 (40H), 0.90 (m, 12H). Example 14. Lipid Synthesis 14 Petition 870250102289, dated 07 / 11 / 2025, page 165 / 408 161 / 379 General Outline: ho2c HO2C 1-5 EDCI, DMAP CH2CI2 N-Boc 2. sat. aq. NaHCOa 1. triiogen CH2CI2, pyridine 2. change solvent to pyridine NH M-Bnc LIPID 14 1.4M HCl in dioxane CH2Cl2 Synthesis of 14-1: 2-((Benzyloxy)methyl)propane-1,3-diyl dinonanoate pyridine, CHCI3 θ \ OBn 14-1

[00405] 2-[(Phenylmethoxy)methyl]-1,3-propanediol (Bioorg. Med. Chem. 2017, 25, 4008-4030; 25.0 g, 0.127 mol) was dissolved in CHCh (500 mL) and cooled in an ice-water bath under nitrogen. Nonyl chloride (56.5 g, 0.318 mol) was added to this solution in one portion, followed by the dropwise addition of pyridine (40.0 g, 0.508 mol) over 40 minutes. The reaction mixture was allowed to warm to room temperature and then stirred for 14 hours. The turbid mixture was filtered through a celite pad and the filtrate was washed with 5% of NaHCO3 (250 mL), brine (250 mL) and dried over anhydrous Na2SO4. The drying agent was removed by filtration through a glass funnel. Petition 870250102289, dated 07 / 11 / 2025, p. 166 / 408 Sintered 162 / 379 silica gel (150 g, type: ZCX-2, mesh 100-200) was added to the filtrate. The solvent was removed under vacuum (bath temperature <35 °C) and the silica gel with adsorbed 14-1 was added to the top of a combi flash column (600 g, type: ZCX-2, mesh 100-200, packed with petroleum ether:EtOAc 99:1 and eluted with petroleum ether:EtOAc 99:1 to 98:2, 1000 mL fractions). The qualified fractions were determined by TLC, combined and concentrated under vacuum to yield 14-1 (60.0 g, 0.124 mol, 98%) as a colorless oil. 1H-NMR (300 MHz, CDCl3): δ 7.28-7.40 (5H), 4.52 (s, 2H), 4.19 (m, 4H), 3.52 (d, J = 5.7Hz, 2H), 2.36 (m, 1H), 2.29 (t, J = 7.5Hz, 4H), 1.59 (m, 4H), 1.23-1.40 (18H), 0.92 (m, 6H). Synthesis of 14-2:2-(Hydroxymethyl)propane-1,3-diyl dinonanoate

[00406] A solution of 14-1 (60.0 g, 0.124 mol) in MeOH (600 mL), in a 1.0 L pressure vessel, was washed with 3X nitrogen, then 10% Pd / C (18.0 g) was added to the vessel and the mixture was placed under hydrogen pressure (3 atm). The mixture was stirred under hydrogen for 14 hours, then the vessel was vented and the solution was sprayed with nitrogen. The Pd / C was removed by filtration through a Celite pad, the filter cake was rinsed with MeOH (200 mL) and the combined filtrates were concentrated in vacuum to yield 14-2 (32.0 g, 82.8 mmol, 67%) as a clear, colorless oil. 1H-NMR (300MHz, CDCh): δ 4.16 (m, 4H), 3.63 (d, J = 5.7Hz, 2H), 2.33 (t, J = 7.5Hz, 4H), 2.20 (m, 1H), 1.63 (m, 4H), 1.25-1.39 (20H), 0.90 (m, 6H). Synthesis of 14-3: (((3,3'-((tert-butoxycarbonyl)azanodiyl)bis(propanoyl))-bis(oxy))bis(methylene))bis(propane-2,1,3-triyl)tetranonanoate Petition 870250102289, dated 07 / 11 / 2025, page 167 / 408 163 / 379

[00407] To a solution of 1-5 (5.00 g, 19.1 mmol) in CH2Cl2 (75 mL), cooled in an ice-cold water bath under nitrogen, was added 14-2 (14.8 g, 38.3 mmol), DMAP (2.34 g, 19.1 mmol) and EDCl (14.7 g, 76.7 mmol). The mixture was allowed to warm to room temperature and then stirred for 14 hours. The reaction mixture was molded in 10% citric acid (125 mL). The organic phase was separated, washed with brine (125 mL) and dried over anhydrous Na2SO4. Filtration through a sintered glass funnel and concentration under vacuum gave crude 14-3 (14.0 g, 14.0 mmol, 73%) which was transported without further purification.

[00408] Synthesis of 14-4: (((3,3'-azanediylbis(propanoyl))bis(oxy)) bis(methylene))-bis(propane-2,1,3-triyl) tetranonanoate

[00409] To a solution of 14-3 (14.0 g gross, presumed 14.0 mmol) in CH2Cl2 (80 mL), cooled in an ice-water bath under nitrogen, 4.0 M HCl in dioxane (35 mL, 0.140 mol) was added in a Petition 870250102289, dated 07 / 11 / 2025, page 168 / 408 164 / 379 rate such that the internal temperature was maintained between 0-10°C. The mixture was stirred for 30 minutes after the addition was complete, then allowed to warm to room temperature and stirred for 16 hours. The reaction mixture was transformed into NaHCO3 (100 mL), the organic phase was separated, washed with saturated aqueous NaHCO3 solution (100 mL), brine (100 mL) and dried over anhydrous Na2SO4. Filtration and concentration under vacuum yielded crude 14-4 as a viscous yellow oil which was dissolved in CH2Cl2 (200 mL) and silica gel (20 g, type ZCX-2, mesh 100-200). Vacuum concentration yielded silica gel with adsorbed 14-4 which was placed on a silica gel column (100g, type ZCX-2, mesh 100-200), eluted with a gradient from 67:33 to 50:50 using combi-flash. The qualified fractions were localized by TLC, combined and concentrated in vacuum to yield 14-4 (5.20 g, 5.79 mmol, 30% in 2 steps) as a viscous, light yellow and clear oil. 1H-NMR (300MHz, CDCh): δ 4.12-4.18 (12H), 2.93 (t, J = 6.6Hz, 4H). 2.57 (t, J = 6.6Hz, 4H), 2.42 (m, 2H), 2.33 (t, J = 7.5Hz, 8H), 1.61 (m, 8H), 1.22-1.40 (40H), 0.90 (m, 12H). Lipid Synthesis 14 1. triphosgene CH2CI2, pyridine 2. Change solvent to pyridine. 14-4

[00410] To a solution of 14-4 (5.20 g, 5.79 mmol) in CH2Cl2 (175 mL), cooled in an ice-water bath under nitrogen, tryphosgene (1.72 g, 5.75 mmol) was added in a portion, followed by the addition of pyridine (2.29 g, 28.9 mmol, 2.34 mL) at a rate such that the temperature Petition 870250102289, dated 07 / 11 / 2025, page 169 / 408 165 / 379 remained at 0-5°C. The mixture was stirred for 30 minutes after the addition was complete, then allowed to warm to room temperature and stirred for 4 hours. The solvent was removed under vacuum and the residue was dissolved in pyridine (100 mL) and the solution was cooled in an ice-water bath under nitrogen. To this stirred solution, 3-dimethylamino-propane-1-thiol (0.82 g, 6.88 mmol) was added dropwise over a period of 10 minutes. The mixture was allowed to stir for 30 minutes after the addition was complete, then the mixture was heated to room temperature and stirred for 14 hours. The solvent was removed under vacuum and the residue was dissolved in CH2Cl2 (200 mL) and washed with 10% citric acid (2 x 100 mL), aq. NaHCO3 (2 x 100 mL), brine (2 x 100 mL) and dried over Na2SO4.Vacuum filtration and concentration yielded crude 14 as a viscous yellow oil which was purified by combined reversed-phase flash chromatography (A: water + 0.1% CF3CO2H, B: acetonitrile; gradient from 60% B to 80% B for 20 minutes and then 100% for 20 minutes). The qualified fractions were combined and concentrated in vacuum to yield 14 (1.12 g, 1.07 mmol, 18.5%) as a clear, light yellow oil. 1HNMR (300MHz, CDCh): δ 4.12-4.20 (12H), 3.65 (brt, J = 7.2Hz, 4H), 3.11 (m, 2H), 2.93 (t, J = 6.9Hz, 2H), 2.82 (s, 6H), 2.65 (brm, 4H), 2.45 (m, 4H), 2.31 (t, J = 7.5Hz, 8H), 1.61 (m, 8H), 1.18-1.35 (40H), 0.88 (m, 12H). Example 15. Lipid Synthesis 15: LIPID 15. Petition 870250102289, dated 07 / 11 / 2025, p. 170 / 408 166 / 379 General Outline: OEtO'P^CO2Et EtÓ O --------► NaH, THF oxalyl chloride DMF, CH2CI or Cl N-Boc CO2Et 10% Pd / C EtOH N-Boc HO. OR EDCI, DMAP, CH2CI' CDI ch2ci2 Et3N, CH2CI2 15)2H CO2Et1t NaOH, THF, H2O ho2c1-5 OR CF3CO2H CF3CO2' 1. CH3OSO2CF3, ch2ci2 Et3N, CH2CI2 LIPID 15 2. HS dmap, pyridine CH2CI NaBH3CN 2. aq. 3N HCI 15-3 ho2c CH3CO2H, THF Synthesis of 15-1: 2-(4-methylcyclo-hexylideno)ethyl acetate or ^'P^COgEt EtÓ NaH,THF

[00411] To a suspension of NaH (12.5 g, 60% in oil, washed with hexanes (2 x 25 mL), 0.312 mol) in anhydrous THF (600 mL), under nitrogen and cooled in an ice water bath, triethylphosphonaacetate (70.0 g, 0.312 mol) was added dropwise over 30 minutes. The mixture was stirred for 2 hours in the ice water bath, then 4-methylcyclohexanone (35.0 g, 0.312 mol) was added over 30 minutes. The mixture was stirred for 30 minutes and then allowed to warm to room temperature and stirred for 14 hours. The mixture was poured into water (1.2 L) and EtOAc (600 mL). The organic phase was separated and gelled. Petition 870250102289, dated 07 / 11 / 2025, p. 171 / 408 167 / 379 of silica (200g, type: ZCX-2, mesh m100-200) was added and the solvent was then removed in vacuum (bath temperature <35°C) to provide silica gel with adsorbed crude 1. The silica gel is placed on a silica gel column (1000g, type: ZCX-2, mesh m100-200) eluted with a gradient to petroleum ether:EtOAc 100:0 to 95:5, collecting 1000 mL fractions using a combi-flash. The qualified fractions were localized by TLC, combined and concentrated in vacuum to provide 15-1 (45.0 g, 0.247 mol, 79%) as a clear, colorless oil. LC-MS (+mode): RT 1,804, 183.2 (M+H+); 1H-NMR (300MHz, CDCh): δ 5.61 (s, 1H), 4.14 (q, J = 7.2Hz, 2H), 3.75 (m, 1H), 2.14-2.30 (2H), 1.90 (m, 1H), 1.80 (m, 2H), 1.62 (m, 1H), 1.28 (t, J = 7.2Hz, 3H), 1.00-1.15 (2H), 0.82 (d, J = 9.0Hz, 3H). Synthesis of 15-2: ethyl 2-(4-methylcyclohexyl)acetate / \_ / C°2EtH2, 10%Pd / C / \ / ǰ2E^9— / EtOH ' 15-2

[00412] Ester 15-1 (45.0 g, 0.247 mol), dissolved in EtOH (450 mL) under nitrogen at room temperature, was added to 10% Pd / C (13.5 g). Hydrogen was then bubbled through the reaction mixture for 16 hours. The solvent was then sprayed with nitrogen for 1 hour, the catalyst was removed by filtration through a celite pad, and the filter cake was rinsed with EtOH (450 mL). The combined filtrates were concentrated in vacuum to yield 15-2 (35.0 g, 0.190 mol, 77%) as a light yellow oil. 1H-NMR (300MHz, CDCh): δ 4.14 (q, J = 7.2Hz, 2H), 2.25-2.40 (2H), 2.18 (m, 1H), 1.52-1.78 (3H), 1.28 (t, J = 7.2Hz, 3H), 0.78-1.03 (9H). Synthesis of 15-3: 2-(4-methylcyclohexyl)acetic acid / \ ^C°2E^ 1 NaOH, THF, H2O / \ZCO2H'—' 2. aq. 3N HCI '—' 15-2 15-3

[00413] To a solution of 15-2 (35.0 g, 0.190 mol) in THF:H2O (350 mL, 50:50), at room temperature under nitrogen, was added Petition 870250102289, dated 07 / 11 / 2025, p. 172 / 408 168 / 379 Solid NaOH (84.0 g, 2.10 mol) was mixed for 30 minutes. The mixture was stirred for 16 hours and then concentrated under vacuum to remove the THF. The aqueous solution was then adjusted to pH 3.0 by the addition of 3N aq. HCl. The reaction mixture was extracted with EtOAc (350 mL) and the organic phase was dried over Na2SO4. Filtration and concentration under vacuum yielded 15-3 (25.0 g, 0.160 mol, 84%) as a white solid. Synthesis of 15-4: 2-(4-methylcyclohexyl)acetyl chloride / \ CO2H oxallyl chloride / \ V Cl '--- DMF, CH2CI2λ--15-3 15-4

[00414] To 15-3 (25.0 g, 0.160 mol) in CH2Cl2 (250 mL), containing DMF (1.0 mL), cooled in an ice water bath under nitrogen, oxalyl chloride (40.7 g, 0.321 mol) was added dropwise over a period of 20 minutes. The mixture was stirred for 30 minutes after the addition was complete, then heated to room temperature and stirred for 14 hours. Concentration in vacuum, bath temperature <30°C, yielded 15-4 (25.2 g, 0.144 mol, 90%) and a clear, colorless oil. 1H NMR (300 MHz, CDCh): δ 2.75 (m, 2H), 1.30-1.64 (5H), 1.18-1.28 (2H), 0.80-1.05 (6H). Synthesis of 15-5: 2-Oxopropane-1,3-diyl bis(2-(4-methylcyclohexyl) acetate)

[00415] To 1,3-dihydroxyacetone (5.90 g, 65.5 mmol), in CH2Cl2 (500 mL) under nitrogen at room temperature, DMAP (2.40 g, 19.6 mmol) and pyridine (11.4 g, 0.144 mol) was added, followed by the addition of 15 Petition 870250102289, dated 07 / 11 / 2025, page 173 / 408 169 / 379 (25.2 g, 0.144 mol) dropwise for 30 minutes. The mixture was stirred for 16 hours at room temperature and then poured into water (400 mL). The organic phase was separated, washed with water (400 mL), brine (400 mL) and dried over Na2SO4. The drying agent was removed by filtration and silica gel (60 g, type: ZCX-2, mesh 100-200) was added to the filtrate. The solvent was removed under vacuum to yield to the adsorbed silica gel, crude, 15-5. Silica gel was plated onto a silica gel column (300 g, type: ZCX-2, mesh 100-200), eluted with a petroleum ether:EtOAc gradient from 100:0 to 90:10, 500 mL fractions, using a combined flash. Qualified fractions were found by TLC, combined, and concentrated in vacuum to yield 15-5 (18.0 g, 49.1 mmol, 75%) as a clear, colorless oil. LC-MS (+ mode): RT 0.36 min, 367.3 (M+H+); 1H-NMR (300 MHz, CDCk): δ 4.76 (s, 4H), 2.40 (d, J = 6.0 Hz, 1H), 2.00-2.30 (4H), 0.75-1.10 (25H).Synthesis of 15-6: 2-Hydroxypropane-1,3-diyl bis(2-(4-methylcyclohexyl) acetate) / O. NaBH3CN O ------------< > )OH ch3co2h, thf \__ / 15-5 O 15-6 O

[00416] To a solution of 15-5 (18.0 g, 49.1 mmol) in THF under nitrogen, cooled in an ice-water bath, CH3CO2H (25.0 g, 0.42 mol) was added. To this stirred solution, NaBH3CN (12.9 g, 0.205 mol) was added in portions over 20 minutes. The mixture was stirred for 30 minutes after the addition was complete and then heated to room temperature and stirred for 2 hours. The mixture was dropped into water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic phases were dried over Na2SO4, the drying agent was removed by filtration, and silica gel (50 g, type: ZCX-2, mesh 100-200) was Petition 870250102289, dated 07 / 11 / 2025, page 174 / 408 170 / 379 added to the filtrate. Concentration under vacuum yielded silica gel-containing adsorbed crude 15-6 which was placed on a silica gel column (250g, type: ZCX-2, mesh 100-200), eluted with a petroleum ether:EtOAc gradient from 100:0 to 92:8, 500 mL fractions were collected using a combination-flare. Qualified fractions were found using TLC, then combined and concentrated under vacuum yield 15-6 (17.0 g, 46.1 mmol, 94%) as a clear, colorless oil. LC-MS (+ mode): RT 1.47 min, 391.2 (M+Na+); 1H-NMR (300MHz, CDCh): δ 5.30 (s, 1H), 4.00-4.20 (4H), 2.30 (m, 1H), 2.18 (m, 2H), 1.902.05 (2H), 1.18-1.75 (14H), 0.80-1.00 (12H). Synthesis of 15-7: ((4,4'-((tert-Butoxycarbonyl)azanediyl)bis(butanoyl)) bis(oxy)) bis(propane-2,1,3-triyl) tetrakis(2-(4-methylcyclohexyl)acetate)

[00417] To 1-5 (6.10 g, 21.1 mmol) in CH2Cl2 (120 mL), cooled in an ice-water bath under nitrogen, DMAP (1.00 g, 8.18 mmol) and 15-6 (17.0 g, 46.1 mmol) were added in one portion, followed by the addition of EDCl (9.70 g, 50.6 mmol) in portions over a period of 30 minutes. The mixture was stirred for 30 minutes after the addition was complete, then heated to room temperature and stirred for 16 hours. The mixture was dropped into brine (120 mL), the organic phase was separated and washed with brine (120 mL) and dried over Petition 870250102289, dated 07 / 11 / 2025, page 175 / 408 171 / 379 Na2SO4. The drying agent was removed by filtration and silica gel (60 g, type: ZCX-2, mesh 100-200) was added to the filtrate. Concentration under vacuum yielded silica gel-containing adsorbed crude 15-7ss which was placed on a silica gel column (300 g, type: ZCX-2, mesh 100-200), eluted with a petroleum ether:EtOAc gradient from 100:0 to 70:30, 500 mL fractions were collected using a combi-flare. Qualified fractions were found using TLC, then combined and concentrated under vacuum to yield 15-7ss (10.0 g, 10.1 mmol, 48%) as a clear, colorless oil. LC-MS (+ mode): RT 1.654 min, 1012.9 (M+Na+); 1H-NMR (300MHz, CDCb): δ 5.25 (m, 2H), 4.31 (m, 4H), 4.18 (m, 4H), 3.20 (brm, 4H), 2.31-2.40 (6H), 2.15-2.23 (5H), 2.00 (m, 1H), 1.78 (m, 4H), 1.50-1.75 (14H), 1.30-1.50 (3H), 1.35 (s, 9H), 1.18-1.30 (9H), 0.77-1.00 (26H). Synthesis of 15-8: bis(4-((1,3-bis(2-(4-Methylcyclohexyl)acetoxy)propan-2-yl)oxy)-4-oxobutyl)ammonium trifluoroacetate

[00418] To a solution of 15-7 (10.0 g, 10.1 mmol) in CH2Cl2 (40 mL), cooled in an ice-water bath under nitrogen, CF3CO2H (5.00 g, 43.9 mmol, 3.36 mL) was added in one portion. The mixture was stirred for 30 minutes after the addition and then heated to room temperature and stirred for 4 hours. The mixture was concentrated in vacuum to yield crude 15-8 (5.60 g, 5.58 mmol, 55%). Petition 870250102289, dated 07 / 11 / 2025, p. 176 / 408 172 / 379 as a viscous, colorless oil. LC-MS (+ mode): RT 0.608 min, 890.6 (M+H+); 1H-NMR (300MHz, CDCh): δ 11.10 (brs, 2H), 5.26 (m, 2H), 4.45 (m, 4H), 4.18 (m, 4H), 3.18 (m, 4H), 2.40 (t, J = 6.5Hz, 4H), 2.31 (t, J = 7.2Hz, 2H), 2.16-2.25 (6H), 1.82-2.08 (10H), 1.14-1.67 (22H), 0.75-1.00 (24H). Synthesis of 15-9: ((4,4'-((1H-Imidazol-1-carbonyl)azanediyl)bis(butanoyl))-bis(oxy))bis(propane-2,1,3-triyl) tetrakis(2-(4-methylcyclohexyl)acetate)

[00419] To a solution of 15-8 (5.60 g, 5.58 mmol) in CH2Cl2 (100 mL), under nitrogen, Et3N (1.30 g, 12.8 mmol, 1.21 mL) was added followed by carbonyldiimidazole (CDI, 2.00 g, 12.33 mmol). The mixture was stirred at room temperature for 14 hours and then diluted with n-heptane (100 mL). The solution was washed with water (3 x 100 mL) and the organic phase was dried over Na2SO4. Filtration and concentration under vacuum gave crude 15-9 (4.00 g, 4.06 mmol, 73%) as a viscous yellow oil. LC-MS (+ mode): RT 0.645 min 984.9 (M+H+); 1H-NMR (300MHz, CDCl3): δ 7.96 (m, 1H), 7.26 (m, 1H), 7.13 (m, 1H), 4.32 (m, 4H), 4.16 (m, 4H), 3.41 (m, 4H), 2.21-2.32 (6H), 2.08-2.16 (6H), 1.812.00 (6H), 1.50-1.72 (14H), 1.14-1.50 (12H), 0.75-1.00 (24H). Lipid Synthesis 15: ((4,4'-(((((3-(dimethylamino)propyl)thio)carbo Petition 870250102289, dated 07 / 11 / 2025, page 177 / 408 173 / 379 nyl)-azanediyl)bis(butanoyl)) bis(oxy))bis(propane-2,1,3-triyl) tetrakis(2-(4-methylcyclohexyl)acetate) 1. ch3oso2cf3, ch2ci2 2. HS Et3N, CH2CI2 N HCI

[00420] To a solution of 15-9 (4.00 g, 4.06 mmol) in CH2Cl2 (80 mL), cooled in an ice-water bath under nitrogen, CF3SO2OCH3 (0.70 g, 4.27 mmol) was added over a period of 5 minutes. The mixture was stirred for 1 hour after the addition was complete, then Et3N (0.80 g, 7.90 mmol, 1.10 mL) and 3-dimethylaminopropane-1-thiol HCl salt (0.76 g, 4.87 mmol) were added in order, one portion each. The mixture was stirred for 30 minutes after the additions were complete, then the mixture was heated to room temperature and stirred for 16 hours. Silica gel (15 g, type: ZCX-2, mesh 100-200) was added to the solution. Concentration under vacuum yielded silica gel containing crude adsorbed material 15, which was placed on a silica gel column (75 g, type: ZCX-2, mesh 100-200), eluted with a CH2Cb:MeOH gradient from 100:0 to 96:4, and 300 mL fractions were collected using a combi-flash.The qualified fractions were found using TLC, then combined and concentrated in vacuum to give LIPID 15 (1.70 g) which was subsequently purified by SFC (Column: Torus 2-PIC, 4.6 x 100 mm 5 μm; mobile phase B: i-PrOH; flow rate 4 mL / min; gradient: isocratic 10% B; wavelength 220 nM) to give LIPID 15 (1.00 g, 0.965 mmol, 23.8%) as a clear light yellow oil after vacuum concentration. ESMS: 1035.7 (M+H+); HPLC Purity: 98.47%; 1H-NMR (300MHz, CDCb): δ 5.24 (m, 2H), 4.31 (m, 4H), 4.14 (m, 4H), 3.38 (brm, 4H), 2.92 (t, J =. Petition 870250102289, dated 07 / 11 / 2025, page 178 / 408 174 / 379 7.3Hz, 2H), 2.11-2.52 (18H), 1.56-2.11 (23H), 1.12-1.56 (14H), 0.751.11 (23H). Example 16. Synthesis of LIPID 16: ((4,4'-(((3-(Dimethylamino)propyl)thio)carbonyl) azanediyl)bis(butanoyl))bis(oxy))bis(propane-2,1,3triyl) tetrakis(4-ethylcyclohexane-1-carboxylate) THE General Outline: CH2CI2, DMF (cat.) CO2h oxalyl chloride ho^A^oh 16-2 16-3 16-1 dmap, pyridine CH2CI2 NaBH3CN HOAC, THF carbonyldiimidazole Et3N, CH2CI2 Lipid 16 Synthesis of 16-1: 4-ethylcyclohexane-1-carbonyl chloride Petition 870250102289, dated 07 / 11 / 2025, page 179 / 408 175 / 379 CH2CI2, DMF (cat.) CO2H oxalyl chloride Cl 16-1

[00421] A solution of 4-ethylcyclohexanecarboxylic acid (22.5 g, 0.144 mol) in CH2Cl2 (225 mL) was cooled in an ice-water bath under nitrogen. DMF (0.5 mL) was added, followed by the addition of oxalyl chloride (36.6 g, 0.288 mol) over a period of 25 minutes. The mixture was stirred for 30 minutes after the addition was complete, then heated to room temperature and stirred for 16 hours. Concentration under vacuum yielded crude 16-1 (22.6 g, 0.129 mol, 90%) as a clear, colorless oil. 1H-NMR (300MHz, CDCl3): δ 2.62 (m, 1H), 2.62 (m, 2H), 1.37-1.53 ​​(2H), 1.10-1.27 (4H), 0.80-1.00 (6H). Synthesis of 16-2: 2-Oxopropane-1,3-diyl bis(4-ethylcyclohexane-1-carboxylate)

[00422] To a solution of dihydroxyacetone (5.30 g, 58.8 mmol) in CH2Cl2 (500 mL), cooled in an ice-water bath under nitrogen, DMAP (0.36 g, 2.94 mmol) and pyridine (10.24 g, 0.129 mol) were added in one portion, followed by the addition of 16-1 (22.6 g, 0.129 mol) over a period of 10 minutes. The mixture was stirred for 30 minutes after the addition was complete, then heated to room temperature and stirred for 14 hours. The solvent was removed under vacuum and the residue was dissolved in CH2Cl2 (100 mL). Silica gel (25 g, type ZCX2, mesh 100-200) was added to the solution, then the solvent was removed under vacuum to provide silica gel impregnated with adsorbed 16-2. Petition 870250102289, dated 07 / 11 / 2025, page 180 / 408 176 / 379 Silica gel was placed on a silica gel column (250 g, ZCX2 type, 100-200 mesh) and a combi-flash was used to purify the crude product. 16-2 eluting with a petroleum ether:EtOAc gradient from 100:0 to 90:10, collecting 300 mL fractions. The qualified fractions were localized by TLC, combined, and concentrated in vacuum to yield 162 (20.4 g, 55.6 mmol, 94%) as a clear, colorless oil. LC-MS (+ mode): RT 0.450 min, 367.3 (M+H+); 1H-NMR (300MHz, DMSO-d6): δ 4.83 (s, 4H), 2.27 (m, 2H), 2.15 (m, 1H), 1.77-1.90 (5H), 1.48 (m, 4H), 1.00-1.33 (10H), 0.80-0.95 (8H). Synthesis of 16-3: 2-Hydroxypropane-1,3-diyl bis(4-ethylcyclohexane-1-carboxylate)

[00423] A solution of 16-2 (20.4 g, 55.66 mmol) in THF (400 mL), cooled in an ice-water bath under nitrogen, was mixed with HOAc (33.4 g, 0.556 mol) in portions, followed by the addition of NaBHaCN (17.5 g, 0.278 mol) in portions over a period of 30 minutes. The mixture was stirred for 30 minutes after the addition was complete, then heated to room temperature and stirred for 2 hours. The mixture was dropped into water (2.0 L) and the resulting solution was extracted with EtOAc (3 x 200 mL). The combined organic phases were dried (Na2SO4), filtered, concentrated under vacuum, and the residue was dissolved in CH2Cl2 (100 mL). Silica gel (50g, type ZCX-2, mesh 100-200) was added to the crude 16-3 solution, and the solvent was removed under vacuum to obtain silica gel containing adsorbed crude 16-3. The silica gel was placed on a silica gel column (250g, type ZCX-2, mesh 100-200), and a combi-flash was used to purify the crude product.16-3 eluting with a 100:0 petroleum ether:EtOAc gradient. Petition 870250102289, dated 07 / 11 / 2025, page 181 / 408 177 / 379 92:8, collecting 300 mL fractions. The qualified fractions were localized by TLC, combined, and concentrated in vacuum to yield 16-3 (16.0 g, 43.42 mmol, 78%) as a clear, colorless oil. LC-MS (+ mode): RT 1.463 min, 391.3 (M+Na+); 1H-NMR (300 MHz, CDCh): δ 4.00-4.25 (5H), 2.32 (brs, 1H), 2.25 (m, 2H), 1.91 (m, 4H), 1.77 (m, 4H), 1.37 (m, 4H), 1.00-1.25 (8H), 0.75-0.95 (8H). Synthesis of 16-4: ((4,4'-(( tert- Butoxycarbonyl)azanodiyl)bis(butanoyl)) bis(oxy)) bis(propane-2,1,3-triyl) tetrakis(4-ethylcyclohexane-1-carboxylate)

[00424] To a solution of 1-5 (5.42 g, 18.73 mmol) in CH2Cl2 (100 mL), under nitrogen, the following were added in the order: DMAP (0.91 g, 7.49 mmol) and 16-3 (15.2 g, 41.21 mmol). The resulting solution was cooled in an ice water bath and then EDCl (8.60 g, 44.96 mmol) was added in 5 portions over a period of 30 minutes. The mixture was stirred for 30 minutes after the addition was complete, then the solution was heated to room temperature and left to stir for 14 hours. The mixture was dropped into brine (100 mL), the organic phase was separated and dried over Na2SO4. Filtration yielded a crude 16-4 solution to which silica gel (15g, type ZCX-2, 100-200 mesh) was added, and the solvent was removed under vacuum to obtain silica gel containing adsorbed crude 16-4. The silica gel was placed on a silica gel column. Petition 870250102289, dated 07 / 11 / 2025, page 182 / 408 178 / 379 (75g, type ZCX-2, mesh 100-200) and a combi-flash was used to purify the crude product. 16-4 eluting with a petroleum ether:EtOAc gradient from 100:0 to 80:20, collecting 300mL fractions. The qualified fractions were localized by TLC, combined and concentrated in vacuum to yield 16-4 (12.98g, 13.10mmol, 70%) as a clear, colorless oil. LC-MS (+ mode): RT 1,703 min. 890.6 (M-Boc + 2H+); 1H-NMR (300 MHz, CDCl3): δ 5.50 (m, 2H), 4.32 (m, 4H), 4.21 (m, 4H), 3.20 (brm, 4H), 2.16-2.35 (7H), 1.82 (m, 8H), 1.75-1.80 (9H), 1.38 (s, 9H), 1.001.38 (24H), 0.75-0.90 (20H). Synthesis of 16-5: bis(4-((1,3-bis((4-ethylcyclohexane-1-carbonyl)oxy)propan-2-yl)oxy)-4-oxobutyl)ammonium trifluoroacetate CH2CI2 CFqCO·

[00425] To a solution of 16-4 (12.98 g, 13.11 mmol) in CH2Cl2 (50 mL), cooled in an ice-water bath under nitrogen, CF3CO2H (7.47 g, 65.54 mmol) was added over a period of 10 minutes. The mixture was stirred for 15 minutes after the addition was complete, then heated to room temperature and stirred for 16 hours. Concentration under vacuum gave crude 16-5 (14.82 g) as a colorless oil. LC-MS (+ mode): RT 0.677 min. 890.6 (M+H+) (18H), 1.00-1.50 (22H), 0.750.95 (20H). Petition 870250102289, dated 07 / 11 / 2025, p. 183 / 408 179 / 379 Synthesis of 16-6: ((4,4'-((1H-Imidazol-1-carbonyl)azanediyl)bis(butanoyl)) bis(oxy))bis(propane-2,1,3-triyl) tetrakis(4-ethylcyclohexane-1carboxylate) carbonyldiimidazole Et3N, CH2CI2 CF3CO;

[00426] A 16-5 solution (14.82 g, crude) was dissolved in CH2Cl2 (300 mL) and cooled in an ice-water bath under nitrogen. To this solution, Et3N (6.74 g, 66.59 mmol) and carbonyldiimidazole (5.39 g, 33.30 mmol) were added in that order. The mixture was stirred for 30 minutes after the additions were complete, then the solution was heated to room temperature and stirred for 3 hours. The solvent was removed under vacuum and the residue was dissolved in n-heptane (300 mL) and water was added to the flask. With vigorous stirring, the pH of the aqueous phase was adjusted to approximately 6.0 by adding 3% aq. citric acid solution. After the target pH was reached, the organic phase was separated and dried over Na2SO4. Vacuum filtration and concentration yielded crude 16-6 (13.77) which was used in the next step without further purification. LC-MS (+ mode): RT 0.773 min. 984.5 (M+H+); 1HNMR (300 MHz, CDCh): δ 7.99 (m, 1H), 7.27 (m, 1H), 7.12 (m, 1H), 5.20 (m, 2H), 4.31 (m, 4H), 4.18 (m, 4H), 3.41 (m, 4H), 2.31 (m, 4H), 2.23 (m, 4H), 1.82-2.00 (12H), 1.79 (m, 8H), 1.00-1.40 (20H), 0.75-0.92 (20H). Synthesis of LIPID 16: ((4,4'-(((3-(Dimethylamino)propyl)thio)carbonyl) azanodiyl) bis(butanoyl))bis(oxy))bis(propano-2,1,3-triyl) tetrakis(4ethylcyclo-hexano-1 -carboxylate) Petition 870250102289, of 07 / 11 / 2025, p. 184 / 408 180 / 379οLIPIDIUM 16

[00427] A solution of 16-6 (13.77 g, crude) in CH2Cl2 (150 mL) was cooled in an ice-water bath under nitrogen. Methyl trifluoromethanesulfonate (2.52 g, 20.99 mmol) was added to this cooled solution over a period of 10 minutes. The mixture was stirred for 1 hour in an ice-water bath, then Et3N (4.24 g, 41.97 mmol) was added over a period of 5 minutes followed by the addition of 3-dimethylaminopropane-1-thiol (2.49 g, 20.99 mmol) over a period of 5 minutes. The mixture was stirred for 30 minutes, then heated to room temperature and stirred for 8 hours. The mixture was concentrated under vacuum and the residue was dissolved in CH2Cl2 (100 mL) to which silica gel (30 g, type ZCX-2, mesh 100-200) was added and the solvent was removed under vacuum to obtain silica gel containing adsorbed crude 16. The silica gel was placed on a silica gel column (80 g, type ZCX-2, mesh 100-200) and a combi-flash was used to purify the crude product.Lipid 16 was eluted with a CH2Cl2:MeOH gradient from 100:0 to 96:4, collecting 300 mL fractions. The qualified fractions were localized by TLC, combined, and concentrated under vacuum to yield Lipid 16 (10.14 g, 9.797 mmol, 75% yield in 3 steps) as a clear, light yellow oil. ES-MS: 1036.0 (M+H+); HPLC purity 94.24%; 1H-NMR (300MHz, CDCh): δ 5.24 (m, 2H), 4.30 (dd, J = 11.9, 4.6Hz, 4H), 4.14 (dd, J = 11.9, 5.7Hz, 4H), 3.38 (brm, 4H), 2.94 (t, J = 7.1Hz, 2H), 2.46 (s, 6H), 2.34 (brm, 4H), 2.20 (m, 4H), 1.72-1.91 (20H), 1.37 (m, 8H), 1.08-1.22 (16H), 0.80-0.91 (20H). Petition 870250102289, dated 07 / 11 / 2025, page 185 / 408 181 / 379 Example 17. Synthesis of LIPID 17: ((4,4'-(((3-(Dimethylamino)propyl)thio)carbonyl) azanediyl)bis(butanoyl))bis(oxy))bis(propane-2,1,3 triyl) tetrakis(3-cyclohexyl-2-methylpropanoate) LIPID 17 General Outline: Petition 870250102289, dated 07 / 11 / 2025, p. 186 / 408 182 / 379 HCl dioxane carbonyldiimidazole Et3N, CH2CI2 Ox ZO 'Sz.F3C^ ^och3, CH2CI2 2. I Et3N, CH2CI2 Synthesis of 17-1: Ethyl (E)-3-cyclohexyl-2-methylacrylate the EtO-P^COaEt EtÓ J NaH, THF Petition 870250102289, dated 07 / 11 / 2025, p. 187 / 408 183 / 379

[00428] In a 2 L round-bottom, four-necked flask, purged and maintained with an inert nitrogen atmosphere, NaH (60%, 21.42 g, 0.534 mol, 1.0 equiv) and THF (822 mL) were charged. Then, ethyl 2-(diethoxyphosphoryl)propanoate (127.2 g, 0.536 mol, 1.0 equiv) was added dropwise over 30 min at room temperature, and the mixture was stirred for 1.5 h after the addition was complete. Cyclohexane carboxaldehyde (60.0 g, 0.536 mol, 1.0 equiv) in THF (318 mL) was added dropwise over 30 min, and the mixture was stirred for 2 h at room temperature. The reaction was quenched with saturated aqueous NH4Cl (1.5 L) and extracted with MTBE (2 x 0.75 L). The combined organic layers were washed with H2O (0.75 L), brine (0.75 L, 12.5 V), dried with anhydrous Na2SO4, filtered, and concentrated under vacuum. This resulted in 105 g 17-1 (crude) as a yellow oil which was used in the next step without further purification. Synthesis of 17-2: ethyl 3-cyclohexyl-2-methylpropanoate 17-1 17-2

[00429] In a 2 L round-bottom flask, washed with nitrogen, 17-1 (120.0 g, 1.0 equiv.) was loaded into EtOH (1.2 L). Then, 10% by weight of Pd / C (36.0 g, 30% w / w) was added in a portion. The mixture was then stirred under H2 atmosphere for 4 hours at room temperature. The filtrate and filter cake were washed with CH2Cl2 (1.2 L). The filtrate was concentrated under vacuum to yield crude product 17-2. Crude 17-2 was dissolved in CH2Cl2 (1 L) and 200 g of silica gel (type: ZCX-2, mesh 100-200, 1.67 w / w) were added; the solvent was then removed under vacuum while maintaining the temperature below 35°C. One kilogram of silica gel (type: ZCX-2, mesh 100-200, 8.33 w / w) was loaded into the column, followed by the final step of preparing dry silica gel that absorbed the reaction mixture. Petition 870250102289, dated 07 / 11 / 2025, pages 188 / 408 184 / 379 combi-flash was used to purify the product by eluting with a petroleum ether / EtOAc gradient from 100:0 to 95:5, collecting 1000 mL fractions. Samples were collected for TLC analysis and qualified products were combined. This resulted in 94 g (76% yield) of 17-2 as yellow oil. Synthesis of 17-3: 3-cyclohexyl-2-methylpropanoic acid yyyc°2Etaq. NaOH yy Eton yy 17-2 17-3

[00430] In a 2 L round-bottom, 3-necked flask, purged and maintained with an inert nitrogen atmosphere, 17-2 (57.0 g, 0.288 mol, 1.0 equiv) was placed in EtOH (285 mL) at room temperature. Then, NaOH (17.3 g, 0.433 mol, 1.5 equiv) in H2O (285 mL) was added in a portion. The resulting solution was then heated to 70 °C and stirred for 3 hours. The reaction was cooled to room temperature and extracted with n-heptane (2 x 200 mL). The H2O layer was adjusted to pH=2 with aqueous HCl (12 mol / L), then extracted with MTBE (2 x 300 mL). The combined organic layers were washed with H2O (2 x 150 mL), dried with anhydrous Na2SO4, filtered, and concentrated under vacuum. This resulted in 47 g (0.276 mol, 96% yield) 17-3 as colorless oil. ELSD A: water / 5mM NH4+HCO3-: B: CH3CN 90:10 to 10:9 A / B at 2 min., hold 1 min): RT 0.56 min, m / z 170.1 (Calc.), (obtained) 169.13 (MH). Synthesis of 17-4: 2-Oxopropane-1,3-diyl bis(3-cyclohexyl-2-methylpropanoate) 17-4

[00431] In a 1 L round-bottom, 3-neck flask, purged Petition 870250102289, dated 07 / 11 / 2025, p. 189 / 408 185 / 379 and maintained under an inert nitrogen atmosphere, 1,3-dihydroxyacetone (17.5 g, 0.194 mol, 1.0 equiv) and 17-3 (66.0 g, 0.388 mol, 2.0 equiv) in CH2Cl2 (350 mL) were added. The temperature was reduced to 0 °C in an ice-water bath. DMAP (12.0 g, 0.098 mol, 0.5 equiv) and EDCI (112 g, 0.583 mol, 3.0 equiv) at 0 °C were added to the cooled solution. The ice-water bath was removed and the temperature was gradually increased. The reaction mixture was stirred overnight at room temperature. Directly to the reaction mixture, 200 g of silica gel (type: ZCX-2, 100-200 mesh, 11.4 wt / wt) were added, and the solvent was removed under vacuum while maintaining the temperature below 35°C. 1 kg of silica gel (type: ZCX-2, 100-200 mesh, 57.1 wt / wt) was loaded into the column, followed by the final step of preparing dry silica gel that absorbed the reaction mixture.Using combi-flash to purify the product, eluting with a petroleum ether / EtOAc gradient from 100:0 to 90:10, collecting 1000 fractions. A sample was collected for TLC analysis and qualified products were combined. This resulted in 73 g (0.184 mol, 95% yield) of 17-4 as a light yellow oil. The product has no MS signal and is used as such in the next step. Synthesis of 17-5: 2-Hydroxypropane-1,3-diyl bis(3-cyclohexyl-2-methylpropanoate) NaBH3CN HOAc, THF

[00432] In a 1 L round-bottom, 3-necked flask, purged and maintained with an inert nitrogen atmosphere, a solution of 17-4 (56.0 g, 0.142 mol, 1.0 equiv) in THF (560 mL) was placed. The temperature was reduced to 0 °C in an ice-water bath. HOAc (12.8 g, 0.213 mol, 1.5 equiv) at 0 °C was added to the solution, and then NaBH3CN (12.5 g, 0.199 mol, 1.4 equiv) at 0 °C was added to the mixture. The bath of Petition 870250102289, dated 07 / 11 / 2025, pp. 190 / 408 The 186 / 379 ice / water ratio was removed and the temperature was gradually increased. The reaction mixture was stirred for 8 h at room temperature. The reaction mixture was quenched with H2O (1.1 L) and extracted with CH2Cl2 (1.6 L). The organic layer was washed with aqueous NaHCO3 (560 mL), H2O (2 x 280 mL), dried with anhydrous Na2SO4, and filtered. The filtrate was used directly in the next step. Synthesis of 17-6: ((4,4'-(( tert- Butoxycarbonyl)azanodiyl)bis(butanoyl)) bis(oxy)) bis(propane-2,1,3-triyl) tetrakis(3-cyclohexyl-2-methylpropanoate)

[00433] In a 2 L round-bottom, 3-necked flask, purged and maintained with an inert nitrogen atmosphere, 1-5 (20.0 g, 0.069 mol, 1.0 equiv) and 17-5 (solution above, 0.138 mol, 2.0 equiv) were added. The temperature was reduced to 0 °C in an ice-water bath. DMAP (8.4 g, 0.069 mol, 1.0 equiv) and EDCI (53 g, 0.277 mol, 4.0 equiv) were added to the solution at 0 °C. The ice-water bath was removed and the temperature was gradually increased. The reaction mixture was stirred overnight at room temperature. 200 g of silica gel (type: ZCX-2, 100-200 mesh, 10.0 w / w) were added directly to the reaction mixture. The mixture was then concentrated under vacuum while maintaining the temperature below 35°C. 1.5 kg of silica gel (type: ZCX-2, 100-200 mesh, 75.0 w / w) was loaded into the column, followed by the final step of preparing dry silica gel that absorbed the reaction mixture. Using combined Petition 870250102289, dated 07 / 11 / 2025, pp. 191 / 408 187 / 379 flash to purify the product, eluting with petroleum ether / EtOAc gradient from 100:0 to 90:10, collecting 500 mL fractions. A sample was collected for TLC analysis and combined qualified products. This resulted in 30.8 g (59.6 mmol, 42% for 2 steps) of 17-6 as light yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., hold 1.0 min): RT 2.08 min, m / z (Calc.) 1045.7, (obtained) 946.6 (M-Boc+H). Synthesis of 17-7: bis(4-((1,3-bis((3-Cyclohexyl-2-methylpropanoyl)oxy)propan-2-yl)oxy)-4-oxobutyl)ammonium chloride N-Boc dioxane

[00434] In a 1 L round-bottom flask purged and maintained with an inert nitrogen atmosphere, a solution of 17-6 (48.0 g, 0.046 mol, 1.0 equiv) was placed in 1,4-dioxane (240 mL) and the solution was cooled in an ice water bath. To the solution, 4M HCl in 1,4-dioxane (240 mL) was added dropwise at 0-10°C for 10 min. The resulting solution was stirred overnight at room temperature. The mixture was concentrated under vacuum. This yielded 48 g (crude) of 17-7 as yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 3 min., wait 1.0 min): RT 0.92 min, m / z (Calc.) 945.6, (obtained) 946.6 (M+H). Synthesis of 17-8: ((4,4'-((1H -Imidazol-1-carbonyl)azanediyl)bis(butanoyl))-bis(oxy))bis(propane-2,1,3-triyl) tetrakis(3-cyclohexyl-2-methylpropanoate) Petition 870250102289, dated 07 / 11 / 2025, p. 192 / 408 188 / 379 carbonyldiimidazole

[00435] Under a nitrogen atmosphere, 17-7 (48.0 g, 0.046 mol, 1.0 equiv) was charged in CH2Cl2 (1.06 L) in a 2 L capacity round-bottom bottle with 3 necks. Then, carbonyldiimidazole (15.9 g, 0.098 mol, 2.1 equiv) was added followed by pyridine (15.4 g, 0.196 mol, 4.26 equiv) and the mixture was stirred overnight at room temperature. The resulting solution was washed with 3% aqueous citric acid (2 x 500 mL), H2O (3 x 500 mL) and brine (500 mL), dried with anhydrous Na2SO4 and concentrated at 35°C under vacuum. The crude mixture was dissolved in CH2Cl2 (800 mL) and 100 g of silica gel (type: ZCX-2, mesh 100-200, 2.08 wt / wt) were added and the solvent was removed under vacuum while maintaining the temperature below 35°C. 300 g of silica gel (type: ZCX-2, mesh 100-200, 6.25 wt / wt) was loaded onto the column, followed by the final step of preparing dry silica gel that absorbed the reaction mixture.Using a combi-flash to purify the product, eluting with a petroleum ether / EtOAc gradient from 100:0 to 70:30, collecting 400 mL fractions. Samples were collected for TLC analysis and qualified products were combined. This resulted in 39 g (37.5 mmol, 81% yield) 17-8 as an oil. ELSD A: water / 0.05% TFA: B: CHaCN / 0.05% TFA 95:5 to 5:95 A / B at 2 min, hold 0.6 min): RT 1.0 min, m / z (Calc.) 1039.6, (obtained) 1040.6 (M+H). Synthesis of LIPID 17: ((4,4'-(((3-(Dimethylamino)propyl)thio)carbonyl)-azanediyl)bis(butanoyl))bis(oxy))bis(propane-2,1,3-triyl) tetrakis (3-cyclohexyl-2-methylpropanoate) Petition 870250102289, dated 07 / 11 / 2025, page 193 / 408 189 / 379 Et3N, CH2CI;'o LIPID 17

[00436] In a 500 mL three-necked round-bottom flask, purged and maintained with an inert nitrogen atmosphere, a solution of 17-8 (20.0 g, 0.019 mol, 1.0 equiv) in CH2Cl2 (200 mL) was placed. The reaction temperature was reduced to 0 °C in an ice / water batch. Methyl trifluoromethanesulfonate (3.3 g, 0.020 mol, 1.05 equiv) was added to the mixture at 0 °C. After the addition, the reaction was stirred for 3 hours at 0 °C. 2.0 M trimethylamine in THF (28.9 mL, 0.058 mol, 3.0 equiv) was loaded into the reactor at 0 °C. After the addition, the reaction was stirred for 0.5–1 hours at 0 °C. 3-(dimethylamino)propane-1-thiol (3.0 g, 0.025 mol, 1.3 equiv) was loaded into the reactor at 0°C. After the addition, the reaction was allowed to reach room temperature and then continued to be stirred for 5.0 hours. Aqueous sodium chloride solution (10.0% by weight, 200 mL) and 10% aqueous citric acid solution (10.0% by weight, 200 mL) were loaded into the reactor.The reactor was stirred for 15 minutes and then allowed to rest for 15 minutes to allow phase separation at room temperature. The organic layer was collected. This operation was repeated once more. Aqueous sodium chloride solution (10.0% by weight, 200 mL) was added, and aqueous sodium bicarbonate solution (5.0% by weight, 200 mL) was added to the reactor. It was stirred for 15 minutes and then allowed to rest for 15 minutes to allow phase separation at room temperature. The organic layer was collected. This operation was repeated once more. Aqueous sodium chloride solution (10.0% by weight, 400 mL) was added to the reactor. It was stirred for... Petition 870250102289, dated 07 / 11 / 2025, pp. 194 / 408 190 / 379 for at least 15 minutes, and then the reactor was allowed to stand for at least 15 minutes to allow phase separation at room temperature. The organic layer was collected. n-Heptane (250 mL) was loaded into the reactor. The solution was concentrated to approximately 300 mL under vacuum while maintaining the temperature between 20-40°C. A 10.0% by weight methanol / citric acid water solution (10:1, 200 mL) was loaded into the reactor. After addition, it was stirred for 15 minutes and then the reactor was allowed to stand for 15 minutes to allow phase separation at 36 ± 5 °C. The MeOH / H2O layer was collected. n-Heptane (250 mL) was loaded into the reactor to wash the MeOH / H2O phase. This washing operation with n-heptane was repeated eight times. N-heptane (500 mL), 15.0% by weight sodium carbonate solution (250 mL) and 10.0% by weight sodium chloride solution (250 mL) were loaded into the reactor.The mixture was stirred for 15 minutes, then allowed to stand for 15 minutes to allow phase separation at room temperature. The organic layer was collected. A 5.0% by weight sodium bicarbonate solution (400 mL) was added to the reactor. It was stirred for 15 minutes, then allowed to stand for 15 minutes to allow phase separation at room temperature. The organic layer was collected, dried over anhydrous sodium sulfate, and concentrated under vacuum. To the residue in CH2Cl2 (300 mL), 30 g of silica gel (type: ZCX-2, 100-200 mesh, 1.5 w / w) were added, and the mixture was then concentrated under vacuum while maintaining the temperature below 35°C. 200 g of silica gel (type: ZCX-2, mesh 100-200, 10.0 wt / wt) were loaded into the column, followed by the final step of preparing dry silica gel that absorbed the reaction mixture.Using combi-flash to purify the product, eluting with a CH2Cl2 / MeOH gradient from 100:0 to 90:10, collecting 400 mL fractions. Samples were collected for TLC analysis and qualified products were combined. That's it. Petition 870250102289, dated 07 / 11 / 2025, pp. 195 / 408 191 / 379 resulted in 11.5 g (55% yield) of LIPID 17 as yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 80:20 to 20:80 A / B at 3 min., wait 1 min): RT 0.97 min, m / z (Calc.) 1090.7, (obtained) 1091.7 (M+H). 1H-NMR (300 MHz, CDCh): δ 5.25 (m, 2H), 4.34 (dt, J = 11.9, 4.0 Hz, 4H), 4.15 (m, 4H), 3.38 (brm, 4H), 2.92 (t, J = 7.3 Hz, 2H), 2.67-2.49 (4H), 2.48 - 2.22 (12H), 1.89-1.84 (6H), 1.78 - 1.51 (24H), 1.35-1.07 (32H), 0.99 - 0.76 (8H). Example 18. Synthesis of LIPID 18: ((4,4'-(((3-(Dimethylamino)propyl)thio)carbonyl) azanediyl)bis(butanoyl))bis(oxy))bis(propane-2,1,3trlilyhtetraguisi^-methioctanoatol 0 General Scheme: O o HoJzOH DMAP, EDCI \— 1 ch2ci2 1-5 ° EDCI, DMAP o CH2CI2 II X \ / -- / o —X 7 18-3 1. triphosgene CH2CI2, pyridine 2. concentrate dissolved in pyridine 1 3· OX°> > 0 °·Χ °Ύθ / - o—' 'o ,__ LIPID 18 \ p 1. 0 / \ NaBH3CN )—C / ----3--- / 0^ \ )=O HOAc, THF \ XOH λ\ / °^ --\ o — ' O 18-1 18-2 ' \ O °~Λ \__ HCI in / V cj \ \ dioxane / O \ μ N-Boc ---------► Nt — / dioxane o Q ,— / C|.H . HCl in / ° X-. dioxane 0 Xo 18'4 °~Λ ^Xo 0 j? VX '^X^'Vo' / - \ / —' 0 LIPID 18 Petition 870250102289, dated 07 / 11 / 2025, pp. 196 / 408 192 / 379 Synthesis of 18-1: 2-Oxopropane-1,3-diyl bis(2-methyloctanoate) 18-1

[00437] In a 50 mL round-bottom, three-necked flask, purged and maintained with an inert nitrogen atmosphere, 1,3-dihydroxyacetone (1.42 g, 1.0 equiv.) and 2-methyloctanoic acid (5.0 g, 2.0 equiv., Org. Biomol. Chem. 2014, 12, 3649-3663) were added in CH2Cl2 (30 mL). The solution was cooled in an ice-water bath, and then DMAP (0.96 g, 0.5 equiv.) and EDCI (12.1 g, 4.0 equiv.) were added at 0°C. The reaction mixture was brought to room temperature and stirred overnight. 20 g of silica gel (type: ZCX-2, mesh 100-200, 15.5 w / w) were added to the mixture, the solvent was removed under vacuum while maintaining the temperature below 35°C. 100 g of silica gel (type: ZCX-2, mesh 100-200, 77.5 w / w) were loaded into the column, followed by the final step of preparing dry silica gel that absorbed the reaction mixture.The crude product was purified using a Combi Flash purification system, eluting with a petroleum ether / EtOAc gradient of 100:0 to 90:10 collected every 200±50 mL. The sample was taken for TLC analysis and the qualified fractions were combined and concentrated under vacuum. This resulted in 4.9 g (85% yield) of 18-1 as a light yellow oil. ELSD A: water / 0.05% TFA; B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 2 min., hold 1.3 min): RT 1.6 min, m / z (Calc.) 370.3, (obtained) 371.3 (M+H). Synthesis of 18-2: 2-Hydroxypropane-1,3-diyl bis(2-methyloctanoate) Petition 870250102289, dated 07 / 11 / 2025, page 197 / 408 193 / 379

[00438] In a purged 100 mL round-bottom flask with three necks, maintained with an inert nitrogen atmosphere, a solution of 18-1 (4.9 g, 1.0 equiv) in THF (50 mL) was placed and the solution was cooled in an ice water bath. HOAc (1.03 g, 1.3 equiv) at 0°C was added to the solution, followed by the addition of NaBH3CN (1.0 g, 1.2 equiv.) at 0°C. The ice water bath was removed after the addition of all reagents. The reaction mixture was stirred overnight at room temperature. The reaction mixture was quenched with H2O (100 mL) and extracted with CH2Cl2 (150 mL). The organic layer was washed with 5% aqueous NaHCO3 (50 mL), H2O (2 x 50 mL), dried with anhydrous Na2SO4, and filtered. The filtrate, containing 18-2, was used directly for the next step. Synthesis of 18-3: ((4,4'-(( tert-butoxycarbonyl)azanediyl)bis(butanoyl)) bis(oxy))bis(propane-2,1,3-triyl) tetrakis(2-methyloctanoate) / —' o 18-3

[00439] In a 100 mL round-bottom 3-neck flask Petition 870250102289, dated 07 / 11 / 2025, pp. 198 / 408 After purging and maintaining an inert nitrogen atmosphere, 18-2 (8.8 g, 2.3 equiv.) and 1-5 (3.0 g, 1.0 equiv.) of CH2Cl2 (60 mL) were added, and the mixture was cooled in an ice water bath. DMAP (1.26 g, 1.0 equiv.) and EDCI (7.96 g, 4.0 equiv.) were added to the solution at 0°C. The ice water bath was removed after the addition of all reagents. The reaction mixture was stirred overnight at room temperature. 20 g of silica gel (type: ZCX-2, mesh 100-200, 6.7 w / w) were added to the mixture, and the solvent was removed under vacuum while maintaining the temperature below 35°C. 120 g of silica gel (type: ZCX-2, mesh 100-200, 40.0 w / w) was loaded onto the column, followed by the final step of preparing dry silica gel that absorbed the reaction mixture. A combiflash was used to purify the product, eluting with a petroleum ether / EtOAc gradient from 100:0 to 90:10, collecting 200 mL fractions. A sample was collected for TLC analysis and qualified products were combined.This resulted in 4.3 g (42% yield) of 18-3 as light yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 80:20 to 20:80 A / B at 3 min., hold 1 min): RT 1.97 min, m / z (Calc.) 997.7, (obtained) 1020.6 (M+Na). Synthesis of 18-4: bis(4-((1,3-bis((2-methyloctanoyl)oxy)propan-2-yl)oxy)-4-oxobutyl)ammonium chloride Petition 870250102289, dated 07 / 11 / 2025, pp. 199 / 408 195 / 379

[00440] In a 100 mL round-bottom flask purged and maintained with an inert nitrogen atmosphere, a solution of 18-3 (4.3 g, 1.0 equiv) in 1,4-dioxane (21 mL) was placed and the solution was cooled in an ice water bath. To the cooled solution, 4M HCl in 1,4-dioxane (21 mL) was added dropwise at 0-10°C for 10 min. The resulting solution was stirred overnight at room temperature. The reaction mixture was concentrated under vacuum. This resulted in 4 g (crude) of 18-4 as yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B at 2 min., wait 1.3 min): RT 1.6 min, m / z (Calc.) 897.6, (obtained) 898.6 (M+H). Synthesis of LIPID 18: ((4,4'-(((3-(Dimethylamino)propyl)thio)carbonyl)-azanediyl)bis (butanoyl))bis(oxy))bis(propane-2,1,3-triyl) tetrakis(2-methyloctanoate) 1. triphosgene CH2CI2, pyridine 2. concentrate dissolved in pyridine I 3.HS'^

[00441] In a 250 mL round-bottom, three-necked flask, purged and maintained with an inert nitrogen atmosphere, a solution of 18-4 (3.8 g, 1.0 equiv) in CH2Cl2 (80 mL) was placed and the solution was cooled in an ice water bath. Triphosgene (1.26 g, 1.0 equiv) was added to the mixture at 0°C, followed by the dropwise addition of pyridine (1.67 g, 5.0 equiv) with stirring at 0°C. The ice water bath was removed after the addition of all reagents. The mixture was stirred for 4 h at room temperature and then concentrated under vacuum (temperature <30°C). The residue was dissolved with pyridine (80 mL), res Petition 870250102289, dated 07 / 11 / 2025, pages 200 / 408 196 / 379 cooled in an ice water bath under nitrogen, then 3-(dimethylamino)propane-1-thiol (1.0 g, 2.0 equiv) was added dropwise with stirring at 0°C over 10 min. The resulting solution was stirred overnight at room temperature. The reaction mixture was concentrated under vacuum and the residue was diluted with CH2Cl2 (80 mL). The solution was washed with 10% aqueous citric acid solution (40 mL), H2O (40 mL), saturated NaHCO3 (2 x 40 mL) and brine (40 mL, 10 V). The organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum. To the residue, dissolved in CH2Cl2 (60 mL), 8 g of silica gel (type: ZCX-2, mesh 100-200, 2.11 w / w) were added, and the solvent was removed under vacuum while maintaining the temperature below 35°C. 100 g of silica gel (type: ZCX-2, mesh 100-200, 26.3 w / w) was loaded onto the column, followed by the final step of preparing dry silica gel that absorbed the reaction mixture.Using a combi-flash to purify the product, eluting with a CH2Cb / MeOH gradient from 100:0 to 90:10, collecting 100 mL fractions. Samples were collected for TLC analysis and qualified products were combined. This resulted in 1.3 g (29% yield for 2 steps) of LIPID 18 as yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 80:20 to 20:80 A / B in 3 min., hold 2.1 min): RT 1.1 min, m / z (Calc.) 1042.7, (obtained) 1043.6 (M+H). 1H-NMR (300 MHz, CDCl3): δ 5.25 (m, 2H), 4.34 (m, 4H), 4.16 (m, 4H), 3.38 (brm, 4H), 2.92 (m, 4H), 2.66 (s, 6H), 2.46 (m, 4H), 2.35 (brs, 4H), 2.09 (m, 2H), 1.90 (brs, 4H), 1.64 (m, 4H), 1.47-1.20 (38H), 1.15-1.13 (12H), 0.95 - 0.81 (12H). Example 19. Synthesis of LIPID 19: ((4,4'-(((3-(Dimethylamino)propyl)thio)carbonyl) azanediyl)bis(butanoyl))bis(oxy))bis(propane-2,1,3triyl) tetrakis(2,2-dimethylheptanoate) Petition 870250102289, dated 07 / 11 / 2025, pp. 201 / 408 197 / 379 General Outline: LIPID 19 THE HO. NaBH3CN aq. NaOH THE HOAc, THF MeOH dioxane 3. HS. LIPID 19 EDCI, DMAP CH2CI DMAP, EDO CH2CI 1.LDA, THF, -78°C COoEt HCl in dioxane 1. triiosgen CH2CI2, pyridine 2. concentrate dissolved in pyridine Synthesis of 19-1: ethyl 2,2-dimethylheptanoate 19-1

[00442] In a 500 ml round-bottom, 3-necked flask, purged cattle were kept in an inert nitrogen atmosphere. Petition 870250102289, dated 07 / 11 / 2025, pp. 202 / 408 198 / 379 Ethyl isobutyrate (40.0 g, 1.0 equiv) in THF (400 mL) was dissolved. The resulting solution was cooled to -78 °C, then LDA (205.6 mL, in hexane, 1.05 equiv) was added dropwise and the resulting solution was stirred for 1 h at -78 °C. Next, 1-iodopentane (92.8 g, 1.2 equiv) was added dropwise and the resulting solution was stirred for 5 h at 78 °C. The cooling bath was removed and the solution was stirred overnight at room temperature. The pH of the solution was adjusted to 6 with aqueous HCl solution (1 mol / L). The resulting solution was extracted with ethyl acetate (2 x 300 mL) and the organic layers were combined. The resulting mixture was washed with brine (500 mL), dried over anhydrous sodium sulfate, and concentrated under vacuum. This yielded 51 g (75.6%) of 19-1 as yellow oil, which was used in the next step without further purification. Synthesis of 19-2: Aq. 2,2-dimethyl heptanoic acid. NaOH O 19-1 19-2

[00443] In a 2 L round-bottom, 3-necked flask, purged and maintained with an inert nitrogen atmosphere, 19-1 (70.0 g, 1.0 equiv) was placed in MeOH (700 mL). A solution of NaOH (49.0 g, 3.0 equiv) in H2O (350 mL) was added dropwise to the solution at room temperature. The resulting solution was heated and stirred for 4 hours at 60 °C. The resulting mixture was concentrated under vacuum after cooling to room temperature. The residue was dissolved in H2O (200 mL), extracted with MTBE (200 mL), and the aqueous layer was separated. The pH of the aqueous layer was adjusted to 5 with aqueous HCl solution (1 mol / L). The resulting solution was extracted with ethyl acetate (2 x 100 mL) and the organic layers combined. The resulting mixture was washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. This yielded 32 g (68%) of 19-2 Petition 870250102289, dated 07 / 11 / 2025, pp. 203 / 408 199 / 379 as yellow oil that was used without purification. Synthesis of 19-3: 2-Oxopropane-1,3-diyl bis(2,2-dimethylheptanoate)

[00444] In a 500 mL three-necked round-bottom flask, purged and maintained with an inert nitrogen atmosphere, 1,3-dihydroxyacetone (12.0 g, 1.0 equiv) was added to CH2Cl2 (240 mL). The solution was cooled to 0°C in an ice-water bath. 19-2 (44.0 g, 2.1 equiv), DMAP (16.3 g, 1.0 equiv) followed by EDCI (76.7 g, 3.0 equiv) at 0°C were added to the solution. The ice-water bath was removed and the reaction mixture was stirred overnight at room temperature. 25 g of silica gel (type: ZCX-2, 100-200 mesh, 2.08 w / w) were added to the reaction solution. The mixture was then concentrated under vacuum while maintaining the temperature below 35°C. 500 g of silica gel (type: ZCX2, 100-200 mesh, 41.7 w / w) were loaded onto the column, followed by the preparation of dry silica gel that absorbed the reaction mixture. Using a combiflash to purify the product, eluting with a petroleum ether / EtOAc gradient from 95:5 to 90:10, 1000 fractions were collected.Samples were collected for TLC analysis and qualified products were combined. Concentration under vacuum resulted in 40.6 g (75.8%) 19-3 as colorless oil. ELSD A: water / 0.05% TFA: B: CHaCN / 0.05% TFA 95:5 to 5:95 A / B at 2 min., hold 1.3 min): RT 1.8 min, m / z (Calc.) 370.2, (obtained) 393.2 (M+Na). Synthesis of 19-4: 2-Hydroxypropane-1,3-diyl bis(2,2-dimethylheptanoate)

[00445] In a 500 mL round-bottom 3-neck flask Petition 870250102289, dated 07 / 11 / 2025, pages 204 / 408 200 / 379 purged and maintained with an inert nitrogen atmosphere, 193 (15.5 g, 1.0 equiv) was placed in THF (155 mL). The solution was cooled to 0 °C in an ice-water bath. HOAc (3.26 g, 1.3 equiv) was added to the solution at 0 °C, and then NaBH3CN (3.16 g, 1.2 equiv) was added to the mixture in a batch at 0 °C. The ice-water bath was removed and the mixture was stirred for 16 hours at room temperature. The reaction was quenched with water (200 mL). The mixture was extracted with CH2Cl2 (3 x 200 mL). The combined organic phases were washed with brine (500 mL), then dried with Na2SO4. Filtration and vacuum concentration yielded crude product 19-4, which was dissolved in CH2Cl2 (75 mL), and 30 g of silica gel (type: ZCX-2, mesh 100-200, 1.94 wt / wt) were added to the solution. The mixture was concentrated under vacuum while maintaining the temperature below 35°C.200 g of silica gel (type: ZCX-2, mesh 100-200, 12.9 w / w) were loaded into the column, followed by the final step of preparing dry silica gel that absorbed the reaction mixture. Using a combi-flash to purify the product, eluting with a petroleum ether / EtOAc gradient from 90:10 to 85:15, 400 mL fractions were collected. Samples were collected for TLC analysis and qualified products were combined. Concentration under vacuum gave 12.3 g (79.3% yield) as 19-4 yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B in 2 min, wait 1.2 min): RT 1.5 min, m / z (Calc.) 372.2, (obtained) 395.2 (M+Na). Synthesis of 19-5: ((4,4'-((tert-Butoxycarbonyl)azanediyl)bis(butanoyl)) bis(oxy)) bis(propane-2,1,3-triyl) tetrakis(2,2-dimethylheptanoate) 19-4 Petition 870250102289, dated 07 / 11 / 2025, pp. 205 / 408 201 / 379

[00446] In a purged 250 mL round-bottom flask with 3 necks, maintained with an inert nitrogen atmosphere, 1-5 (4.77 g, 1.0 equiv) was placed in CH2Cl2 (80 mL). The solution was cooled to 0 °C in an ice-water bath, and then 19-4 (12.3 g, 2.0 equiv) and DMAP (2.0 g, 1.0 equiv) were added in order, followed by EDCI (9.5 g, 3.0 equiv) at 0 °C. The ice-water bath was removed, and the resulting solution was stirred for 16 hours at room temperature. To the reaction solution, 15 g of silica gel (type: ZCX-2, mesh 100-200, 3.14 w / w) were added, and the mixture was concentrated under vacuum while maintaining the temperature below 35 °C. 200 g of silica gel (type: ZCX2, mesh 100-200, 41.9 wt / wt) was loaded onto the column, followed by the final step of preparing dry silica gel that absorbed the reaction mixture. Using a combi-flash to purify the product, eluting with a petroleum ether / EtOAc gradient from 90:10 to 86:14, 400 mL fractions were collected.Samples were collected for TLC analysis and then matched qualified products. This resulted in 15.8 g (96.3%) of 19-5 as yellow oil. Synthesis of 19-6: bis(4-((1,3-bis((2,2-dimethylheptanoyl)oxy)propan-2-yl)oxy)-4-oxobutyl)ammonium chloride

[00447] In a 250 mL round-bottom flask that has been purged and maintained with an inert nitrogen atmosphere, a solution of Petition 870250102289, dated 07 / 11 / 2025, pp. 206 / 408 202 / 379 19-5 (6.0 g, 1.0 equiv) in CH2Cl2 (30 mL). The solution was cooled to 0 °C in an ice / water bath. HCl in dioxane (60 mL, 4 mol / L) was added dropwise at 0-10 °C. The ice / water bath was removed and the resulting solution was stirred overnight at room temperature. The reaction mixture was concentrated under vacuum resulting in 6.2 g (crude) of 19-6 as a light yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B in 2 min., hold 1.2 min): RT 1.5 min, m / z (Calc.) 897.6, (obtained) 898.5 (M+H). Synthesis of LIPID 19: ((4,4'-(((((3-(Dimethylamino)propyl)thio)carbonyl)-azanediyl)bis(butanoyl)) bis(oxy))bis(propane-2,1,3-triyl) tetrakis(2,2-dimethylheptanoate) 1. triphosgene CH2CI2, pyridine 2. concentrate dissolved in pyridine LIPID 19

[00448] In a 500 mL round-bottom, three-necked flask, purged and maintained with an inert nitrogen atmosphere, a solution of 19-6 (6.0 g, 1.0 equiv) in CH2Cl2 (210 mL) was placed. The solution was cooled to 0 °C in an ice-water bath. Triphosgene (2.69 g, 1.5 equiv) was added to the mixture at 0 °C. This was followed by the dropwise addition of pyridine (2.53 g, 5.0 equiv) with stirring at 0 °C. The ice-water bath was removed and the mixture was stirred for 4 h at room temperature and then concentrated under vacuum (temperature <30 °C). The residue was dissolved with pyridine (120 mL, 20 V) and the solution was cooled to 0 °C in an ice-water bath. To this solution, 3-(dimethylamino)propane-1-thiol (1.53 g, 2.0 equiv) was added dropwise with stirring at 0°C for 10 min. The ice / water batch was removed and the resulting solution was... Petition 870250102289, dated 07 / 11 / 2025, pages 207 / 408 203 / 379 stirred overnight at room temperature. The reaction mixture was concentrated under vacuum and the crude product 19 was dissolved in CH2Cl2 (100 mL) and 12 g of silica gel (type: ZCX-2, mesh 100-200) were added and the mixture was concentrated under vacuum while maintaining the temperature below 35°C. 100 g of silica gel (type: ZCX2, mesh 100-200) was loaded onto the column, followed by the final step of preparing dry silica gel that absorbed the reaction mixture. Using a combi-flash to purify the product, eluting with a CH2Cl2 / acetone gradient from 75 / 25 to 70 / 30, 200 mL fractions were collected. Samples were collected for TLC analysis and qualified products were combined. This resulted in 1.0 g (13.8% yield) as yellow oil. ELSD A: water / 0.05% TFA: B: CH3CN / 0.05% TFA 95:5 to 5:95 A / B in 2 min., hold 1.2 min): RT 1.5 min, m / z (Calc.) 1042.7, (obtained) 1043.9 (M+H). 1H-NMR (300 MHz, CDCl3): δ 5.28 (m, 2H), 4.32 (dd, J = 11.9, 4.4 Hz, 4H), 4.11 (dd, J = 11.9, 5.7 Hz, 4H), 3.38 (brm, 4H), 2.91 (m, 2H), 2.18-2.33 (6H), 2.23 (s, 6H), 1.78 (brm, 4H), 1.55 - 1.42 (8H), 1.35 - 1.10 (50H), 0.87 (t, J = 6.9 Hz, 12H). Example 20. Synthesis of LIPID 20: ((3,3'-(((3-(Dimethylamino)propyl)thio)carbonyl) azanediyl) bis(propanoyl))bis(oxy))bis (methylene))bis(2-methylpropane-2,1,3-triyl) tetrakis(3-(4-methylcyclohexyl)propanoate) LIPID 20 Petition 870250102289, dated 07 / 11 / 2025, pages 208 / 408 204 / 379 General Outline: Lipid 20 Synthesis of 20-2: 3-(4-methylcyclohexyl)propanoy...

Claims

1. Compound, characterized in that it has Formula I, or a pharmaceutically acceptable salt thereof: (I), wherein: R1 and R2 are each independently H or C1-6 alkyl; or R1 and R2 are joined to form a saturated heterocyclic ring, wherein: R1 is a linear C1-4 alkylene; and R2 is -(CH2)m(X)n-, wherein X is O, S or NR9, wherein R9 is H or C1-6 alkyl; m is 1, 2, 3 or 4, en is 0 or 1; L1 is a linear C1-6 alkylene optionally substituted with one to three methyl groups; Y is selected from the group consisting of: wherein: Petition 870250102289, dated 07 / 11 / 2025, p. 385 / 408 2 / 16 each asterisk (*) indicates the atom bonded to L2 and L3; and R10 is H or C1-6 alkyl; L2 and L3 are each independently a linear C1-8 alkylene; L4, L5, L6, L7, L8 and L9 are each independently absent or -CH2-, provided that: at least two of L4, L6 and L8 are -CH2-; and at least two of L5, L7 and L9 are -CH2-; R3 and R4 are each independently H, methyl or ethyl;and R5, R6, R7 and R8 are selected independently from the group consisting of: C1-20 linear alkyl, wherein each said C1-20 linear alkyl is optionally substituted with one or more substituents selected from the group consisting of: C6-10 aryl, wherein each C6-10 aryl is a monocyclic or bicyclic aromatic hydrocarbon optionally substituted with one or more C6-10 aryls that is optionally substituted with one or more C1-6 alkyls; 6- to 10-membered heteroaryl, wherein each 6- to 10-membered heteroaryl is a monocyclic or bicyclic aromatic system optionally substituted with one or more C1-6 alkyls; C6-10 aryl, where each C6-10 aryl is a monocyclic or bicyclic aromatic hydrocarbon optionally substituted by one or more C6-10 aryl groups that are optionally substituted by one or more C1-6 alkyl groups;and 6- to 10-membered heteroaryl groups, wherein each 6- to 10-membered heteroaryl group is a monocyclic or bicyclic aromatic system optionally substituted with one or more C1-6 alkyl groups. Petition 870250102289, dated 07 / 11 / 2025, pp. 386 / 408 3 / 16; 2. Compound according to claim 1, characterized in that: R1 is H or C1-6 alkyl and R2 is C1-6 alkyl; or R1 and R2 are joined to form said saturated heterocyclic ring.

3. Compound according to claim 1 or 2, characterized in that Y is selected from the group consisting of: and 4. Compound according to claim 1 or 2, characterized in that Y is: O 5. Compound according to claim 1 or 2, characterized in that Y is: OI ALT 6. Compound according to claim 1 or 2, characterized in that Y is: OI 7. Compound according to claim 5 or 6, characterized in that: at least one of R1 and R2 is H; and L1 is -CH2- or -CH2CH2-. Petition 870250102289, dated 07 / 11 / 2025, pp. 387 / 408 4 / 16 8. Compound according to any one of claims 1 to 6, characterized in that R1 and R2 are each independently C1-6 alkyl.

9. Compound according to claim 8, characterized in that R1 and R2 are each independently C1-3 alkyl.

10. Compound according to claim 9, characterized in that R1 and R2 are each methyl.

11. A compound according to any one of claims 1 to 6, characterized in that R1 and R2 are joined to form said heterocyclic ring.

12. Compound according to claim 11, characterized in that the heterocyclic ring is selected from the group consisting of: and wherein each asterisk (*) indicates the atom bonded to L1.

13. Compound according to claim 12, characterized in that the heterocyclic ring is selected from the group consisting of: and Petition 870250102289, dated 07 / 11 / 2025, page 388 / 408 5 / 16 14. Compound according to claim 13, characterized in that the heterocyclic ring is selected from the group consisting of: S * / 1 ς * / NR9 í» * / \ S * / \ α ^-N^J |_N^J |-N\e |-N\ / NR9 .

15. A compound according to any of the preceding claims, characterized in that R5, R6, R7 and R8 are each independently linear C1-8 alkyl, wherein each said linear C1-8 alkyl may be optionally substituted by one or more substituents selected from: C6-10 aryl, wherein each C6-10 aryl is a monocyclic or bicyclic aromatic hydrocarbon optionally substituted by one or more C6-10 aryls which is optionally substituted by one or more C1-6 alkyls; and 6- to 10-membered heteroaryl, wherein each 6- to 10-membered heteroaryl is a monocyclic or bicyclic aromatic system optionally substituted by one or more C1-6 alkyls.

16. Compound according to any one of claims 1 to 14, characterized in that R5, R6, R7 and R8 are each independently C6-10 aryl, wherein each said C6-10 aryl is a monocyclic or bicyclic aromatic hydrocarbon, optionally substituted by one or more C6-10 aryls which is optionally substituted by one or more C1-6 alkyls.

17. Compound according to any one of claims 1 to 14, characterized in that R5, R6, R7 and R8 are each independently a 6- to 10-membered heteroaryl, wherein each said 6- to 10-membered heteroaryl is a monocyclic or bicyclic aromatic system optionally substituted with one or more C1-6 alkyl groups. Petition 870250102289, dated 07 / 11 / 2025, p. 389 / 408 6 / 16 18. A compound, according to any of the preceding claims, characterized in that R5 and R6 are equal.

19. A compound, according to any of the preceding claims, characterized in that R7 and R8 are equal.

20. A compound according to any of the preceding claims, characterized in that L1 is an unsubstituted linear alkylene.

21. Compound, according to any of the preceding claims, characterized in that L1 is propylene.

22. A compound according to any one of the preceding claims, characterized in that L2 and L3 are each independently linear C1-5 alkylenes.

23. A compound, according to any of the preceding claims, characterized in that L2 and L3 are equal.

24. A compound, according to any of the preceding claims, characterized in that L4 and L5 are equal.

25. A compound, according to any of the preceding claims, characterized in that L6 and L7 are equal.

26. A compound, according to any of the preceding claims, characterized in that L8 and L9 are equal.

27. Compound, according to any of the preceding claims, characterized in that L4, L5, L6, L7, L8 and L9 are each -CH2-.

28. Compound according to any one of claims 1 to 26, characterized in that L6, L7, L8 and L9 are each -CH2-; and L4 and L5 are absent.

29. Compound according to any one of claims 1 to 26, characterized in that L4, L5, L8 and L9 are each -CH2-; and L6 and L7 are absent. Petition 870250102289, dated 07 / 11 / 2025, pp. 390 / 408 7 / 16 30. A compound according to any one of claims 1 to 26, characterized in that L4, L5, L6 and L7 are each -CH2-; and L8 and L9 are absent.

31. A compound according to any of the preceding claims, characterized in that R3 and R4 are each independently H or methyl.

32. A compound, according to any of the preceding claims, characterized in that R3 and R4 are each H.

33. Compound, according to any of the preceding claims, characterized in that R3 and R4 are each methyl.

34. Compound according to claim 1, characterized in that it is selected from the group consisting of: Lipid 42, Lipid 43, and Lipid 45, or pharmaceutically acceptable salts thereof. Petition 870250102289, dated 07 / 11 / 2025, p. 391 / 408 8 / 16 35. Compound, characterized by the fact that it is selected from the group consisting of: \ O οχχ «χ xyx ° / X\— 0X-0 o-7 y\X° A Á Lipid 44 —λ / ° o—, AA5 AV-\ ° í—VX Lipid 46 —Λ / ° o·^. ΑΥχΥJC J Hs, AV\ ° P~ Lipid 48 --Λ ___ O O-^ '—o ' \ N— .--0 ___ / / -- Ό Lipid 50 \ N— , _ / ~~X / 0 O—. \ \ / \ N— ON— J-^ =p47p AAP 47= \ rx 9 ^NÁ , 0 , Lipid 47 --V / 0 o-». v οΆ á A- C _ / — / Ay—°\ / — A 0 Ax; Λ / y-χ 9 r-' o 0 —\ A '—v—s 0_(( X-' o-xy Xo / --o-^ 0 , , Lipid 49 / ° o-. x \z \ N— _0—Z \ PN“ / --' 0 \ °\ / -- / J o ' \ / z )—o r--0 __ / , 0 , Lipid 51 Petition 870250102289, dated 07 / 11 / 2025, page 392 / 408 9 / 16 Lipid 53 o Lipid 52 Lipid 54 o Lipid 56 Lipid 57 Petition 870250102289, dated 07 / 11 / 2025, page 393 / 408 10 / 16 Lipid 59 Lipid 58, Lipid 62, and Lipid 61 Lipid 63; or pharmaceutically acceptable salts thereof.

36. Lipid composition, characterized in that it comprises a nucleic acid and a compound, as defined in any of the preceding claims. Petition 870250102289, dated 07 / 11 / 2025, pp. 394 / 408 11 / 16 37. Lipid composition, according to claim 36, characterized in that the nucleic acid is selected from an siRNA, an mRNA, a self-replicating RNA, a DNA plasmid and an antisense oligonucleotide.

38. Lipid composition, according to claim 36 or 37, characterized in that the nucleic acid is a self-replicating mRNA or RNA comprising a coding region encoding a therapeutic protein of interest.

39. Lipid composition according to claim 38, characterized in that the therapeutic protein of interest is an enzyme, an antibody, an antigen, a receptor or a transporter.

40. Lipid composition, according to claim 38 or 39, characterized in that the therapeutic protein of interest is a gene-editing enzyme.

41. Lipid composition according to claim 40, characterized in that the gene-editing enzyme is selected from TALEN, CRISPR, meganuclease or zinc finger nuclease.

42. Lipid composition, according to any one of claims 36 to 41, characterized in that the lipid composition comprises liposomes, lipoplexes or lipid nanoparticles.

43. Lipid nanoparticle, characterized in that it comprises a plurality of ligands, wherein each ligand is independently a compound, as defined in any one of claims 1 to 35, wherein the plurality of ligands self-organizes to form the lipid nanoparticle comprising an interior and an exterior.

44. Lipid nanoparticle, according to claim 43, Petition 870250102289, dated 07 / 11 / 2025, pp. 395 / 408 12 / 16, characterized in that the average particle size of the lipid nanoparticle is less than about 100 nm.

45. Lipid nanoparticle, according to claim 43 or 44, characterized in that the average particle size of the lipid nanoparticle is from about 55 nm to about 85 nm.

46. ​​Lipid nanoparticle, according to any one of claims 43 to 45, characterized in that the lipid nanoparticle further comprises a nucleic acid encapsulated inside.

47. Lipid nanoparticle, according to claim 46, characterized in that the nucleic acid is selected from an siRNA, an mRNA, a self-replicating RNA, a DNA plasmid and an antisense oligonucleotide.

48. Lipid nanoparticle, according to claim 46 or 47, characterized in that the nucleic acid is a self-replicating mRNA or RNA comprising a coding region encoding a therapeutic protein of interest.

49. Lipid nanoparticle, according to claim 48, characterized in that the therapeutic protein of interest is an enzyme, an antibody, an antigen, a receptor or a transporter.

50. Lipid nanoparticle, according to claim 48 or 49, characterized in that the therapeutic protein of interest is a gene-editing enzyme.

51. Lipid nanoparticle, according to claim 50, characterized in that the gene-editing enzyme is selected from TALEN, CRISPR, meganuclease or zinc finger nuclease.

52. Lipid nanoparticle, according to any one of claims 43 to 51, characterized in that the lipid nanoparticle further comprises an auxiliary lipid selected from: dileoylphosphatidylethanolamine (DOPE), dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylcholine (DPPC) and phosphatidylcholine (PC).

53. Lipid nanoparticle, according to claim 52, characterized in that the auxiliary lipid is distearolphosphatidylcholine (DSPC).

54. Lipid nanoparticle, according to any one of claims 43 to 53, characterized in that it further comprises cholesterol.

55. Lipid nanoparticle, according to any one of claims 43 to 54, characterized in that it further comprises a polyethylene glycol (PEG)-lipid conjugate.

56. Lipid nanoparticle, according to claim 55, characterized in that the PEG-lipid conjugate is PEGDMG.

57. Lipid nanoparticle, according to claim 56, characterized in that the PEG-DMG is PEG2000-DMG.

58. Lipid nanoparticle, according to any one of claims 43 to 57, characterized in that the lipid nanoparticle comprises about 45% to 65 mol% of the compound, as defined in any one of claims 1 to 35, about 2 mol% to about 15 mol% of an auxiliary lipid, about 20 mol% to about 42 mol% of cholesterol and about 0.5 mol% to about 3 mol% of a PEG-lipid conjugate.

59. Lipid nanoparticle, according to claim 58, characterized in that the lipid nanoparticle comprises about 50% to about 61% of the compound, as defined in any one of claims 1 to 35, about 5 mol% to about 9 mol% of the auxiliary lipid, about 29 mol% to about 38 mol% of cholesterol and about 1 mol% to about 2 mol% of the PEG-lipid conjugate.

60. Lipid nanoparticle, according to claim 59, characterized in that the lipid nanoparticle comprises about 56% to about 58% of the compound, as defined in any one of claims 1 to 35, about 6 mol% to about 8 mol% of DSPC, about 31 mol% to about 34 mol% of cholesterol and about 1.25 mol% to about 1.75 mol% of the PEG-lipid conjugate.

61. Lipid nanoparticle, according to any one of claims 43 to 60, characterized in that the lipid nanoparticle has a total lipid:nucleic acid weight ratio of about 50:1 to about 10:

1.

62. Lipid nanoparticle, according to claim 61, characterized in that the lipid nanoparticle has a total weight ratio of lipid to nucleic acid of about 40:1 to about 20:

1.

63. Lipid nanoparticle, according to claim 61, characterized in that the lipid nanoparticle has a total weight ratio of lipid to nucleic acid of about 35:1 to about 25:

1.

64. Lipid nanoparticle, according to claim 61, characterized in that the lipid nanoparticle has a total weight ratio of lipid to nucleic acid of about 32:1 to about 28:

1.

65. Lipid nanoparticle, according to claim 61, characterized in that the lipid nanoparticle has a total weight ratio of lipid to nucleic acid of about 31:1 to about 29:

1.

66. Pharmaceutical composition, characterized in that it comprises the compound, as defined in any one of claims 1 to 35, or the lipid nanoparticle, as defined in any one of claims 43 to 65, and a pharmaceutically acceptable excipient. Petition 870250102289, dated 07 / 11 / 2025, pp. 398 / 408 15 / 16 67. Pharmaceutical composition according to claim 66, characterized in that the pharmaceutical composition is a lyophilized composition.

68. Pharmaceutical composition, according to claim 66 or 67, characterized in that the pharmaceutical composition comprises a HEPES buffer with a pH of about 7.

4.

69. Pharmaceutical composition, according to claim 68, characterized in that the HEPES buffer is at a concentration of about 7 mg / mL to about 15 mg / mL.

70. Pharmaceutical composition, according to any one of claims 66 to 69, characterized in that the pharmaceutical composition further comprises from about 2.0 mg / mL to about 4.0 mg / mL of NaCl.

71. Pharmaceutical composition, according to any one of claims 66 to 70, characterized in that the pharmaceutical composition further comprises one or more cryoprotectants.

72. Pharmaceutical composition, according to claim 71, characterized in that one or more cryoprotectants are selected from sucrose, glycerol or a combination of sucrose and glycerol.

73. Pharmaceutical composition, according to claim 72, characterized in that the pharmaceutical composition consists of a combination of sucrose in a concentration of about 70 mg / mL to about 110 mg / mL and glycerol in a concentration of about 50 mg / mL to about 70 mg / mL.

74. Method for treating a disease in an individual in need of treatment, characterized in that it comprises administering to the individual a therapeutically effective amount of the lipid nanoparticle, as defined in any one of claims 43 to 65, or of the pharmaceutical composition, as defined in Petition 870250102289, dated 07 / 11 / 2025, pp. 399 / 408 16 / 16 any one of claims 66 to 73.

75. Method according to claim 74, characterized in that the pharmaceutical composition or lipid nanoparticle is administered intravenously or intramuscularly.

76. Method for expressing a protein or polypeptide in a target cell, characterized in that it comprises contacting the target cell with a lipid nanoparticle, as defined in any one of claims 43 to 65, or with the pharmaceutical composition, as defined in any one of claims 66 to 73.

77. A method according to claim 76, characterized in that the protein or polypeptide is an antigen and the expression of the antigen elicits an immunogenic response in vivo.

78. A method for administering a nucleic acid to an individual in need thereof, characterized in that it comprises encapsulating a therapeutically effective amount of the nucleic acid in a lipid nanoparticle, as defined in any of compounds 43 to 65, and administering the lipid nanoparticle to the individual.